form10-q.htm

The Company recorded a provision for income taxes of $2.0 million for the nine months ended September 30, 2010 on pre-tax net loss of $94,000. The effective tax rate for the nine months is above the statutory rate as a result of the non-deductible CHS acquisition related costs and a lower post-combination state tax rate expected to be applicable when the deferred tax assets are reversed. Both of these factors are treated as discrete items. The provision for income taxes for the nine months ended September 30, 2009 was $1.2 million with an effective tax rate of 8.5%. The lower effective tax rate of 8.5% for the nine months ended September 30, 2009 compared to the statutory rate was primarily a result of a reduction in the valuation allowance due to the utilization of a portion of the net operating losses in 2009.

The Company and its subsidiaries file income tax returns with Federal, state and local jurisdictions. The Company’s uncertain tax positions are related to tax years that remain subject to examination. As of September 30, 2010, U.S. tax returns for 2007, 2008 and 2009 remain subject to examination by Federal tax authorities. Tax returns for the years 2006 through 2009 remain subject to examination by state and local tax authorities for a majority of the Company’s state and local filings.

NOTE 11 – SECURITY INTEREST AND LETTERS OF CREDIT

On March 25, 2010, in connection with the CHS acquisition, the Company and its primary drug wholesaler entered into an amendment to its existing Prime Vendor Agreement (the “PVA”) to subordinate the liens of the primary wholesaler in the Company’s inventory to liens granted under the Senior Secured Facility. On June 17, 2010, the Company further amended the PVA to, among other things, add CHS and its subsidiaries to the PVA and to the liens granted by the Company to its primary drug wholesaler.

In addition, in the ordinary course of business, the Company obtained certain letters of credit (“LC”) from commercial banks in favor of various parties. At September 30, 2010, there was $3.4 on deposit as collateral for these LCs, which are recorded in prepaid expenses and other current assets.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2009 (the “Form 10-K”) filed with the U.S. Securities and Exchange Commission (“SEC”), as well as our unaudited consolidated interim financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q for the three month period ended September 30, 2010 (this “Report”).

This Report contains statements not purely historical and which may be considered forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements regarding our expectations, hopes, beliefs, intentions or strategies regarding the future. These forward looking statements may include, but are not limited to:

Our expectations regarding financial condition or results of operations in future periods;

our future sources of, and needs for, liquidity and capital resources;

our expectations regarding economic and business conditions;

our expectations regarding the size and growth of the market for our products and services;

our business strategies and our ability to grow our business;

the implementation or interpretation of current or future regulations and legislation, particularly governmental oversight of our business;

our ability to maintain contracts and relationships with our customers;

sales and marketing efforts;

status of material contractual arrangements, including the negotiation or re-negotiation of such arrangements;

future capital expenditures;

our ability to successfully complete the integration of Critical Homecare Solutions Holdings, Inc. (including its subsidiaries, collectively “CHS”) and other acquisitions and realize the anticipated synergies of these acquisitions;

our revenue following the merger;

our high level of indebtedness;

our ability to make principal payments on our debt and satisfy the other covenants contained in our senior secured credit facility and other debt agreement;

our ability to hire and retain key employees;

our ability to successfully execute our succession plan; and

other risks and uncertainties described from time to time in our filings with the SEC.

Investors are cautioned that any such forward-looking statements are not guarantees of future performance, involve risks and uncertainties and that actual results may differ materially from those possible results discussed in the forward-looking statements as a result of various factors. This Report contains information regarding important factors that could cause such differences. These factors include, among other things:

Risks associated with increased government regulation related to the health care and insurance industries in general, and more specifically, pharmacy benefit management and specialty pharmaceutical distribution organizations;

unfavorable economic and market conditions;

reductions in Federal and state reimbursement;

delays or suspensions of Federal and state payments for services provided;

efforts to reduce healthcare costs and alter health care financing;

existence of complex laws and regulations relating to our business;

achieving financial covenants under our credit facility;

availability of financing sources;

declines and other changes in revenue due to expiration of short-term contracts;

network lock-outs and decisions to in-source by health insurers including lockouts with respect to acquired entities;

unforeseen contract terminations;

difficulties in the implementation and conversion of our new pharmacy systems;

increases or other changes in the Company’s acquisition cost for its products;

Table of Contents

increased competition from our competitors, including competitors with greater financial, technical, reimbursement, marketing and other resources, could have the effect of reducing prices and margins;

the significant indebtedness incurred to complete the acquisition may limit our ability to execute our business strategy and increase the risk of default under our debt obligations,

introduction of new drugs can cause prescribers to adopt therapies for existing patients that are less profitable to us; and

changes in industry pricing benchmarks could have the effect of reducing prices and margins.

You should not place undue reliance on such forward-looking statements as they speak only as of the date they are made. Except as required by law, we assume no obligation to publicly update or revise any forward-looking statement even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized.

Business Overview

We are a leading national provider of specialty pharmacy and home care products and services that partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and the delivery of cost-effective access to prescription medications and home health services. Our services are designed to improve clinical outcomes to patients with chronic and acute healthcare conditions while controlling overall healthcare costs. As of September 30, 2010, we had a total of 113 locations in 29 states plus the District of Columbia, including 31 community pharmacy locations, 33 home nursing locations, three mail service facilities and 46 home infusion locations, including three contract affiliated infusion pharmacies.

On March 25, 2010, we acquired CHS, a privately held leading provider of home infusion and home nursing products and services. CHS was principally owned by funds managed by Kohlberg & Company, L.L.C., or Kohlberg. Our acquisition of CHS provided us with a national network of specialty and home infusion pharmacies and home and health care service providers. As a result of the acquisition, we are cross-selling all of our service offerings, enabling accelerated pull-through opportunities with our existing payors, as well as the additional payors from CHS. The additional CHS payor relationships of more than 450 increases our total payor relationships to over 1,000. The acquisition also significantly expanded our national footprint with the addition of a strong regional and local management team.

On July 29, 2010, the Company acquired the prescription pharmacy business and assets of DS Pharmacy, Inc. (“DS Pharmacy”), a wholly-owned subsidiary of drugstore.com, inc. The acquisition provides the Company with an expanded presence in on-line pharmacy and a six year license of drugstore.com capabilities, trademarks and trade names. In connection with the acquisition, the Company and drugstore.com entered into a Transitional Services Agreement and a Services Agreement pursuant to which, for a period of six years following the closing of the acquisition, drugstore.com will provide marketing services. The agreements also allow drugstore.com customers to continue to order from the Company through the drugstore.com website. The Company paid $5.0 million cash upon closing and may pa y an additional earn-out currently estimated at $4.7 million.

During the three month period ended September 30, 2010 we renegotiated certain discount cash card broker agreements to provide for the payment of higher broker fees for new and existing cash card sales. We expect these new rates to provide additional incentives for new member growth over the next several quarters thereby increasing these programs profitability over the long term. Beginning in the fourth quarter we expect broker fees to increase $1.9 million on $1.6 million of additional revenue over the prior quarter. If anticipated growth is achieved, broker fees could increase $3.0 – $5.0 million quarterly compared to prior year. The net impact to operating income is expected to be positive versus prior year for the second quarter of 2011 and going forward.

Our platform provides nationwide service capabilities and the ability to deliver clinical management services that offers patients a high-touch, community- and home-based care environment. Our core services are provided in coordination with, and under the direction of the patient’s physician. Our home health professionals, including pharmacists, nurses, respiratory therapists and physical therapists, work with the physician to develop a plan of care suited to our patients specific needs. Whether in the home, physician office, ambulatory infusion center or other alternate site of care, we provide products, services and condition-specific clinical management programs tailored to improve the care of individuals with complex health conditions such as gastrointestinal abnormalities, HIV/AIDS, cancer, iron overload, multiple sclerosis , organ transplants, rheumatoid arthritis, immune deficiencies and congestive heart failure.

Below is a brief discussion of our business and operations as reported in our Unaudited Consolidated Financial Statements for the quarterly period ended September 30, 2010 on a segment basis. Immediately upon the

Table of Contents

consummation of the acquisition of CHS, we began integrating the operations of CHS into our operations and re-evaluating our segment reporting. As a result of this review, we changed our operating and reportable segments from “Specialty Pharmacy Services” and “Traditional Pharmacy Services” to our new operating and reportable segments: “Infusion/Home Health Services” and “Pharmacy Services”. These two new operating and reportable segments reflect how our chief operating decision maker (“CODM”) reviews our results in terms of allocating resources and assessing operating and financial performance. Prior period disclosures reflect the change in reportable segments.

The Infusion/Home Health Services operating and reportable segment consists of our legacy infusion therapy business combined with the infusion, respiratory, durable medical equipment (“DME”) and home health businesses obtained in the CHS acquisition. The infusion services provided in this segment includes home infusion therapy, respiratory therapy and DME. Infusion services include the dispensing and administering of infusion based drugs, which typically require additional nursing and clinical management services, equipment to administer the correct dosage and patient training designed to improve patient outcomes. Through the home health services provided by this segment, we provide skilled nursing and therapy visits, private duty nursing services, rehabilitation services, hospice and medic al social services to patients primarily in their home.

The Pharmacy Services operating and reportable segment consists of our traditional and specialty pharmacy mail operations and community pharmacies, prescription discount card programs and integrated pharmacy benefit management (“PBM”) services. The DS Pharmacy business is also included in this segment. These segment services are designed to offer customers and patients cost-effective delivery of traditional, and specialty pharmacy services. The services also include care management programs customized to each patients care plan in coordination with doctors.

We have presented operating and reportable segment information on the basis of net income (loss) adjusted for net interest expense, income tax expense, depreciation, amortization and stock-based compensation expense (“Segment Adjusted EBITDA”) and prior to the allocation of corporate expenses. Segment Adjusted EBITDA excludes the write-off of receivables owed at the time the CAP contract terminated and acquisition, integration and severance expenses. We believe that Segment Adjusted EBITDA from operations provides a better indication of the segment operating performance. The Segment Adjusted EBITDA measurement is the primary measure used by the CODM in evaluating our operating and financial performance.

Critical Accounting Estimates

Our Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). In preparing our financial statements, we are required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We evaluate our estimates and judgments on an ongoing basis. We base those estimates and judgments on historical experience and on various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates, and different assumptions or conditions may yield different estimates. There have been no changes to critical accounting estimates in the three months ended September 30, 2010. For a full description of our accounting policies please refer to Note 2 of the Audited Consolidated Financial Statements included in the Form 10-K.

Table of Contents

Results of Operations

The following discussion is based on the Unaudited Consolidated Financial Statements of the Company. It compares our results of operations for the three and nine months ended September 30, 2010 with our results of operations for the three and nine months ended September 30, 2009 (in thousands).

	Three Months Ended September 30,
	2010				2009				Change
Revenue	$	441,153			$	333,476			$	107,677
Gross profit	$	75,384	17.1	%	$	41,496	12.4	%	$	33,888
Income from operations	$	12,204	2.8	%	$	6,661	2.0	%	$	5,543
Interest expense, net	$	8,122	1.8	%	$	447	0.1	%	$	7,675
Income before income taxes	$	4,082	0.9	%	$	6,214	1.9	%	$	(2,132	)
Net income	$	1,965	0.4	%	$	5,747	1.7	%	$	(3,782	)

	Nine Months Ended September 30,
	2010					2009				Change
Revenue	$	1,188,251				$	987,974			$	200,277
Gross profit	$	187,825		15.8	%	$	115,874	11.7	%	$	71,951
Income from operations	$	19,421		1.6	%	$	16,129	1.6	%	$	3,292
Interest expense, net	$	19,515		1.6	%	$	1,471	0.1	%	$	18,044
(Loss) income before income taxes	$	(94	)	0.0	%	$	14,658	1.5	%	$	(14,752	)
Net (loss) income	$	(2,075	)	-0.2	%	$	13,409	1.4	%	$	(15,484	)

Revenue. Revenue for the three months ended September 30, 2010 was $441.2 million as compared to revenue of $333.5 million for the three months ended September 30, 2009. Pharmacy Services revenue for the three months ended September 30, 2010 was $329.3 million as compared to revenue of $296.7 million for the same period in 2009, an increase of $32.6 million, or 11.0%. That increase was primarily due to revenue on new contracts, the expansion of the number of patients served on existing contracts and industry-wide drug inflation. The acquisition of the prescription pharmacy business of DS Pharmacy resulted in new revenue of $3.6 million in the period. Infusion/Home Health Services revenue for the three months ended September 30, 2010 was $111.8 million , as compared to revenue of $36.8 million for the three months ended September 30, 2009, an increase of $75.0 million, or 203.8%. Excluding revenue associated with the acquired CHS businesses, our infusion revenue increased $7.0 million, or 19.0%, from a year ago. CHS revenue contributed $68.0 million of revenue during the period.

Revenue for the nine months ended September 30, 2010 was $1.2 billion as compared to revenue of $988.0 million for the nine months ended September 30, 2009. Pharmacy Services revenue for the nine months ended September 30, 2010 was $923.6 million as compared to revenue of $880.4 million for the same period in 2009, an increase of $43.2 million, or 4.9%. That increase was primarily due to revenue on new contracts, the expansion of the number of patients served on existing contracts and industry-wide drug inflation. The acquisition of the prescription pharmacy business of DS Pharmacy resulted in new revenue of $3.6 million during the period. Infusion/Home Health Services revenue for the nine months ended September 30, 2010 was $264.6 million, as compared to revenue of $107.6 million for the same period i n 2009, an increase of $157.0 million, or 145.9%. The acquired CHS business contributed $137.8 million of revenue for the nine months ended September 30, 2010. Excluding revenue associated with the acquired CHS businesses, our infusion revenue increased $19.2 million, or 17.8%, over the prior period. The growth in revenue excluding the acquired CHS businesses in Infusion/Home Health Services for the nine months ended September 30, 2010 was a result of new infusion contracts.

Cost of Revenue and Gross Profit. Cost of revenue for the three months ended September 30, 2010 was $365.8 million as compared to $292.0 million for the same period in 2009. Gross profit during the three months ended September 30, 2010 was $75.4 million as compared to $41.5 million for the three months ended September 30, 2009, an increase of $33.9 million, or 81.7%. Gross profit as a percentage of revenue increased to 17.1% in the three months ended September 30, 2010 from 12.4% in the three months ended September 30, 2009. The increase in gross profit percentage from 2009 to 2010 was primarily the result of the acquisition of CHS and purchasing synergies generated post-acquisition. The increase in gross profit percentage compared to 2009 was partially offset by effects of certain state governmental agencies that declined to make any adjustment to their reimbursement following the implementation of the industry-wide AWP settlement in September 2009. As such, our reimbursement, as well as those of our peers, for services provided to government funded and/or operated programs were reduced. Also partially offsetting the 2010 increase in gross profit from the CHS acquisition are the effects of unfavorable competitive market conditions in our traditional mail operations.

Cost of revenue for the nine months ended September 30, 2010 was $1.0 billion as compared to $872.1 million for the same period in 2009. Gross profit for the nine months ended September 30, 2010 was $187.8 million as

Table of Contents

compared to $115.9 million for the same period a year ago, an increase of $71.9 million, or 62.0%. Gross profit as a percentage of revenue increased to 15.8% in the nine months ended September 30, 2010 from 11.7% in the nine months ended September 30, 2009. The increase in gross profit percentage from 2009 to 2010 was primarily the result of the acquisition of CHS and purchasing synergies generated post-acquisition. The increase in gross profit percentage compared to 2009 was partially offset by previously disclosed price concessions granted to a major customer totaling $2.5 million. Also partially offsetting the increase in gross profit from the CHS acquisition was a $1.2 million decrease in reimbursement from certain state governmental agencies that declined to adjust their reimbursement rates followi ng the implementation of the industry-wide AWP settlement in September 2009. As such, our reimbursement for services provided to government funded and/or operated programs were reduced. Finally, delays in brand to generic conversions also partially offset growth in gross profit.

Selling, General and Administrative Expenses. Selling, general and administrative expenses (“SG&A”) for the three months ended September 30, 2010 were $55.9 million, or 12.7% of total revenue, as compared to $32.4 million, or 9.7% of total revenue, for the same period in 2009. The increase in SG&A was primarily due to $20.2 million of additional expense in the period related to CHS and $1.5 million in additional wages and salaries and an increase of $1.5 million in broker fees related to growth in our prescription discount card business. Due to the acuity level of patients associated with the home health nursing and traditional home infusion services, the Infusion/Home Health Services segment operates at a higher operating expense ratio to revenue than the Pharmacy Services segment.

SG&A for the nine months ended September 30, 2010 were $147.0 million, or 12.4% of total revenue, as compared to $94.3 million, or 9.5% of total revenue, for the same period in 2009. The increase in SG&A was primarily due to $41.7 million of additional expense related to CHS, a $5.8 million increase in wages and salaries to strengthen the management and sales team and an increase of $3.4 million in brokers fees related to growth in our prescription discount card business. Due to the acuity level of patients associated with the home health nursing and traditional home infusion services, the Infusion/Home Health Services segment operates at a higher operating expense ratio to revenue than the Pharmacy Services segment.

Bad Debt Expense. For the three months ended September 30, 2010, bad debt expense was $5.3 million, or 1.2% of revenue, as compared to $2.4 million, or 0.7% of revenue, in the same period of 2009. Of this $2.9 million increase, $1.1 million is related to the acquisition of CHS. The remaining increase in bad debt expense in the three months ended September 30, 2010 is due to our current and year to date collection experience on aged balances, which include government payors as well as non-electronic payors. Based on our current collection experience, we expect bad debt expense for the remainder of 2010 to be approximately 1.0% of revenue.

For the nine months ended September 30, 2010, bad debt expense was $12.5 million, or 1.1% of revenue, as compared to $5.4 million, or 0.5% of revenue, for the same period in 2009. Of this $7.1 million increase, $1.5 million is increased provision related to uncollected receivables remaining under the Centers for Medicare and Medicaid (“CMS”) Competitive Acquisition Program (“CAP”) contract, which was terminated effective December 31, 2008. The remaining unreserved net CAP receivable balance at September 30, 2010 is $1.6 million. Although the Federal and state governmental agency process to collect these amounts has become protracted, we are pursuing receivables diligently and believe our reserves are adequate. The write-off of CAP receivables in the first quarter resulted in an increase in bad debt expense of 0.2% of revenue for the nine months ended September 30, 2010. Another $2.5 million of the bad debt expense increase was related to the acquisition of CHS. Bad debt expense increased $2.2 million in the nine months ended September 30, 2010 relative to 2009 based on our current collection experience on aged balances, which include government payors as well as non-electronic payors. The remainder of the $7.1 million increase is due to revenue growth which occurred on business mix which experiences a slightly higher bad debt rate than our average mix of business.

Acquisition and Integration Expenses. During the three months ended September 30, 2010, we recorded $0.6 million of costs related to the acquisitions of CHS and DS Pharmacy. These expenses were primarily related to overtime and temporary wage costs and other integration costs associated with the DS Pharmacy acquisition. We did not have any acquisition related expenses in the three months ended September 30, 2009.

During the nine months ended September 30, 2010, we recorded $6.7 million of costs related to the acquisition of CHS. These costs were primarily related to legal, audit and financial advisory fees associated with the acquisition of CHS. We did not have any acquisition related expenses in the same period in 2009.

Table of Contents

Amortization of Intangibles. During the three months ended September 30, 2010, we recorded amortization of intangible assets of $1.3 million. The amortization was due to intangible assets recorded as a result of the 2010 CHS and DS Pharmacy acquisitions. There was no amortization of intangible assets recorded in the same period of 2009.

During the nine months ended September 30, 2010, we recorded amortization of intangible assets of $2.2 million. The amortization was due to intangible assets recorded as a result of the 2010 CHS and DS Pharmacy acquisitions. There was no amortization of intangible assets recorded in the same period in 2009.

Interest Expense, Net. Net interest expense was $8.1 million for the three months ended September 30, 2010 as compared to $0.4 million for the same period in 2009. The increase in interest expense was due to the new debt structure used to acquire CHS, resulting in $8.0 million of interest expense related to the new credit facilities.

Net interest expense was $19.5 million for the nine months ended September 30, 2010 as compared to $1.5 million for the same period a year ago. The increase in interest was due to our new debt structure, including $16.7 million of interest expense related to our new credit facilities and a $2.3 million finance fee related to the bridge loan financing that was available if the unsecured notes had not been sold by the time the acquisition was finalized.

Income Tax Expense. Income tax expense of $2.1 million was recorded for the three months ended September 30, 2010 on pre-tax net income of $4.1 million, a 51.8% effective tax rate. The effective tax rate of 51.8% is above the statutory rate as a result of the decrease in deferred tax assets due to a lower post-combination state tax rate expected to be applicable when the deferred tax assets are reversed. The provision for income taxes for the three months ended September 30, 2009 was $0.5 million with an effective tax rate of 7.5%. In 2009, the Company maintained a valuation allowance against it deferred tax assets. The effective tax rate of 7.5% was below the statutory rate as a result of a reduction in the Company’s valuation allowance associated with the utilization of a portion of net operating losses in 2009.

Income tax expense of $2.0 million was recorded for the nine months ended September 30, 2010 on pre-tax net loss of $94,000. The effective tax rate for the nine months is above the statutory rate as a result of the non-deductible CHS acquisition related costs and a lower post-combination state tax rate expected to be applicable when the deferred tax assets are reversed. Both factors are treated as discrete items. The provision for income taxes for the nine months ended September 30, 2009 was $1.2 million with an effective tax rate of 8.5%. The lower effective tax rate of 8.5% for the nine months ended September 30, 2009 compared to the statutory rate was primarily a result of a reduction in the valuation allowance due to the utilization of a portion of the net operating losses in 2009.

Net Income (Loss) and Income (Loss) Per Share. Net income for the three months ended September 30, 2010 was $2.0 million, or $0.04 per diluted share. This compares to net income of $5.7 million, or $0.14 per diluted share, for the same period last year.

Net loss for the nine months ended September 30, 2010 was $2.1 million, or $0.04 per diluted share. This compares to net income of $13.4 million, or $0.34 per diluted share, for the same period last year.

Non-GAAP measures. The following table reconciles GAAP Net Income (Loss) to Consolidated Adjusted EBITDA and Segment Adjusted EBITDA. Consolidated Adjusted EBITDA and Segment Adjusted EBITDA are measures of earnings that management monitors as an important indicator of financial performance, particularly future earnings potential and recurring cash flow. Adjusted EBITDA is also a primary objective of the management bonus plan for 2010 and is used in calculations pertaining to term loan debt covenants. EBITDA is net income (loss) adjusted for net interest expense, income tax expense, depreciation, amortization and stock-based compensation expense. Adjusted EBITDA excludes the write-off of receivables owed at the time the CAP contract te rminated and acquisition, integration and severance expenses.

Table of Contents

Reconciliation between GAAP and Non-GAAP Measures

(in thousands)

(unaudited)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2010			2009			2010			2009
Results of Operations:
Adjusted EBITDA by Segment before corporate overhead:
Infusion/Home Health Services	$	14,942		$	2,586		$	31,702		$	7,420
Pharmacy Services		10,731			13,224			31,120			34,521
Total Segment Adjusted EBITDA		25,673			15,810			62,822			41,941

Corporate overhead		(7,602	)		(6,896	)		(23,646	)		(19,831	)

Consolidated Adjusted EBITDA	$	18,071		$	8,914		$	39,176		$	22,110

Interest expense, net		(8,122	)		(447	)		(19,515	)		(1,471	)
Income tax expense		(2,117	)		(467	)		(1,981	)		(1,249	)
Depreciation		(2,404	)		(1,356	)		(6,211	)		(3,596	)
Amortization		(1,326	)		-			(2,196	)		-
Stock-based compensation expense		(1,097	)		(897	)		(2,726	)		(2,385	)
Acquisition, integration and severance expenses		(1,040	)		-			(7,139	)		-
Bad debt expense related to contract termination		-			-			(1,483	)		-
Net income (loss):	$	1,965		$	5,747		$	(2,075	)	$	13,409

Liquidity and Capital Resources

We utilize funds generated from operations for general working capital needs, capital expenditures and acquisitions.

Net cash provided by operating activities totaled $5.9 million during the nine months ended September 30, 2010 compared to $14.0 million during the nine months ended September 30, 2009. The decrease in cash provided by operating activities was primarily the result of a net loss of $2.1 million, which includes acquisition related operating expenses and financing fees of $8.9 million. Charges that contributed to the net loss but had no impact on cash from operations were bad debt of $12.5 million, which includes a $1.5 million write-off as a result of the terminated CAP contract, depreciation of $6.2 million, change in deferred income tax of $1.2 million, amortization of intangibles and deferred financing cost of $3.5 million and equity-based compensation expense of $2.7 million. Contributing to the decline in cash provided from operations was a $10.6 million increase in accounts receivable, $10.8 million increase in inventory and $6.6 million of cash used to prepay expenses including prepaid insurance and refundable income taxes.

Net cash used in investing activities during the nine months ended September 30, 2010 was $105.2 million compared to $4.5 million for the same period in 2009. The cash used was primarily related to the acquisitions of CHS and DS Pharmacy.

Net cash provided by financing activities during the nine months ended September 30, 2010 was $150.3 million compared to $9.5 million of cash used during the same period in 2009. The cash provided was primarily due to the issuance of notes and the Senior Secured Facility (defined below). This increase was partially offset by the payoff of the long-term debt assumed in the CHS acquisition as well as the payoff of the prior line of credit and payment of financing costs related to the note issuance and the Senior Secured Facility. For the nine months ended September 30, 2009, the net cash used in financing activities was due to an increase in payments on our original credit facility.

Prior to March 25, 2010, we utilized an $85.0 million revolving credit facility (“Facility”) with an affiliate of Healthcare Finance Group, Inc. (“HFG”). On March 25, 2010 the outstanding balance of $27.0 million was paid in full.

Table of Contents

On March 25, 2010, the we entered into a credit agreement (the “Senior Secured Facility”) by and among the Company, as borrower, all of its subsidiaries as subsidiary guarantors thereto, the lenders party thereto, Jefferies Finance LLC (“Jefferies”), as lead arranger, as book manager, as administrative agent for the lenders, as collateral agent for the secured parties and as syndication agent, Compass Bank, as a co-documentation agent, GE Capital Corporation as a co-documentation agent, Healthcare Finance Group, LLC, as collateral manager, HFG Healthco-4, LLC, as swingline lender for the lenders, and Healthcare Finance Group, LLC, as issuing bank for the lenders. The Senior Secured Facility consists of a $100.0 million senior secured term loan facility (the “Term Loan”) and a $50.0 million senior secured revolving credit facility (the “Revolver”). The Term Loan has a five year term and has a repayment schedule with quarterly amortization equal to 2.5%, 5.0%, 7.5%, 10.0% and 12.5% per annum of its principal amount in years one through five, respectively, with the balance due at maturity. The Revolver is available for five years after the closing of the acquisition. The amount of borrowings that may be made under the Revolver are based on a borrowing base calculation and are comprised of specified percentages of eligible receivables and eligible inventory, up to a maximum of $50.0 million. If the amount of borrowings outstanding under the Revolver exceeds the borrowing base then in effect, we are required to repay such borrowings in an amount sufficient to eliminate such excess. Additionally, if there are no borrowings outstanding under the Revolver and the principal amount of the Term Loan then outstanding exceeds the borrowing base then in effect, we are required to repay the Term Loan in an amount sufficient to eliminate such excess. The Revolver includes $5.0 million of availability for letters of credit and $5.0 million of availability for swingline loans. Interest on both the Term Loan and outstanding borrowings under the Revolver are based on a base rate or Eurodollar rate plus an applicable margin of 3.0% and 4.0%, respectively, with the base rate and Eurodollar rate having floors of 3.0% and 2.0%, respectively. In the event of any default, the interest rate may be increased to 2.0% over the rate applicable to base rate loans. The Revolver also carries an annual commitment fee of 0.75%, payable quarterly in arrears, on the unused portion of the Revolver.

Borrowings under the Senior Secured Facility are subject to mandatory prepayment upon the occurrence of certain events, including the issuance of certain equity securities, the incurrence of certain debt and the sale or other disposition of assets. In addition, borrowings under the Senior Secured Facility are subject to mandatory prepayment in the event we have “excess cash flow”, as defined in the Senior Secured Facility agreement. Both the Term Loan and the Revolver have been guaranteed by all of our subsidiaries and secured by first priority security interests in all of the Company’s assets (including the capital stock of our subsidiaries) and all such subsidiary guarantors. The Senior Secured Facility includes affirmative and negative covenants and customary events of default, as well as financial covenants relat ing to a maximum total leverage ratio and a minimum fixed charge coverage ratio, as well as limits on capital expenditures. Negative covenants include, among other limitations, limitations on additional debt, liens, negative pledges, investments, dividends, stock repurchases, asset sales and affiliate transactions. Events of default include, among other events, non-performance of covenants, breach of representations, cross-default to other material debt, bankruptcy and insolvency, material judgments and changes in control. We were in compliance with all covenants contained in the Senior Secured Facility credit agreement as of September 30, 2010.

We also issued $225.0 million aggregate principal amount of 10¼% senior unsecured notes due October 1, 2015 in an unregistered offering pursuant to Rule 144A and Regulation S under the Securities Act of 1933. The notes will bear interest at a rate of 10¼% per annum. We will pay interest on the notes semi-annually, in arrears, on April 1 and October 1 of each year, beginning October 1, 2010. These notes are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured basis by our existing and future direct and indirect subsidiaries. As of September 30, 2010, we do not have any independent assets or operations and, as a result, our direct and indirect subsidiaries (other than minor subsidiaries), each being 100% owned by us, are fully and unconditionally, jointl y and severally, providing guarantees on a senior unsecured basis to the new notes. As noted above, we and each of our guarantor subsidiaries are subject to restrictive covenants under the Senior Secured Facility. The Senior Secured Facility ranks senior in priority to each subsidiary’s guarantee of the notes and could restrict our ability to obtain funds from the guarantor subsidiaries. As of September 30, 2010, the carrying amount of our long-term debt was $225.0 million, and the fair value of the long-term debt, based on current market rates for debt of the same risk and maturities, was estimated at $228.2 million.

On June 22, 2010 we filed an Offer to Exchange (the “Exchange Offer”) the original unregistered notes with new registered notes, as contemplated in the original note offering. The new notes are substantially identical to the original notes except some of the transfer restrictions, registration rights and additional interest provision relating to the original notes do not apply. On July 13, 2010 our planned registration of the notes became effective. The Exchange Offer expired on August 12, 2010 and the new registered notes commenced trading publicly on August 16, 2010.

Table of Contents

On or after April 1, 2013, we may redeem some or all of the notes at the redemption prices set plus accrued and unpaid interest to the date of redemption. The redemption premium percentages for notes redeemed are as follows: (a) on or after April 1, 2013, 105.125% of the principal amount, and (b) on or after October 1, 2014, 100.0% of the principal amount. Prior to April 1, 2013, we may redeem up to 35% of the aggregate principal amount of the notes at the premium of 110.250% of the principal amount thereof, plus accrued and unpaid interest and liquidated damages, if any, to the redemption date, with the net cash proceeds of certain equity offerings. In addition, we may, at our option, redeem some or all of the notes at any time prior to April 1, 2013, by paying a “make whole” premium.

At September 30, 2010, we had working capital of $180.7 million compared to $91.1 million at December 31, 2009. The increase was primarily due to the excess of new debt proceeds over payments for CHS and DS Pharmacy and increased working capital from the operations of CHS and DS Pharmacy. We have also made substantial information technology (“IT”) systems investments to improve efficiencies, internal controls, and data reporting. We believe that our cash on hand, together with funds available under the Revolver and cash expected to be generated from operating activities, will be sufficient to fund our anticipated working capital, IT systems investments, scheduled debt repayments and other cash needs for at least the next twelve months.

We may also pursue joint venture arrangements, business acquisitions and other transactions designed to expand our business, which we would expect to fund from borrowings under the Facility, other future indebtedness or, if appropriate, the private and/or public sale or exchange of our debt or equity securities.

At September 30, 2010 we had Federal net operating loss carryforwards available to us of approximately $17.8 million, of which $1.2 million is subject to an annual limitation, all of which will begin expiring in 2012 and later. We have post apportioned state net operating loss carryforwards remaining of approximately $8.2 million, the majority of which will begin expiring in 2017 and later.

On March 25, 2010, in connection with the CHS acquisition, we entered into an amendment to our existing Prime Vendor Agreement (as amended, the “PVA”) with our primary drug wholesaler pursuant to which the wholesaler agreed to subordinate the liens in our inventory to liens granted under the Senior Secured Facility. On June 17, 2010, we further amended the PVA to, among other things, add CHS and its subsidiaries to the PVA and to the liens granted by us to our primary drug wholesaler.

In addition, in the ordinary course of business, we obtained certain letters of credit (“LC”) from commercial banks in favor of various parties. At September 30, 2010, there was $3.4 million of cash on deposit as collateral for these LCs.

The following table sets forth our contractual obligations affecting cash in the future as of September 30, 2010 (in thousands):

	Payments Due in Period Ending December 31
Contractual Obligations	Total		Less than 1 Year		1-3 Years		4-5 Years		After 5 Years

Long-term debt (1)	$	464,223	$	8,033	$	107,380	$	348,810	$	-
Operating lease obligations		29,415		1,984		12,650		7,040		7,741
Capital lease obligations		257		32		204		21		-
Purchase commitment		5,215		5,215		-		-		-
Total	$	499,110	$	15,264	$	120,234	$	355,871	$	7,741
(1) Includes principal and interest payments. Interest payments assume Senior Secured Facility borrowings and interest rates remain at the September 30, 2010 level until maturity.

Table of Contents

Item 3. Quantitative and Qualitative Disclosure About Market Risk

Exposure to market risk for changes in interest rates relates to our outstanding debt. At September 30, 2010 we had $314.8 million of long-term debt with approximately $89.6 million subject to variable interest rates and $3.8 million of short term debt, which was also subject to variable interest rates. We are exposed to interest rate risk primarily through our borrowing activities under the Senior Secured Facility discussed in Item 2 of this Report. A 1% increase in current market interest rates would have approximately $930,000 impact on our annual interest expense. We do not use financial instruments for trading or other speculative purposes and are not a party to any derivative financial instruments at this time.

Management does not believe that our exposure to interest rate market risk is material at this time because the variable interest rate negotiated in the Senior Secured Facility is subject to a rate floor. Market rates can increase and not cause an increase in our variable interest rate. Our Senior Secured Facility agreement provides for the use of interest rate swaps as a strategy to manage interest rate market risk. We regularly assess the significance of interest rate market risk as part of our treasury operations and as circumstances change and will enter into interest rate swaps as appropriate.

At September 30, 2010, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, claims payable, payables to Plan Sponsors and others approximate fair value due to their short-term nature. Borrowings under our Senior Secured Facility include debt with variable interest rates totaling $93.4 million at September 30, 2010. We believe the carrying value of our long-term debt under our Senior Secured Credit Facility approximates current market value.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported on a timely basis and that such information is accumulated and communicated to management, including the Chief Executive Officer (“CEO”) and the Chief Financial Officer (“CFO”) as appropriate, to allow for timely decisions regarding required disclosures. Based on their evaluation as of September 30, 2010, pursuant to Exchange Act Rule 13a-15(b), our management, including our CEO and CFO, believe that our disclosure controls and procedures are effective.

Except as set forth below, during the three months ended September 30, 2010, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

On March 25, 2010 we completed our acquisition of CHS. As permitted by the Securities and Exchange Commission, management has elected and plans to exclude CHS from management’s assessment of the effectiveness of our internal control over financial reporting as of December 31, 2010. We are currently integrating policies, processes, people, technology and operations for the combined company. Management will continue to evaluate our internal control over financial reporting as we execute acquisition integration activities.

Table of Contents

PART II

OTHER INFORMATION

Item 1. Legal Proceedings

We are subject to risks relating to litigation and other proceedings in connection with our operations, including the dispensing of pharmaceutical products by our mail service, infusion services and community pharmacies. While we believe that these suits are without merit and intend to contest them vigorously, we can give no assurance that an adverse outcome in one or more of these suits would not have a material adverse effect on our consolidated results of operations, consolidated financial position and/or consolidated cash flow from operations, or would not require us to make material changes to our business practices. We are presently responding to several subpoenas and requests for information from governmental agencies, including one from the United States Attorney’s Office in Minneapolis, MN. We cannot predict with certainty what the outcome of any of the foregoing might be. In addition to potential monetary liability arising from these suits and proceedings, we are incurring costs in the defense of the suits and in providing documents to government agencies. Many of the current pending claims and associated costs are covered by our insurance, but certain other costs are not insured, such as deductibles on each claim. While these costs are not currently material to our financial performance, there can be no assurance that such costs will not increase and/or become in the future.

The sellers of a company, Northland Pharmacy, acquired by one of our subsidiaries, are claiming a right to additional purchase price of at least $5.64 million in connection with an earn out provision in the stock purchase agreement regarding the acquisition. The sellers, named DiCello, first sued in federal court in Ohio in July 2007, but the court stayed the case and directed arbitration of the disagreement by the accounting firm KPMG, LLP, as the stock purchase agreement provides. We deny owing the sellers any additional purchase price. The parties have made extensive filings as directed by the arbitrator and are waiting for the arbitrator’s decision in the matter. We are confident in our position and do not believe an adverse ruling is likely; however, there can be no assurance that an adverse ruling will not be rendered . If the arbitrator rules in favor of DiCello, such ruling could have a material adverse effect on our business, operations or financial position.

On March 31, 2009, Professional Home Care Services, Inc. (“PHCS”), one of our subsidiaries, was sued by Alexander Infusion, LLC, a New York based home infusion company in the Supreme Court of the State of New York. The complaint alleges principally breach of contract arising in connection with PHCS’s failure to consummate an acquisition of Alexander after failing to satisfy the conditions to PHCS’s obligation to close. Alexander has sued for $2.5 million in damages. The Company believes Alexander’s claims to be without merit and intends to continue to defend against the allegations vigorously.

On September 18, 2008, a complaint was filed in federal court in New Mexico, naming BioScrip Pharmacy Services, Inc., a subsidiary of ours, as a defendant. The action is captioned Hope Huerta as Next Friend and Parent of Blanca M. Valdez, a minor v. Spectrum Chemicals and Laboratory Products, et. al., 1:08-cv-00853 (D. NM). The complaint alleges that our and the other defendants’ actions are responsible for alleged injuries to the plaintiff due to the administration of medication that allegedly had been recalled by the manufacturer, Spectrum Chemicals, and was dispensed by us. The complaint asserts various tort causes of action, including but not limited to, negligence, breach of warranties and violations of New Mexico statutes. The complaint seeks unspecified money damages, including punitive damages. The court grante d our motion for summary judgment and the plaintiffs filed a timely appeal. We intend to deny the allegations and defend the action vigorously.

Item 1A. Risk Factors

Please refer to Item 1A. Risk Factors included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2009 filed with the Securities and Exchange Commission (“SEC”) and incorporated herein by reference. There have been no material changes to the risk factors described in our most recent Form 10-K, other than related to the acquisition of CHS, as described below:

Risks Related to Our Business

We may not realize the anticipated benefits of our acquisition of CHS because of integration difficulties.

Integrating the operations of the businesses of CHS successfully or otherwise realizing any of the anticipated benefits of the merger with CHS, including anticipated cost savings and additional revenue opportunities, involves a number of potential challenges. The failure to meet these integration challenges could seriously harm our financial condition and results of operations.

Table of Contents

Realizing the benefits of the merger will depend in part on the integration of information technology, or IT, operations and personnel. These integration activities are complex and time-consuming and we may encounter unexpected difficulties or incur unexpected costs, including:

Our inability to achieve the cost savings and operating synergies anticipated in the merger, including synergies relating to increased purchasing efficiencies and a reduction in costs associated with the merger, which would prevent us from achieving the positive earnings gains expected as a result of the merger;

diversion of management attention from ongoing business concerns to integration matters;

difficulties in consolidating and rationalizing IT platforms and administrative infrastructures;

complexities associated with managing the geographic separation of the combined businesses and consolidating multiple physical locations where management may determine consolidation is desirable;

difficulties in integrating personnel from different corporate cultures while maintaining focus on providing consistent, high quality customer service;

challenges in demonstrating to customers of BioScrip and to customers of CHS that the merger will not result in adverse changes in customer service standards or business focus; and

possible cash flow interruption or loss of revenue as a result of change of ownership transitional matters.

We may not successfully integrate the operations of the businesses of CHS in a timely manner, and we may not realize the anticipated net reductions in costs and expenses and other benefits and synergies of the merger with CHS to the extent, or in the time frame, anticipated. The anticipated net reductions in costs and expenses are projections that are uncertain, and are based on assumptions and preliminary information which may prove to be inaccurate. In addition to the integration risks discussed above, our ability to realize these net reductions in costs and expenses and other benefits and synergies could be adversely impacted by practical or legal constraints on our ability to combine operations.

If we are unable to manage our growth profitably after the merger is completed, our business and financial results could suffer.

Our future financial results will depend in part on our ability to profitably manage our growth on a combined basis with CHS. Management will need to maintain existing customers and attract new customers, recruit, retain and effectively manage employees, as well as expand operations and integrate customer support and financial control systems. We expect to spend approximately $3.0 million of integration-related capital expenditures in the first 12 months after completion of the merger and to incur $5.0 million of integration-related expenses during that 12-month period. If the integration-related expenses and capital expenditure requirements are greater than anticipated or if we are unable to manage our growth profitably after the merger, our financial condition and results of operations may suffer.

A shortage of qualified registered nursing staff and other caregivers could adversely affect our ability to attract, train and retain qualified personnel and could increase operating costs after the merger.

Our business relies significantly on its ability to attract and retain caregivers who possess the skills, experience and licenses necessary to meet the requirements of its patients. We compete for personnel with other providers of the services we provide. Our ability to attract and retain caregivers after the merger will depend on several factors, including our ability to provide these caregivers with attractive assignments and competitive benefits and salaries. There can be no assurance that we will be successful in any of these areas. In addition, there are occasional shortages of qualified healthcare personnel in some of the markets in which we operate. As a result, we may face higher costs to attract caregivers and we may have to provide them with more attractive benefit packages than originally anticipated, either of which could cause our profitability to decline. Finally, if we expand our operations into geographic areas where healthcare providers historically have unionized or unionization occurs in our existing geographic areas, we cannot assure you that negotiating collective bargaining agreements will not have a negative effect on our ability to timely and successfully recruit qualified personnel. If we are unable to attract and retain caregivers, the quality of our services may decline and we could lose patients and referral sources.

Table of Contents

Subject to certain limitations, the former CHS stockholders and certain former optionholders of CHS may sell our common stock beginning September 26, 2010, which could cause our stock price to decline.

The shares of our common stock that the former CHS stockholders and certain former optionholders of CHS received in connection with the merger with CHS are restricted, but such former CHS stockholders and former optionholders may sell the shares of our common stock under certain circumstances. We have entered into a stockholders’ agreement with the former CHS stockholders and certain former optionholders of CHS, pursuant to which we have agreed to register their shares of our common stock with the SEC in order to facilitate sales of those shares. The sale of a substantial number of our shares by such parties or our other stockholders within a short period of time could cause our stock price to decline, making it more difficult for us to raise funds through future offerings of our common stock or acquire other businesses using ou r common stock as consideration.

Our issuance of common stock in the merger will increase the risk that we could experience an “ownership change” in the future that could significantly limit our ability to utilize our net operating losses.

As of September 30, 2010, BioScrip had net operating losses, or NOLs, for U.S. federal income tax purposes of approximately $17.8 million. Our ability to utilize our NOLs to offset future taxable income may be significantly limited if we experience an “ownership change” as defined in Section 382 of the Internal Revenue Code of 1986, as amended, which we refer to as the Code. In general, an ownership change will occur if there is a cumulative change in our ownership by “5-percent shareholders” that exceeds 50 percentage points over a rolling three-year period. A corporation that experiences an ownership change will generally be subject to an annual limitation on its pre-ownership change NOLs equal to the value of the corporation immediately before the ownership change, multiplied by the long- term tax-exempt rate (subject to certain adjustments). The annual limitation for a taxable year would be increased by the amount of any “recognized built-in gains” for such year and the amount of any unused annual limitation in a prior year.

We did not experience an ownership change upon the issuance of common stock in the merger. However, the issuance of common stock in the merger, together with other issuances of common stock during the applicable three-year period, could cause an ownership change under Section 382 of the Code. As a result, the issuance of our common stock in the merger will increase the risk that BioScrip could experience an ownership change during the three-year period following the merger.

Introduction of new drugs or accelerated adoption of existing lower margin drugs could cause us to experience a less profitable therapy mix when prescribers adopt these drugs for their patients.

The pharmaceutical industry pipeline of new drugs includes many drugs that, due to costs to develop and produce, may reduce our margins due to the prescribing of a lower margin drugs. An example would be an infused drug that is replaced with an oral medication. New as well as existing drug technologies may also cause us to experience higher drug costs which would also reduce our margins.

The loss of a relationship with one or more of our discount cash card brokers could negatively impact our business.

Our contracts with discount cash card brokers are typically subject to termination by a broker’s written notice 90 days prior to effective date. Depending on the amount of revenues generated by any broker agreement, one or more terminations could have a material and adverse effect on our results of operations and financial performance. We are unaware of any intention by a discount cash card broker to terminate or not renew an agreement with us.

Table of Contents

Risks Related to the New Notes

The significant indebtedness incurred to complete the acquisition imposed operating and financial restrictions on us which, together with the resulting debt service obligations, may significantly limit our ability to execute our business strategy and increase the risk of default under our debt obligations.

We incurred an aggregate of approximately $325.0 million of indebtedness (not including up to $50.0 million that would also be available under our new revolving credit facility) in connection with the acquisition of CHS. The terms of our new credit facilities require us to comply with certain financial covenants, including a maximum total leverage ratio and a minimum fixed charge coverage ratio. In addition, the terms of our new indebtedness also include certain covenants restricting or limiting our ability to, among other things:

Incur indebtedness or liens;

make investments or capital expenditures;

engage in mergers, acquisitions or asset sales;

declare dividends or redeem or repurchase capital stock;

modify our organizational documents; and

change our fiscal year.

These covenants may adversely affect our ability to finance future operations or limit our ability to pursue certain business opportunities or take certain corporate actions. The covenants may also restrict our flexibility in planning for changes in our business and the industry and make us more vulnerable to economic downturns and adverse developments.

Our ability to meet our cash requirements, including our debt service obligations, will be dependent upon our ability to substantially improve our operating performance, which will be subject to general economic and competitive conditions and to financial, business and other factors affecting our operations, many of which are or may be beyond our control. In addition, the New Credit Facility has interest payments that are subject to variable interest rates and are therefore dependent upon future fluctuations in interest rates, which are beyond our control. We expect to use cash flow from operations to pay our expenses and amounts due under the new notes and our other outstanding indebtedness. We cannot provide assurance that our business operations will generate sufficient cash flows from operations to fund these cash requirements and debt service obligations. If our operating results, cash flow or capital resources prove inadequate, or if interest rates increase significantly, we could face substantial liquidity problems and might be required to dispose of material assets or operations to meet our debt and other obligations. If we are unable to service our debt, we could be forced to reduce or delay planned expansions and capital expenditures, sell assets, restructure or refinance our debt or seek additional equity capital, and we may be unable to take any of these actions on satisfactory terms or in a timely manner. Further, any of these actions may not be sufficient to allow us to service our debt obligations or may have an adverse impact on our business. Our failure to generate sufficient operating cash flow to pay our debts or to successfully undertake any of these actions could have a material adverse effect on us.

In addition, the degree to which we may be leveraged as a result of the indebtedness incurred in connection with the merger or otherwise could:

Materially and adversely affect our ability to obtain additional financing for working capital, capital expenditures, acquisitions, debt service requirements or other purposes;

make us more vulnerable to general adverse economic, regulatory and industry conditions;

limit our flexibility in planning for, or reacting to, changes and opportunities in the markets in which we compete;

place us at a competitive disadvantage compared to our competitors that have less debt or could require us to dedicate a substantial portion of our cash flow to service our debt;

make it more difficult for us to satisfy our obligations with respect to the new notes;

reduce the funds available to us for operations and other purposes;

limit our ability to fund the repurchase of the new notes upon a change of control; or

restrict us from making strategic acquisitions or exploiting other business opportunities.

Table of Contents

The new notes are not secured by our assets or those of our guarantor subsidiaries.

The new notes and the related guarantees are our and our guarantor subsidiaries’ general unsecured obligations and are effectively subordinated in right of payment to all of our and our guarantor subsidiaries’ secured indebtedness and obligations, including all indebtedness under the New Credit Facility. If we become insolvent or are liquidated, or if payment under any of the instruments governing our secured debt is accelerated, the lenders under those instruments will be entitled to exercise the remedies available to a secured lender under applicable law and pursuant to the instruments governing such debt. Accordingly, our secured indebtedness and obligations, including all indebtedness under the New Credit Facility, is effectively senior to the new notes to the extent of the value of the collateral securing that indebte dness. In that event, because the new notes and the guarantees will not be secured by any of our assets, it is possible that our remaining assets might be insufficient to satisfy claims of holders of the new notes in full or at all.

As of September 30, 2010, we had approximately $93.4 million aggregate principal amount of secured indebtedness outstanding under the New Credit Facility. Additionally, under the terms of our prime vendor agreement with our primary drug wholesaler, we granted our primary drug wholesaler a secured second primary lien in all of our inventory as well as the proceeds thereof. Any additional borrowings pursuant to our existing or future credit facilities would also be secured indebtedness, if incurred. Although the indenture governing the new notes contains limitations on the amount of additional indebtedness that we may incur, under certain circumstances the amount of such indebtedness could be substantial and, under certain circumstances, such indebtedness may be secured indebtedness.

Despite our substantial indebtedness, we may still incur significantly more debt. This could exacerbate the risks associated with our substantial leverage.

We may be able to incur substantial additional indebtedness, including additional secured indebtedness, in the future. Although the indenture governing the new notes and the New Credit Facility contain restrictions on the incurrence of additional debt, these restrictions are subject to a number of qualifications and exceptions and, under certain circumstances, debt incurred in compliance with these restrictions, including secured debt, could be substantial. The New Credit Facility permits, among other things, revolving credit borrowings of up to $50.0 million. Adding additional debt to current debt levels could exacerbate the leverage-related risks described above.

To service our indebtedness and other obligations, we will require a significant amount of cash. Our ability to generate cash depends on many factors beyond our control.

Our ability to make payments on and to refinance our indebtedness, including the new notes, and to fund working capital needs and planned capital expenditures will depend on our ability to generate cash in the future. A significant reduction in our operating cash flows resulting from changes in economic conditions, increased competition or other events beyond our control could increase the need for additional or alternative sources of liquidity and could have a material adverse effect on our business, financial condition, results of operations, prospects and our ability to service our debt and other obligations.

We cannot assure you that our business will generate sufficient cash flows from operations or that future borrowings will be available to us under the New Credit Facility or otherwise in an amount sufficient to enable us to pay our indebtedness, including our indebtedness under the New Credit Facility and the new notes, or to fund our other liquidity needs. We may need to refinance all or a portion of our indebtedness, including the new notes, on or before the maturity of the debt. We cannot assure you that we will be able to refinance any of our indebtedness on commercially reasonable terms or at all.

Table of Contents

If we default on our obligations to pay our indebtedness, we may not be able to make payments on the new notes.

Any default under the agreements governing our indebtedness, including a default under the New Credit Facility, that is not waived by the required lenders, and the remedies sought by the holders of such indebtedness, could prevent us from paying principal, premium, if any, and interest on the new notes and substantially decrease the market value of the new notes. If we are unable to generate sufficient cash flow and are otherwise unable to obtain funds necessary to meet required payments of principal, premium, if any, and interest on our indebtedness, or if we otherwise fail to comply with the various covenants, including financial and operating covenants, in the instruments governing our indebtedness (including covenants in the New Credit Facility and the indenture governing the new notes), we could be in default under the terms of t he agreements governing such indebtedness. In the event of such default, the holders of such indebtedness could elect to declare all the funds borrowed thereunder to be due and payable, together with accrued and unpaid interest, the lenders under the New Credit Facility could elect to terminate their commitments thereunder, and cease making further loans and institute foreclosure proceedings against our assets, and we could be forced into bankruptcy or liquidation. If our operating performance declines, we may in the future need to obtain waivers from the required lenders under the New Credit Facility or holders of other indebtedness to avoid being in default. If we breach our covenants under the New Credit Facility or any other indebtedness and seek a waiver, we may not be able to obtain a waiver from the required lenders. If this occurs, we would be in default under the New Credit Facility or such other indebtedness, the lenders could exercise their rights, as described above, and we could be forced into b ankruptcy or liquidation.

The new notes may impose significant operating and financial restrictions, which may prevent us from pursuing our business strategies or favorable business opportunities.

Subject to a number of important exceptions, the indenture governing the new notes and the New Credit Facility may limit our ability to:

Incur or guarantee additional indebtedness or issue certain preferred stock;

transfer or sell assets;

make certain investments;

pay dividends or distributions, redeem subordinated indebtedness or make other restricted payments;

create or incur liens;

incur dividend or other payment restrictions affecting certain subsidiaries;

issue capital stock of our subsidiaries;

consummate a merger, consolidation or sale of all or substantially all of our assets; and

enter into transactions with affiliates.

Consequently, the restrictions contained in the indenture governing the new notes and the New Credit Facility may prevent us from taking actions that we believe would be in the best interest of our business, and may make it difficult for us to successfully execute our business strategy or effectively compete with companies that are not similarly restricted. Additionally, the terms of the New Credit Facility require us to comply with certain financial covenants, including a maximum total leverage ratio and a minimum fixed charge coverage ratio. We cannot assure you that we will meet those tests or that the lenders under the New Credit Facility will waive any failure to meet those tests.

A breach of any of these covenants or the inability to comply with the required financial ratios could result in a default under the New Credit Facility or the indenture governing the new notes, as applicable. If any such default occurs, the lenders under the New Credit Facility and the holders of the new notes may elect to declare all of their respective outstanding debt, together with accrued interest and other amounts payable thereunder, to be immediately due and payable. The lenders under the New Credit Facility also have the right in these circumstances to terminate any commitments they have to provide further borrowings. If we were unable to pay such amounts, the lenders under the New Credit Facility could proceed against the collateral pledged to them. We will pledge a substantial porti on of our assets to the lenders under the New Credit Facility. In such an event, we cannot assure you that we would have sufficient assets to pay amounts due on the new notes. As a result, you may receive less than the full amount you would otherwise be entitled to receive on the new notes.

Table of Contents

We may not be able to satisfy our obligations to holders of the new notes upon a Change of Control or Asset Sale.

Upon the occurrence of a Change of Control, holders of the new notes will have the right to require us to purchase the new notes at a price equal to 101% of the principal amount of such new notes, plus any accrued and unpaid interest to the date of purchase.

In addition, upon the occurrence of an Asset Sale, holders of the new notes may, under certain circumstances, have the right to require us to purchase a portion of the new notes at a price equal to 100% of the principal amount of such new notes, plus any accrued and unpaid interest to the date of purchase.

We cannot assure you that, if a Change of Control offer or Asset Sale offer is made, we will have available funds sufficient to pay the Change of Control purchase price or Asset Sale purchase price for any or all of the new notes that might be delivered by holders of the new notes seeking to exercise the Change of Control put right or Asset Sale put right. If we are required to purchase new notes pursuant to a Change of Control offer or Asset Sale offer, we would be required to seek third-party financing to the extent we do not have available funds to meet our purchase obligations. There can be no assurance that we will be able to obtain such financing on acceptable terms to us or at all. Accordingly, none of the holders of the new notes may receive the Change of Control purchase price or Asset Sale purchase price for their new notes. Our failure to make or consummate the Change of Control offer or Asset Sale offer, or to pay the Change of Control purchase price or Asset Sale purchase price when due, will give the holders of the new notes the rights described in “Description of Notes — Events of Default and Remedies”, which is in the Company’s Form S-4 filed with the SEC on June 22, 2010.

In addition, the events that constitute a Change of Control or Asset Sale under the indenture governing the new notes may also be events of default under the New Credit Facility. These events may permit the lenders under the New Credit Facility to accelerate the debt outstanding thereunder and, if such debt is not paid, to enforce security interests in our specified assets, thereby limiting our ability to raise cash to purchase the new notes and reducing the practical benefit of the offer-to-purchase provisions to the holders of the new notes.

The trading prices of the new notes will be directly affected by our ratings with major credit rating agencies, the prevailing interest rates being paid by companies similar to us, and the overall condition of the financial and credit markets.

The trading prices of the new notes in the secondary market will be directly affected by our ratings with major credit rating agencies, the prevailing interest rates being paid by companies similar to us, and the overall condition of the financial and credit markets. It is impossible to predict the prevailing interest rates or the condition of the financial and credit markets. Credit rating agencies continually revise their ratings for companies that they follow, including us. Any ratings downgrade could adversely affect the trading price of the new notes or the trading market for the new notes, to the extent a trading market for the new notes develops. The condition of the financial and credit markets and prevailing interest rates have fluctuated in the past and are likely to fluctuate in the future.

A subsidiary guarantee could be voided if it constitutes a fraudulent transfer under U.S. bankruptcy or similar state law, which would prevent the holders of the new notes from relying on that subsidiary to satisfy claims.

The new notes are guaranteed by our domestic restricted subsidiaries. The guarantees may be subject to review under U.S. federal bankruptcy law and comparable provisions of state fraudulent conveyance laws if a bankruptcy or another similar case or lawsuit is commenced by or on behalf of our or a guarantor subsidiary’s unpaid creditors or another authorized party. Under these laws, if a court were to find that, at the time any guarantor subsidiary issued a guarantee of the new notes, either it issued the guarantee to delay, hinder or defraud present or future creditors or it received less than reasonably equivalent value or fair consideration for issuing the guarantee and at the time:

It was insolvent or rendered insolvent by reason of issuing the guarantee;

it was engaged, or about to engage, in a business or transaction for which its remaining unencumbered assets constituted unreasonably small capital to carry on its business;

it intended to incur, or believed that it would incur, debts beyond its ability to pay as they mature; or

it was a defendant in an action for money damages, or had a judgment for money damages docketed against it if, in either case, after final judgment, the judgment is unsatisfied, then the court could void the obligations under the guarantee, subordinate the guarantee of the new notes to other debt or take other action detrimental to holders of the new notes.

Table of Contents

We cannot be sure as to the standard that a court would use to determine whether a guarantor subsidiary was solvent at the relevant time, or, regardless of the standard that the court uses, that the issuance of the guarantees would not be voided or that the guarantees would not be subordinated to other debt. If such a case were to occur, the guarantee could also be subject to the claim that, since the guarantee was incurred for our benefit, and only indirectly for the benefit of the guarantor subsidiary, the obligations of the applicable guarantor subsidiary were incurred for less than fair consideration. A court could thus void the obligations under the guarantee, subordinate the guarantee to the applicable guarantor subsidiary’s other debt or take other action detrimental to holders of the new notes. If a court were to void a guarantee, you would no longer have a claim against the guarantor subsidiary. Sufficient funds to repay the new notes may not be available from other sources, including the remaining guarantor subsidiaries, if any. In addition, the court might direct you to repay any amounts that you already received from or are attributable to the guarantor subsidiary.

Each subsidiary guarantee contains a provision intended to limit the guarantor subsidiary’s liability to the maximum amount that it could incur without causing the incurrence of obligations under its subsidiary guarantee to be a fraudulent transfer. This provision may not be effective to protect the subsidiary guarantees from being voided under fraudulent transfer law.

Our subsidiary guarantors may be unable to fulfill their obligations under their guarantees.

The ability of our subsidiary guarantors to make any required payments under their guarantees depends on our future performance, which will be affected by financial, business, economic, and other factors, many of which we cannot control. Such subsidiaries’ businesses may not generate sufficient cash flow from operations in the future and their anticipated growth in revenue and cash flow may not be realized, either or both of which could result in their being unable to honor their guarantees or to fund other liquidity needs. If such subsidiaries do not have enough money, they may be required to refinance all or part of their then-existing debt, sell assets, or borrow more money. They may not be able to accomplish any of these alternatives on terms acceptable to them, or at all. In addition, the terms of existing or future debt ag reements, including the New Credit Facility and the indenture governing the new notes, may restrict such subsidiaries from adopting any of these alternatives. The failure of our subsidiaries to generate sufficient cash flow or to achieve any of these alternatives could materially and adversely affect the value of the new notes and the ability of such subsidiaries to pay the amounts due under their guarantees, if any.

Table of Contents

Item 6. Exhibits

(a) Exhibits.

Exhibit 3.1	Second Amended and Restated Certificate of Incorporation of BioScrip, Inc. (Incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form S-4 (File No. 333-119098), as amended, which became effective on January 26, 2005)
Exhibit 3.2	Amended and Restated By-Laws of BioScrip, Inc. (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 16, 2007, accession No. 0000950123-07-007569)
Exhibit 31.1	Certification of Richard H. Friedman pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 31.2	Certification of Stanley G. Rosenbaum pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 32.1	Certification of Richard H. Friedman pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 32.2	Certification of Stanley G. Rosenbaum pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOSCRIP, INC.

Date: November 3, 2010	/s/ Phillip J. Keller
	Phillip J. Keller, Senior Vice President of Finance and
	Principal Accounting Officer

EX-31.1 2 ceo302cert.htm 302 CERTIFICATION OF CEO ceo302cert.htm

EXHIBIT 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Richard H. Friedman, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of BioScrip, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 3, 2010

/s/ Richard H. Friedman

Richard H. Friedman,

Chief Executive Officer

EX-31.2 3 cfo302cert.htm 302 CERTIFICATION OF CFO cfo302cert.htm

EXHIBIT 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Stanley G. Rosenbaum, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of BioScrip, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 3, 2010

/s/ Stanley G. Rosenbaum

Stanley G. Rosenbaum, Chief Financial Officer,

Treasurer and Principal Financial Officer

EX-32.1 4 ceo906cert.htm 906 CERTIFICATION OF CEO ceo906cert.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioScrip, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Richard H. Friedman, Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 3, 2010

/s/ Richard H. Friedman

Richard H. Friedman,

Chief Executive Officer

EX-32.2 5 cfo906cert.htm 906 CERTIFICATION OF CFO cfo906cert.htm

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioScrip, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stanley G. Rosenbaum, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 3, 2010

/s/ Stanley G. Rosenbaum

Stanley G. Rosenbaum, Chief Financial Officer,

Treasurer and Principal Financial Officer

GRAPHIC 6 bioscriplogo1.jpg BIOSLOGO begin 644 bioscriplogo1.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0"B17AI9@``24DJ``@````%`!H!!0`! M````2@```!L!!0`!````4@```"@!`P`!`````@```#$!`@`0````6@```&F' M!``!````:@````````!@`````0```&`````!````4&%I;G0N3D54('8T+C`P M``$`AI("`!T```!\`````````$Q%040@5&5C:&YO;&]G:65S($EN8RX@5C$N M,#$``/_;`$,``@$!`0$!`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8' M"0@&!PD'!@8("P@)"@H*"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H' M!@<*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H* M"@H*"@H*"O_``!$(`#``D0,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0`````` M`````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q M008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4 ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+C MY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4& M!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R M@0@40I&AL<$)(S-2\!5B7J"@X2%AH>(B8J2DY25EI>8F9JB MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(RKR M\_3U]O?X^?K_V@`,`P$``A$#$0`_`/WZSM!;C%`/&"/I7-?%MC'X!O/9H?\` MT='3+;XA>"[%X=#N/$,*7`B5!D-LSM_OXV_K4N5G8YI8BG"NZ/+'2=2\+7=EKFI_9;20)YDX/^K^9=O_CV*OSW-CIF MG?;IKA8X(HLF5ST6KZ&G/:;3T25]_P!"[MSQC%)\JUAZ#X]\)>(YSI^CZK$\ MB<&/:R?]\[@-WX5NG;[?E2'"<*D;Q=T5+V\M=-M'N]0NHH(HQF2260(B#ZGI M5'P]XU\(>+?-'A?Q9IVH^4?WQL+R.79_O;"<5S(+?[18^'X M;<6EC,086N)%:1IV7^)E&U5SP/G(YZ7?B!X%TS5](DU333#IVK6$7F:7JB!4 M>W=02N6[QG[K*>"N:W5.":C)N[MZ*^J.-UZ\E*I!)Q3:M?5VT=NB.O).0303 MG`4"O/\`P_\`'3P[XBT>SO=#TK4-6N)H$>ZATBS:9+=]OS*TC83<&^7;NS[5 MO^%_'F@>*II[&S,]M>6H'VK3KV!H9H@W1F5NJGLPR/>HG0JT[N2M8VI8O#U; M*,EKL=%DD?X4GS=QGVKG_&OQ#\%?#RP&H^,/$-OI\3<1"0_/(?157+-^`JOX M%^+7P[^(_G0^"_$\-X]OQ+"`R./]K:P#;?\`:QBA4:KI\_*^7O9V^\;Q6%C6 M5)U%S/I=7^XZC)!Q0.#Q^5%6\:6GB2S?2XUS)>B8;(QWW?W3STZ\TO85N52Y79[.V_H)8S M"RG*FIQYENKJZ7F=`>/PHW`C.>G7BN0A^-'PJNM0L='M_'%C)MW8YY9E05:$(-24FTVFM+*^W7Y'L.WS;0=O\`P+%=E:WD%[;Q7%E<))%(H>-X\%77 MVK.I1JTK.<6D^Z9TT<7AL1)QI34FMTFG;UL7**3/XRN[=]=WS5%\9A_Q;K43[P_^C4I MVD^,-)M/`D.L-<1JMO:A98L_.'5=NS;_`'MPQBI?Q'G5/9+&3Y_Y5^;N>'O%+J/(T^[V3-_<2557= M1+HS][^6%_2^H[XLVT&E>&H/$MG;XGTFYAD@\KY,C<%V_P"[STK7\4>* M]*\(:8=5U=I,/*D4$$$9>6XE;[L4:+RSGT^IZ9K%^*M_9ZOX?M_"VG7<4EQJ MUU`D:)A_DW;M_'\/R_>I_BUK>R^)7A:\U9?]&\N]@MI'QLBNW6/R_P`3&LZC M_>QWK2C%2G9^;^Y'1.HZ=2&;;78 MO[-GFO2EU-YBAIH7:.-@BM_K4&7;[W(Z5DWLSZIXT^S^(#-XRMM`O7BEABA6 M7Y+B)9(I6CCQ%YD74?^$BLWM[K0XH8UBLA)%YD!56 M/RY50-OY(9LDUZ>'G&I&]K-:?\&^^VFZ/)QU&=&MR1I=W^R&2-O8A?6N0U^X^(M@NA^+++P+IWA:+3] MEG=2S7"3>7!^&_`L>AW\GB#5M6N=4U6:+RVU"]" MYC3.?+CC0!8US\Q`Y/O"_C/QSHLVH>&4LO+E@:$O&9-TFY=O1F^9&VGJ% MQ6]\/O!OPB\5?%JS^*OP@\7:=9P65C_IF@V5CY+R;ED7>PW#:OSKT3&5Z\U; M^*GQCG\&?&.S\!^/]+TT^$-1L_,EN;RS>3#[7^JG#JN>.`V:\^M;3P`_[4OA M]?@.`8`I?5?LA;R4^]OQN_AV=>V=N.:]:C&K/"I.\?<=FM8M=GV?0^:Q4J%' M,I2C::=17B])J6B333U6SLS4_9G\%>&?C#K_`(N^(GCO2H=5DGU$QPB[^=(] MVYFPO^[L`]!TJUJOP4U_X.?"[XB1KJUL^BZA%YFFVD,S%[=5D.W=N4<^6R@\ MG.P51_9\\;>&?@7XN\7?#CX@ZF-+\K4?,LY9PP20+N]/56C8>HI[_$WQS\6/ MAI\2=>O;W/AVWC\O0SY*IQOW?>50QPFS.<_>JZJQ7UN\7^[O"U]K75K>?H94 M'EW]G1C)?O[5+VW3L[N76UNYO?LO_`;X?1^`=(\?ZMH_VK5II/M<-U-,_P"X MVNWEA5W8XQGGO7&^!L>3\;_^N5U_Z,N:]I_9FS_PHKP\`/\`ER?_`-&-7BG@ M,?N/C=G_`)YW7_HRYJ*-6I5Q&(YW>S27DN9;&V)PU'#X/!^SBE>,F[*UVZ>[ M[LZ/]G?X`^`/%GP%&IZYH$-QJ.J"Z\N[E'[RWVNT:[6_AP4S[]\BNK_8Q\2S M:Y\&8["J?+(OZ28_"N*_9Z_:)\">"O@8_AO7]56VO])$_V>T, M9!N-SM(NS_@3;?;&3Q7:_L;>%;CPS\&([F^@$1U:_FO`I_N-MC4_BJ9'L166 M8+$*G6]M?XERW^>WR['3DCPDL1AOJUK^S?/;>_N[];W[GK]%%%?/GW!4O[&Q MO[7[%?VLZT.5@J) M<))\S0ACUD23=\I.=K)CCIZ(`0<<>QJCJ6B:5K6GMIVKZ9;W5M(/G@N85D0C MW5ABM57FTXS?NO\`J_JAR7Q6UW3]5TF7X9Z)WA9@)+B3^XJ+N.3U;`')KN@Q"@]_3-9V@^%O#/A6T-EX9\/6>G1` M?ZFRLUB3\E4"M,`L-QX-1*4>516R-J-.JJDJDVKNRLMDE_PYA^+/`WA#QQ9+ MI_B[PY:ZA%'\\8GBSL/JI^\I^E,\)_#?P1X$24>$?#%I8&7_`%TL$?SR?[S' MD_G708`'-(0N.M-5JBI\BD[=KZ? MF*V"%4=.M(%R.:'5J\JBY.RVUV!87#*@KC/3I32HW'`!]113JSA4YK];^OJ37PM&M1<+):-+1:75M.QXC^SI\% M?".I?"+3C\1/AW$-1BFN`1J5ELGV>:VW=NPV/3=7M4$,-M$L,"!41<*HZ5+C M`XH'4Y/:M,1B:N(JN4NK;MV]#/`8"AE]"-.FEHDF[6;LNHZBDPW][]**P.X_ "_]D_ ` end EX-101.PRE 7 bios-20100930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION EX-101.INS 8 bios-20100930.xml XBRL INSTANCE DOCUMENT 0001014739 2009-06-30 0001014739 2009-01-01 2009-09-30 0001014739 2008-12-31 0001014739 2009-12-31 0001014739 2009-09-30 0001014739 2010-01-01 2010-09-30 0001014739 2010-07-01 2010-09-30 0001014739 2009-07-01 2009-09-30 0001014739 2010-09-30 0001014739 2010-10-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares Q3 No

5038000

1432000

50979000

2726000

2385000

54210

40184

49232

39345

595000

6694000

false -1000000 0

0.04

0.14

-0.04

0.34

365769000

291980000

1000426000

872100000

22723000

15454000

Yes

-10834000

-2606000

1326000

2196000

10-Q 125041731

50979000

53425

38961

49232

38807

56632871

42766478

0.0001

Yes 0001014739

1803000

741000

150269000

-9457000

-6618000

-1014000

5000000

19960000

12913000

--12-31 BioScrip, Inc.

6747000

4522000

1272000

12204000

6661000

19421000

16129000

265815000

155793000

478066000

131427000

3527000

84782000

74535000

-72000

300310000

997920000

1197000

562000

55950000

32402000

146978000

94335000

75384000

41496000

187825000

115874000

53688338

39675865

16408000

11504000

16170000 4938000

323798000

24498000

-2250000

330699000

1008747000

5890000

13979000

-10564000

5913000

6211000

3596000

5309000

2433000

12536000

5410000

366901000

254677000

3796000

3224000

314752000

16519000 3999000

128952000

3864000

30389000

340254000

219281000

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTE 6 – EARNINGS PER SHARE</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table sets forth the computation of basic and diluted income per common share (in thousands, except for per share amounts):</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"> </div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three Months Ended</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended</font></div></td></tr><tr><td style="PADDIN G-BOTTOM: 2px" valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</f ont></div></td></tr><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"& gt;<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Numerator:</font></div></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FA MILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZ E: 10pt; FONT-FAMILY: times new roman">Net income (loss)</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,965</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%">&l t;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,747</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,075</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="botto m" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,409</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Denominator - Basic:</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td> ;<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline ; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Weighted average number of common shares o utstanding</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">53,425</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">38,961</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49,232</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1 %"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">38,807</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic income (loss) per common share</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="D ISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.04</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.15</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width= "1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.04</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.35</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52 %"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Denominator - Diluted:</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign=" bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Weighted average number of common shares outstanding</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">53,425</font></td><td style="TEXT-ALIGN: left" valign="b ottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">38,961</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roma n">49,232</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">38,807</font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Common share equivalents of outstanding stock options and restricted awards</font></div ></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">785</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times n ew roman">1,223</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZ E: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">538</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total diluted shares outstanding</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">54,210</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">40,184</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49,232</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39,345</font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="botto m" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Diluted income (loss) per common share</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.04</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font sty le="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.14</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.04</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1 %"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.34</font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The computation of basic and diluted shares for the three and nine months ended September 30, 2010 includes the weighted average effect of the approximately 13.1 million shares issued and outstanding in connection with the acquisition of CHS on March 25, 2010.  The computation of diluted shares for the three and nine months ended September 30, 2010 excludes the effect of 3.4 million warrants with an exercise price of $10 issued in connection with the acquisition of CHS as well as 4.9 million and 4.0 million shares, respectively, of other common stock equivalents as their inclusion would be anti-dilutive.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The computation of diluted shares for the three and nine months ended September 30, 2009 excludes the effect of 3.0 million and 4.5 million shares, respectively, of stock options as their inclusion would have been anti-diluti ve.</font></div>

2990000

1448000

1250000

0.04

0.15

-0.04

0.35

2010-09-30

<div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTE 7 – OPERATING SEGMENTS</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In accordance with ASC Topic 280, <font style="DISPLAY: inline; FONT-STYLE: italic">Segment Reporting </font>(“ASC 280”), and based on the nature of the Company’s services prior to the acquisition of CHS, the Company historically had two operating and reportable segments: “Specialty Pharmacy Services” and “Traditional Pharmacy Services&a mp;#8221;.  The acquisition and integration of CHS has resulted in a change to the Company’s operating and reportable segments.  Effective April 2010, the Company has two new operating and reportable segments: “Infusion/Home Health Services” and “Pharmacy Services”.  Prior period disclosures reflect the change in reportable segments.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Infusion/Home Health Services operating and reportable segment consists of the Company’s legacy infusion therapy business combined with the infusion, respiratory, durable medical equipment (“DME”) and home health businesses obtained in the CHS acquisition.& ;#160; The infusion services provided in this segment includes home infusion therapy, respiratory therapy and DME.  Infusion services include the dispensing and administering of infusion based drugs, which typically require additional nursing and clinical management services, equipment to administer the correct dosage and patient training designed to improve patient outcomes.  Through the home health services provided in this segment, the Company provides skilled nursing and therapy visits, private duty nursing services, rehabilitation services, hospice and medical social services to patients primarily in their home.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Pharmacy Services operating and reportable segment consists of the Company’s traditional and specialty pharmacy mail operations and community pharmacies, prescription discount card programs and integrated pharmacy benefit management (“PBM”) services.  These segment services are designed to offer customers and patients cost-effective delivery of traditional and specialty pharmacy services.  The services also include care management programs customized to each patients care plan in coordination with doctors.  In addition, the DS Pharmacy business is included in this segment.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company’s chief operating decision maker evaluates segment performance and allocates resources based on net income ( loss) adjusted for net interest expense, income tax expense, depreciation, amortization and stock-based compensation expense (“Segment Adjusted EBITDA”) and prior to the allocation of corporate expenses.  Segment Adjusted EBITDA excludes the write-off of receivables owed at the time the CAP contract terminated and acquisition, integration and severance expenses.   The accounting policies of the operating and reportable segments are consistent with those described in the Company’s summary of significant accounting policies.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Segment Reporting Information</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDEN T: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(in thousands)</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three Months Ended</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="D ISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FON T-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  < ;/font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowra p"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2 009</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Results of Operations:</font></div></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FON T-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bo ttom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Revenue:</font></div></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="D ISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Infusion/Home Health Services</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">111,849</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">36,809</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: t imes new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">264,625</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">107,613</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%">< ;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Pharmacy Services</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">329,304</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%" ><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">296,667</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIG N: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">923,626</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">880,361</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">        Total</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">441,153</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font&g t;</td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">333,476</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> ;1,188,251</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">987,974</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-F AMILY: times new roman">  </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"& gt; </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" colspan="3"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjusted EBITDA by Segment before corporate overhead:</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY : inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom">< font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Infusion/Home Health Services</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,942</font></td>&l t;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,586</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FA MILY: times new roman">31,702</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,420</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font sty le="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Pharmacy Services</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,731</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style= "BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,224</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31,120</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> & lt;/font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">34,521</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">        Total Segmen t Adjusted EBITDA</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25,673</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,810</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" w idth="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">62,822</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">41,941</font> ;</td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width= "1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&am p;#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Corporate overhead</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,602</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,896</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" widt h="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(23,646</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(19,831</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font>&l t;/td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font s tyle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> ;</td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest expense, net</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: t imes new roman">(8,122</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(447</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><fon t style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(19,515</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,471</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"& gt;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Income tax expense</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,117</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(467</font> </td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,981</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,249</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Depreciation</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,404</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font styl e="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,356</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,211</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,596</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amortization</font></div></td><t d style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,326</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMI LY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,196</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%" ><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation expense</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,097</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-A LIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(897</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,726</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times ne w roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,385</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Acquisition, integration and severance expenses</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,040</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN : left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,139</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman "> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bad debt expense related to contract termination</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&am p;#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-F AMILY: times new roman">(1,483</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div sty le="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net income (loss):</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,965</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,747</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,075</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FON T-FAMILY: times new roman">)</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,409</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" w idth="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&g t; </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Supplemental Operating Data</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style ="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>&l t;/td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Capital Expenditures:</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="botto m" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roma n"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Infusion/Home Health Services</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">977</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%">< ;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">48</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,229</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td styl e="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">376</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Pharmacy Services</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,104</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">545</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1% "><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,044</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,010</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </f ont></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Corporate unallocated</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">324</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#1 60;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMIL Y: times new roman">1,474</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,136</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><d iv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">        Total</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,405</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">593</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,747</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowra p" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,522</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times n ew roman">Depreciation Expense:</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign=" bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Infusion/Home Health Services</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,128</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowr ap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">277</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,381</font></td><t d style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">904</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">     Pharmacy Services</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">954</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">858</font></td><td style="TEXT-ALIGN: left" valign="bottom" now rap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,019</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,950 </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Corporate unallocated</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">322</font>& lt;/td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">221</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times ne w roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">811</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">742</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZ E: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">        Total</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,404</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font styl e="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,356</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width=" 9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,211</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,596</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" a lign="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total Assets</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: righ t" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Infusion/Home Health Services</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" v align="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: tim es new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">438,705</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">52,954</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="l eft" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Pharmacy Services</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>< ;/td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">143,153</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: in line; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">121,081</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Corporate unallocated</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman "> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: time s new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">162,023</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline ; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">66,145</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">        Total</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SI ZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-S IZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">743,881</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">240,180</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style=" DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Goodwill</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" w idth="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&g t; </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Infusion/Home Health Services</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width=" 1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">& ;#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">299,300</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Pharmacy Services</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE : 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24,498</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24,498</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bott om" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">        Total</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: in line; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">323,798</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%">< font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24,498</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr></table></div></div>

-105180000

-4522000

-4969000 0 -963000 1048000

7100000

-14027000

441153000

333476000

1188251000

987974000

6000

4000

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTE 8 – STOCK-BASED COMPENSATION PLANS</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioScrip Equity Incentive Plans</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under the Company’s Amended and Rest ated 2008 Equity Incentive Plan, as amended (the “2008 Plan”) the Company may issue, among other things, incentive stock options (“ISOs”), non-qualified stock options (“NQSOs”), stock appreciation rights, restricted stock, performance shares and performance units to employees and directors.  Under the 2008 Plan, 3,580,000 shares were originally authorized for issuance (subject to adjustment for grants made under the Company’s 2001 Incentive Stock Plan (the “2001 Plan”) after January 1, 2008, as well as for forfeitures, expirations or awards that under the 2001 Plan otherwise settled in cash after the adoption thereof).  On June 10, 2010, the Company’s stockholders approved an amendment to the 2008 Plan to increase the number of authorized shares of common stock available for issuance by 3,275,000 shares to 6,855,000 shares.  As of September 30, 2010, there were 2,271,074 shares that remained available for grant under the 2008 Plan.  Upon the effective date of the 2008 Plan, the Company ceased making grants under the 2001 Plan.  The 2008 Plan and the 2001 Plan are administered by the Company’s Management Development and Compensation Committee (the “Compensation Committee”), a standing committee of the Board.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioScrip/CHS Equity Plan</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY : Times New Roman">Effective upon closing of the acquisition of CHS, the CHS 2006 Equity Incentive Plan was adopted by the Company and renamed the “BioScrip/CHS 2006 Equity Incentive Plan” (the “BioScrip/CHS Plan”).  There were 13,000,000 shares of CHS common stock originally authorized for issuance under the CHS 2006 Equity Incentive Plan, which were converted into 3,106,315 shares of BioScrip common stock, and adjusted using an exchange ratio defined by the merger agreement.  Upon adoption by the Company the Board of Directors amended the BioScrip/CHS Plan to have substantially the same terms and provisions as the 2008 Plan.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Of the options autho rized and outstanding under the BioScrip/CHS Plan on the date of the acquisition, 716,086 options were designated as “rollover” options.  These rollover options were issued to the top five executives of CHS, and otherwise remain subject to the term of the BioScrip/CHS Plan, as amended, and were 100% vested on the date of conversion.  Under the terms of the BioScrip/CHS Plan, any shares of BioScrip common stock subject to a rollover option that expire before all or any part of the shares of BioScrip stock subject to such option have been purchased pursuant to the exercise of such option shall remain available for issuance under the BioScrip/CHS Plan.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The remaining 2,390, 229 shares are authorized for issuance under the BioScrip/CHS Plan.  These shares may be used for awards under the BioScrip/CHS Plan, provided that awards using such available shares are not made after the date that awards or grants could have been made under the terms of the pre-existing plan, and are only made to individuals who were not employees or directors of BioScrip, or an affiliate or subsidiary of BioScrip, prior to such acquisition.  As of September 30, 2010, there were 2,286,229 shares that remained available under the Bioscrip/CHS Plan.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stock Options</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style ="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company recognized compensation expense related to stock options of $0.8 million and $2.3 million for the three and nine months ended September 30, 2010, respectively.  The Company recognized compensation expense related to stock options of $0.6 million and $1.5 million for the three and nine months ended September 30, 2009, respectively.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Restricted Stock</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 1 8pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company recognized compensation expense related to restricted stock awards of $0.3 million and $0.4 million for the three and nine months ended September 30, 2010, respectively.  The Company recognized compensation expense related to restricted stock awards of $0.3 million and $0.9 million for the three and nine months ended September 30, 2009, respectively.</font></div>

92464000

2196000

4598000

4068000

2151000

1194000

17414000

26793000

2010

8122000

447000

19515000

1471000

125000000

75000000

0.0001

-90596000

-88521000

10496000

10367000

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTE 3 – ACQUISITIONS</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Critical Homecare Solutions Holdings, Inc.</font></font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&g t;On March 25, 2010, the Company acquired 100 percent of CHS, a leading provider of comprehensive home infusion therapy and home nursing products and services to patients suffering from acute and chronic conditions.  CHS’ home infusion business provides for the dispensing and administration of infusion pharmaceuticals, biopharmaceuticals, nutrients and related services and equipment to patients principally in the home.  Its home nursing service operations provide nursing and therapy visits as well as private duty nursing services to patients in the home.  The Company’s acquisition of CHS added 35 infusion pharmacies servicing 22 states, including 16 ambulatory treatment centers, and 33 nursing locations to the Company’s existing platform.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" alig n="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Consideration</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table sets forth the consideration transferred in connection with the acquisition of CHS and the aggregate purchase price allocation as of March 25, 2010 (in thousands):</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr bgcolor="#cceeff"><td valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LE FT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fair value of equity consideration:</font></div></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    BioScrip common stock issued (13.1 million shares)</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><fon t style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">91,614</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    BioScrip warrants issued (3.4 million warrants)</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,268</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RI GHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Rollover options (716,086 options)</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,802</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash paid to CHS stockholders</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" wi dth="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99,626</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total consideration conveyed to CHS stockholders</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">206,310</f ont></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash paid for merger related expenses incurred by CHS</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style ="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,566</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Assumption and repayment of CHS debt</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">128,952</font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total amounts paid to execute the merger of CHS</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">349,828</font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /&g t;</div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Assets and Liabilities Acquired</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table sets forth the fair value of the assets acquired and liabilities assumed as a result of the acquisition of CHS (in thousands):</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /> </div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr bgcolor="#cceeff"><td valign="bottom" align="left"><div style="DISPLA Y: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash and cash equivalents</font></div></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,162</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-F AMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Receivables</font></div></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,333</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&am p;#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred taxes</font></div></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,182</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> < ;/font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other current assets</font></div></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,993</font></td>& lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Property and equipment</font></div></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td> ;<td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,042</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other assets</font></div ></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,778</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></t r><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">     Total assets acquired</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline ; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">65,490</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts payable</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"> ;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,147</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT : 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Notes payable</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,250</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&a mp;#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amounts due to plan sponsors</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(8,180</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: i nline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accrued expenses and other current liabilities</font></div></td><td style="TEXT-ALIGN: left " valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(34,007</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new r oman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred tax liabilities</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,144</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font>< /td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Total liabilities assumed</font></div></td><td style="TE XT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(54,728</font></td><td style="PADDING-B OTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Tangible assets acquired, net</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,762</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Intangible assets acquired</font></div></td><td style ="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25,200</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt ; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Debt assumed</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign= "bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(128,952</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Goodwill</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">299,300</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DIS PLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total consideration conveyed to CHS stockholders</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY : times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">206,310</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The excess of the purchase price ove r the fair value of the tangible and identifiable intangible assets acquired and liabilities assumed in the acquisition was allocated to goodwill.  The value of the goodwill represents the value the Company expects to be created by combining the various operations of CHS with the Company’s operations, including the ability to cross-sell all of their respective services on a national basis with an expanded footprint in home infusion and the opportunity to focus on higher margin therapies.  The CHS acquisition is included in the Company’s Infusion/Home Health Services segment. Of the goodwill recorded in the CHS acquisition, $21.1 million is deductible for tax purposes.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I n accordance with ASC Topic 805, <font style="DISPLAY: inline; FONT-STYLE: italic">Business Combinations</font> (“ASC 805”), the allocation of the purchase price in connection with the acquisition of CHS is subject to adjustment during the measurement period after the closing date (March 25, 2010) when additional information on assets and liability valuations becomes available.  The Company is still in the process of finalizing its valuation of certain assets and liabilities recorded in connection with the acquisition, including the collectability of accounts receivable, amounts due to plan sponsors and deferred taxes.  Accordingly, the provisional measurements recorded are subject to change and any changes will be recorded as adjustments to the fair value of those assets and liabilities; residual amounts will be allocated to goodwill.  Refer to Note 4 – Goodwill and Intangible Assets for changes in the carrying v alue of goodwill.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> Intangible Assets</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes the identifiable intangible assets acquired (in thousands):</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"> </div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="bottom" align="left" width="74% "><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Estimated</font></div></td><td valign="bottom" align="left" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="74%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" wid th="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Useful Life</font></div></td><td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fair Value</font></div></td></tr><tr><td valign="bottom" align="left" width="74%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 1 0pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" align="left" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="74%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Trademarks/trade names</font></div></td><td valign="bottom" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">various</font></div></td>&l t;td valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,400</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="74%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Infusion customer relationships</font></div></td><td valign="bottom" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inlin e; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3 years</font></div></td><td valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,200</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="74%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Certificates of need</font></div></td><td style="PADDING-BOTTOM: 2px" valign="bot tom" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">indefinite</font></div></td><td style="PADDING-BOTTOM: 2px" valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,600</font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="74%"><font style="DISPLAY: inline; FONT-SI ZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="PADDING-BOTTOM: 4px" valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="PADDING-BOTTOM: 4px" valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25,200</font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDE NT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Impact of Acquisition on Interim Financials</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has consolidated the results of CHS with its own financial results for the three months ended September 30, 2010.  The impact of the inclusion of CHS’ operating results with the Company’s Consolidated Statements of Operations for the three months ended September 30, 2010 includes $68.0 million of revenue, $31.4 million of gross profit and $9.3 million in operating income.  The impact of the inclusion of CHS’ operating results from March 26, 2010 through September 30, 2010 with the Company’s Consolidated Statements of Operations for the nine months ended September 30, 2010 includes $137.8 million of revenue, $65.5 million of gross profit and $19.7 million in operating income.  Operating profit for CHS does not include the allocation of corporate expenses that were previously incurred by CHS and have since been transferred to BioScrip corporate expenses as part of the integration execution.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the nine months ended September 30, 2010, the Company incurred $6.3 million of acquisition related costs.  These costs were primarily related to leg al, audit and financial advisory fees associated with the acquisition of CHS.  The costs were recognized in the acquisition and integration expenses line of the Unaudited Consolidated Statements of Operations.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company included the operating results of CHS in its consolidated statements of operations beginning on March 26, 2010.  The following table sets forth the unaudited pro forma combined results of operations as if the acquisition had occurred on the same terms as of January 1, 2010 and 2009.   Pro forma adjustments have been made related to amortization of intangible assets, interest expense, and income tax expense. The pro forma financial information do es not reflect revenue opportunities and cost savings which the Company expects to realize as a result of the acquisition of CHS or estimates of charges related to the integration activity. The pro forma results for the nine months ended September 30, 2010 include the $6.3 million of acquisition related costs incurred by the Company.  Amounts are in thousands, except for earnings per share.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10p t; FONT-FAMILY: times new roman">Three Months Ended</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="BORDER-BOT TOM: black 2px solid" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FO NT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" n owrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan=" 2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">& ;#160;</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr><td valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(as reported)</ font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(pro forma)</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(pro forma)</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font styl e="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(pro forma)</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr><td valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="D ISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Revenue</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">441,153</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%">& lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">394,549</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,249,030</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,175,431</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net income</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font>& lt;/td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,965</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,137</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZ E: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">112</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,241</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td v align="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic income per common share</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.04</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-AL IGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.10</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.00</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new r oman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.24</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Diluted income per common share</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10p t; FONT-FAMILY: times new roman">0.04</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.10</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width= "9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.00</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.23</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><f ont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">DS Pharmacy, Inc.</font></font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 29, 2010, the Company acquired the prescription pharmacy business and assets of DS Pharmacy, Inc. (“DS Pharmacy”), a wholly-owned subsidiary of drugstore.com, inc.  The acquisition provides the Company with an expanded presence in on-line pharmacy and a six year license of drugstore.com capabilities, trademarks and trade names.  In connection with the acquisition, the Company and drugstore.com entered into a Transitional Services Agreement and a Services Agreement pursuant to which, for a period of six years following the closing of the acquisition, drugstore.com will provide marketing services.  The agreements also allow drugstore.com customers to continue to order from the Company through the drugstore.com website.  The Company paid $5.0 million in cash upon closing and will pay an additional earn-out in cash which is expected to range between $4.2 and $5.5 million based on the results of operations during the twelve month period post-closing.  The Company recorded a liability to DS Pharmacy of $4.7 million to account for the fair value of the earn-out payment liability as of September 30, 2010.  Any changes to the fair value of the earn-out payment liability going forward will be recorded quarterly as income or expense in the Consolidated Statements of Operations.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEF T: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the three months ended September 30, 2010, the Company incurred $0.4 million of integration related costs.  These costs were primarily related to overtime and temporary wage costs and other integration costs associated with the DS Pharmacy acquisition.  The costs were recognized in the acquisition and integration expenses line of the Unaudited Consolidated Statements of Operations.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Assets and Liabilities Acquired</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table sets forth the fair value of the assets acquired and liabilities assumed as a result of the acquisition of DS Pharmacy (in thousands):</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"> </div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr bgcolor="#cceeff"><td valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Inventory</font></div></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">469</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Property and equipment</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">76</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: tim es new roman">     Tangible assets acquired</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">545</font></td> ;</tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">     Intangible assets acquired</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td>& lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,099</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total assets and total consideration</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right " valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,644</font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDE NT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In accordance with ASC Topic 805, <font style="DISPLAY: inline; FONT-STYLE: italic">Business Combinations</font> (“ASC 805”), the allocation of the purchase price in connection with the acquisition of DS Pharmacy is subject to adjustment during the measurement period after the closing date (July 29, 2010) when additional information on assets and liability valuations becomes available.  The Company is still in the process of finalizing its valuation of certain assets recorded in connection with the acquisition.  Accordingly, the provisional measurements recorded are subject to change and any changes will be recorded as adjustments to the fair value of those assets and liabilities.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MAR GIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> Intangible Assets</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes the identifiable intangible assets acquired (in thousands):</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="bottom" align="left" width="75%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" widt h="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Estimated</font></div></td><td valign="bottom" align="left" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="75%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; F ONT-SIZE: 10pt; FONT-FAMILY: times new roman">Useful Life</font></div></td><td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fair Value</font></div></td></tr><tr><td valign="bottom" align="left" width="75%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" align="left" width="1%"><font style="DISPLAY: in line; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="75%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Customer list</font></div></td><td valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6 months</font></div></td><td valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>< ;/td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">283</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="75%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Transitional services contract</font></div></td><td valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1 year</font></div></td><td valign="bottom" align="right" width="1%"><font style= "DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,161</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="75%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">License and marketing related intangibles</font></div></td><td style="PADDING-BOTTOM: 2px" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="D ISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6 years</font></div></td><td style="PADDING-BOTTOM: 2px" valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,655</font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="75%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="PADDING-BOTTOM: 4px" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="PADDING-BOTTOM: 4px" valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,099</font></td></tr></table></div>

-128000 -78000

125000

1965000

5747000

-2075000

13409000

4082000

6214000

-94000

14658000

2658963

2647613

46577000 14273000

319000000

3051000 305000

743881000

287220000

5440000

186474000

151113000

8680000

743881000

287220000

32101000

66322000

51256000

Accelerated Filer 53702311

2117000

467000

1981000

1249000

159518000

128203000

EX-101.SCH 9 bios-20100930.xsd XBRL TAXONOMY EXTENSION SCHEMA 001000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 001100 - Statement - PARENTHETICAL DATA TO CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 002000 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 003000 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 006010 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 006020 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 006060 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 006080 - Disclosure - STOCK-BASED COMPENSATION PLANS link:presentationLink link:calculationLink link:definitionLink 006070 - Disclosure - OPERATING SEGMENTS link:presentationLink link:calculationLink link:definitionLink 006090 - Disclosure - CONCENTRATION OF CREDIT RISK link:presentationLink link:calculationLink link:definitionLink 020000 - Disclosure - LINE OF CREDIT link:presentationLink link:calculationLink link:definitionLink 006100 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 006110 - Disclosure - SECURITY INTEREST AND LETTERS OF CREDIT link:presentationLink link:calculationLink link:definitionLink 003000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 020010 - Disclosure - NATURE OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 020020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 020030 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 006035 - Disclosure - GOODWILL AND INTANGIBLES link:presentationLink link:calculationLink link:definitionLink 020050 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 020060 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 020070 - Disclosure - TREASURY STOCK link:presentationLink link:calculationLink link:definitionLink 020080 - Disclosure - DEFINED CONTRIBUTION PLAN link:presentationLink link:calculationLink link:definitionLink 020090 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 010010 - Schedule - Schedule II- Valuation Allowance and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 006030 - Disclosure - ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 006040 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 006050 - Disclosure - IMPACT OF ACQUISITION ON QUARTERLY FINANCIALS link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 bios-20100930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.LAB 11 bios-20100930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cash and cash equivalents Cash and cash equivalents - beginning of period Cash and cash equivalents - end of period Receivables, less allowance for doubtful accounts of $16,408 and $11,504 at September 30, 2010 and December 31, 2009, respectively Inventory Prepaid expenses and other current assets Sum of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, combined with the aggregate carrying amount, as of the balance sheet date, of current assets not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer). Total current assets Total current assets Property and equipment, net Other non-current assets Goodwill Total assets Total assets Line of credit Accounts payable Accounts Payable Current Claims payable, liabilities Claims payable Amounts due to plan sponsors Carrying value as of the balance sheet date of obligations incurred through that date which are related to rebates due from third party vendors and payable to customers, combined with reclassified credits in accounts receivable (amounts due to customers), and amounts that may arise and be deemed due on third party vendor audit. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued expenses and other current liabilities Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities, combined with the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations. Total current liabilities Total current liabilities Deferred taxes Deferred Tax Liabilities Noncurrent Income taxes payable Total liabilities Total liabilities Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued or outstanding Common stock, $.0001 par value; 125,000,000 shares authorized; shares issued: 56,632,871 and 42,766,478, respectively; shares outstanding; 53,688,338 and Treasury stock, shares at cost: x,xxx,xxx and 2,647,613, respectively Treasury stock, shares at cost: 2,658,963 and 2,647,613, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity Total stockholders' equity Total liabilities and stockholders' equity Total liabilities and stockholders' equity Statement of Financial Position [Abstract] ASSETS Current assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Stockholders' equity Allowance for doubtful accounts Preferred stock, par value Preferred stock, shares authorized Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock, shares at cost Revenue Cost of revenue Gross profit Gross profit Selling, general and administrative expenses Bad debt expense Income from operations Income from operations Interest expense, net Income before income taxes Income (loss) before income taxes Income tax expense Net income Net income (loss) Net (loss) income Income Statement [Abstract] Income (loss) per common share Basic Diluted Weighted Average Number of Shares Outstanding, Basic Basic Weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Diluted Diluted Depreciation and amortization Change in deferred income tax Compensation under stock-based compensation plans Receivables, net of bad debt expense Inventory Increase (Decrease) in inventories Prepaid expenses and other assets Accounts payable Claims payable The net change during the reporting period related to the amount of reserves for future policy claims payable and loss expenses to be incurred. Accrued expenses and other liabilities The net change during the reporting period in the aggregate amount of expenses incurred but not yet paid, combined with the net change during the reporting period in other operating obligations not otherwise defined in the taxonomy. Net cash provided by operating activities Net cash provided by operating activities Purchases of property and equipment, net of disposals Purchases of property and equipment Net cash used in investing activities Net cash used in investing activities Borrowings on line of credit Borrowings on line of credit Repayments on line of credit Repayments on line of credit Surrender of stock to satisfy minimum tax withholding Treasury Stock shares withheld from vested Preferred Shares to cover taxes Surrender of stock to satisfy minimum tax withholding Net proceeds from exercise of employee stock compensation plans Net cash used in financing activities Net cash provided by (used in) financing activities Net change in cash and cash equivalents Net change in cash and cash equivalents Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: Cash flows from investing activities: Cash flows from financing activities: Cash paid during the period for income taxes Cash paid during the period for interest BASIS OF PRESENTATION Notes to Financial Statements [Abstract] RECENT ACCOUNTING PRONOUNCEMENTS EARNINGS PER SHARE STOCK-BASED COMPENSATION PLANS OPERATING SEGMENTS CONCENTRATION OF CREDIT RISK LINE OF CREDIT INCOME TAXES SECURITY INTEREST AND LETTERS OF CREDIT Amounts due to plan sponsor Amounts due to plan sponsors The net change during the reporting period in the carrying value as of the balance sheet date of obligations incurred through that date which are related to rebates due from third party vendors and payable to customers, combined with reclassified credits in accounts receivable (amounts due to customers), and amounts that may arise and be deemed due on third party vendor audit. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Document Type Amendment Flag Amendment Description Document Period End Date Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Preferred stock, shares issued Preferred stock, shares outstanding Deferred taxes Deferred taxes Deferred Tax Assets Net Noncurrent Other non-current liabilities Commitments and Contingencies Amortization of intangibles Goodwill and intangible impairment Loss recognized during the period that results from the write-down of goodwill after comparing the implied fair value of reporting unit goodwill with the carrying amount of that goodwill. Goodwill is assessed at least annually for impairment. And, the amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of intangible asset s to fair value. Goodwill and intangible impairment Document Information [Text Block] Entity [Text Block] Depreciation Amortization of intangible assets NATURE OF BUSINESS SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUBSEQUENT EVENTS GOODWILL AND INTANGIBLE ASSETS PROPERTY AND EQUIPMENT COMMITMENTS AND CONTINGENCIES TREASURY STOCK DEFERRED COMPENSATION PLANS SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) Schedule to Financial Statements [Abstract] Schedule II - Valuation and Qualifying Accounts Excess tax benefits relating to employee stock compensation Excess Tax Benefit from Share-based Compensation, Financing Activities Excess tax benefits relating to employee stock compensation Document Fiscal Year Focus Document Fiscal Period Focus DISCLOSURE OF CASH FLOW INFORMATION: Changes in assets and liabilities, net of acquired business: Deferred Finance Costs Current Net Deferred financing costs Current portion of long-term debt Long-term debt, net of current portion Intangible assets, net Deferred financing costs ACQUISITIONS DEBT This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period. Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual [Text Block] IMPACT OF ACQUISITION ON QUARTERLY FINANCIALS Notes payable Acquisition and integration expenses Loss on disposal of fixed assets Cash consideration paid to CHS, net of cash acquired Cash consideration paid to CHS, net of cash acquired Proceeds from new credit facility, net of fees paid to issuers Deferred revenue Amortization of deferred financing costs Principal payments on long-term debt Principal payments on long-term debt Deferred financing costs paid for the new credit facility Deferred financing costs Principal payments on CHS long-term debt, paid at closing Principal payments on CHS long-term debt, paid at closing Cash consideration paid to DS Pharmacy Cash consideration paid to DS Pharmacy Cash consideration paid for Option Health earn-out Cash consideration paid for Option Health earn-out ProceedsFromRepaymentsOfNotesPayable Repayment of note payable RepaymentsOfLongTermCapitalLeaseObligations Repayments of capital leases XML 12 R11.xml IDEA: OPERATING SEGMENTS 2.2.0.7 false OPERATING SEGMENTS 006070 - Disclosure - OPERATING SEGMENTS true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 Notes to Financial Statements [Abstract] 0 bios_NotesToFinancialStatementsAbstract bios false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 OPERATING SEGMENTS 1 us-gaap_SegmentReportingDisclosureTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTE 7 – OPERATING SEGMENTS</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In accordance with ASC Topic 280, <font style="DISPLAY: inline; FONT-STYLE: italic">Segment Reporting </font>(“ASC 280”), and based on the nature of the Company’s services prior to the acquisition of CHS, the Company historically had two operating and reportable segments: “Specialty Pharmacy Services” and “Traditional Pharmacy Services”.  The acquis ition and integration of CHS has resulted in a change to the Company’s operating and reportable segments.  Effective April 2010, the Company has two new operating and reportable segments: “Infusion/Home Health Services” and “Pharmacy Services”.  Prior period disclosures reflect the change in reportable segments.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Infusion/Home Health Services operating and reportable segment consists of the Company’s legacy infusion therapy business combined with the infusion, respiratory, durable medical equipment (“DME”) and home health businesses obtained in the CHS acquisition.  The infusion services pr ovided in this segment includes home infusion therapy, respiratory therapy and DME.  Infusion services include the dispensing and administering of infusion based drugs, which typically require additional nursing and clinical management services, equipment to administer the correct dosage and patient training designed to improve patient outcomes.  Through the home health services provided in this segment, the Company provides skilled nursing and therapy visits, private duty nursing services, rehabilitation services, hospice and medical social services to patients primarily in their home.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Pharmacy Services operating and reportable segment consists of the Company’s traditional a nd specialty pharmacy mail operations and community pharmacies, prescription discount card programs and integrated pharmacy benefit management (“PBM”) services.  These segment services are designed to offer customers and patients cost-effective delivery of traditional and specialty pharmacy services.  The services also include care management programs customized to each patients care plan in coordination with doctors.  In addition, the DS Pharmacy business is included in this segment.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company’s chief operating decision maker evaluates segment performance and allocates resources based on net income (loss) adjusted for net interest expense, income tax expense, depreciation, amortization and stock-based compensation expense (“Segment Adjusted EBITDA”) and prior to the allocation of corporate expenses.  Segment Adjusted EBITDA excludes the write-off of receivables owed at the time the CAP contract terminated and acquisition, integration and severance expenses.   The accounting policies of the operating and reportable segments are consistent with those described in the Company’s summary of significant accounting policies.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Segment Reporting Information</font></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center "><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(in thousands)</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three Months Ended</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FA MILY: times new roman"> </font></td><td valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new rom an">September 30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="BORDE R-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; F ONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div></td>& lt;td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Results of Operations:</font></div></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new rom an"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left"><div style="DIS PLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Revenue:</font></div></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FA MILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Infusion/Home Health Services</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">111,849</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">36,809</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font&g t;</td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">264,625</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">107,613</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Pharmacy Services</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">329,304</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FON T-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">296,667</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">923,626</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">880,361</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td style="PADD ING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">        Total</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">441,153</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM : black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">333,476</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,188,251</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">987,974</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  &l t;/font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font s tyle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td>< ;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" colspan="3"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjusted EBITDA by Segment before corporate overhead:</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Infusion/Home Health Services</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,942</font></td><td style="TEXT-ALIGN: left" valign="bo ttom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,586</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31,702</fon t></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,420</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FO NT-FAMILY: times new roman">    Pharmacy Services</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,731</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-AL IGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,224</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31,120</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BOR DER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">34,521</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">        Total Segment Adjusted EBITDA</font></div&g t;</td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25,673</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,810</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: in line; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">62,822</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">41,941</font></td><td style="TEXT-ALIGN: le ft" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td st yle="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Corporate overhead</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&# 160;</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,602</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,896</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inlin e; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(23,646</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(19,831</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr><tr bgcolor="#cce eff"><td valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: ri ght" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest expense, net</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(8,122</font>&l t;/td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(447</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10p t; FONT-FAMILY: times new roman">(19,515</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,471</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT - -SIZE: 10pt; FONT-FAMILY: times new roman">Income tax expense</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,117</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(467</font></td><td style="TEXT-ALIGN: lef t" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,981</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> (1,249</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Depreciation</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,404</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FON T-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,356</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,211</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1 %"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,596</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amortization</font></div></td><td style="TEXT-ALIGN: left" valign="botto m" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,326</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </f ont></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,196</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FON T-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation expense</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,097</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"&g t;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(897</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,726</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>< ;td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,385</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Acquisition, integration and severance expenses</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ti mes new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,040</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%">&l t;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,139</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td>& lt;/tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bad debt expense related to contract termination</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td st yle="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,483</fo nt></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TE XT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net income (loss):</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,965</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><t d style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,747</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,075</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font ></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,409</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></t d><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: in line; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td>< /tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Supplemental Operating Data</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT - -FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Capital Expenditures:</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>&l t;/td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY : inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td> </tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Infusion/Home Health Services</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">977</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">48</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,229</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" wid th="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">376</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Pharmacy Services</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>&l t;/td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,104</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">545</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FO NT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,044</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,010</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgco lor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Corporate unallocated</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">324</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style= "BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,474</font> ;</td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,136</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0 pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">        Total</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,405</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SI ZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">593</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,747</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY : inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,522</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Depreciation Expense:</f ont></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%">&l t;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></t d><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Infusion/Home Health Services</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,128</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLA Y: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">277</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,381</font></td><td style="TEXT-ALIGN: left" valign="botto m" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">904</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Pharmacy Services< ;/font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">954</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">858</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font styl e="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,019</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,950</font></td><td style="TE XT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Corporate unallocated</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">322</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">221</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></ td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">811</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">742</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&g t; </font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">        Total</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,404</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FON T-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,356</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,211</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,596</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style ="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total Assets</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><fon t style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font ></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Infusion/Home Health Services</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font st yle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td&g t;<td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">438,705</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">52,954</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPL AY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Pharmacy Services</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">143,153</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: time s new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">121,081</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Corporate unallocated</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td>& lt;td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>& lt;/td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">162,023</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times ne w roman">66,145</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">        Total</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"& gt; </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" >$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">743,881</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">240,180</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-F AMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Goodwill</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: in line; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td>< td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Infusion/Home Health Services</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td sty le="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">299,300</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Pharmacy Services</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> ; </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ti mes new roman">24,498</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24,498</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">        Total</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: time s new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">323,798</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24,498</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr></table></div></div> NOTE 7 – OPERATING SEGMENTSIn accordance with ASC Topic 280, Segment Reporting (“ASC 280”), and based on the nature of the Company’s false false false us-types:textBlockItemType textblock This element may be used to capture the complete disclosure of reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10% or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 131 false 1 2 false UnKnown UnKnown UnKnown false true XML 13 R10.xml IDEA: EARNINGS PER SHARE 2.2.0.7 false EARNINGS PER SHARE 006060 - Disclosure - EARNINGS PER SHARE true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 Notes to Financial Statements [Abstract] 0 bios_NotesToFinancialStatementsAbstract bios false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 EARNINGS PER SHARE 1 us-gaap_EarningsPerShareTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTE 6 – EARNINGS PER SHARE</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table sets forth the computation of basic and diluted income per common share (in thousands, except for per share amounts):</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"> </div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr>< ;td valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three Months Ended</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended</font></div></td></tr><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div></td> </tr><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-W EIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: blo ck; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Numerator:</font></div></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">& ;#160;</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times ne w roman">Net income (loss)</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,965</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,747</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,075</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font styl e="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,409</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Denominator - Basic:</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: lef t" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY : times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Weighted average number of common shares outstanding</font></di v></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">53,425</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">38,961</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49,232</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">38,807</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic income (loss) per common share</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10p t; FONT-FAMILY: times new roman">0.04</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.15</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLA Y: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.04</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.35</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Denominator - Diluted:</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font& gt;</td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Weighted average number of common shares outstanding</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">53,425</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width=" 1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">38,961</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49,232</font></ td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">38,807</font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Common share equivalents of outstanding stock options and restricted awards</font></div></td><td style="B ORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">785</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,223</font> ;</td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times ne w roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">538</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total diluted shares outstanding</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">54,210< /font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">40,184</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT- FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49,232</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39,345</font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"> ;<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Diluted income (loss) per common share</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.04</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE : 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.14</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.04</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.34</font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The computation of basic and diluted shares for the three and nine months ended September 30, 2010 includes the weighted average effect of the approxim ately 13.1 million shares issued and outstanding in connection with the acquisition of CHS on March 25, 2010.  The computation of diluted shares for the three and nine months ended September 30, 2010 excludes the effect of 3.4 million warrants with an exercise price of $10 issued in connection with the acquisition of CHS as well as 4.9 million and 4.0 million shares, respectively, of other common stock equivalents as their inclusion would be anti-dilutive.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The computation of diluted shares for the three and nine months ended September 30, 2009 excludes the effect of 3.0 million and 4.5 million shares, respectively, of stock options as their inclusion would have been anti-dilutive.</font></div> NOTE 6 – EARNINGS PER SHAREThe following table sets forth the computation of basic and diluted income per common share (in thousands, except for per false false false us-types:textBlockItemType textblock This element may be used to capture the complete disclosure pertaining to an entity's earnings per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 false 1 2 false UnKnown UnKnown UnKnown false true XML 14 R8.xml IDEA: GOODWILL AND INTANGIBLES 2.2.0.7 false GOODWILL AND INTANGIBLES 006035 - Disclosure - GOODWILL AND INTANGIBLES true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 Notes to Financial Statements [Abstract] 0 bios_NotesToFinancialStatementsAbstract bios false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 GOODWILL AND INTANGIBLE ASSETS 1 us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false label false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTE 4 – GOODWILL AND INTANGIBLE ASSETS</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company follows ASC Topic 350, <font style="DISPLAY: inline; FONT-STYLE: italic">Intangibles—Goodwill and Other</font> (“ASC 350”) in accounting for its goodwill and other intangibles assets.  Under ASC 350, goodwill is not amortized but is subject to at least an annual assessment for impairment by applying a fair-value based test.  Management assesses impairment an nually or whenever there is an impairment indicator.  The changes in the carrying amount of goodwill by operating and reportable segment for the nine months ended September 30, 2010 are as follows (in thousands):</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Infusion/Home</font></div></td><td style="TEXT-ALIGN: left" valign= "bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pharmacy</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" a lign="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Health Servcies</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Services</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="b ottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="64%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance as of December 31, 2009</font></div></td><td style="TEXT-ALIGN: le ft" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24,498</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#16 0;</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24,498</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="64%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Preliminary goodwill valued as of the date of the CHS acquisition</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISP LAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">304,185</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td st yle="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">304,185</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="64%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustments to goodwill related to CHS acquisition</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&g t;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,885</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap ="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,885</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="64%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT- SIZE: 10pt; FONT-FAMILY: times new roman">Balance as of September 30, 2010</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">299,300</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bott om" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24,498</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">323,798</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr></table></div><div st yle="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the nine months ended September 30, 2010, the Company adjusted the fair value of assets acquired and liabilities assumed in the acquisition.  This resulted in an increase in accounts receivable of $0.5 million, an increase in other current assets of $0.2 million, a decrease in other assets of $1.2 million, an increase in accrued expenses and other liabilities of $1.0 million and a decrease in net deferred tax liabilities of $6.4 million.  As a result of the increase in the value of identifiable net assets, the portion of the purchase price allocated to goodwill was reduced.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under ASC 350, an intangible asset with a finite useful life is required to be amortized over the period of that useful life, and an intangible asset with an indefinite useful life shall not be amortized.  Intangible assets are amortized using methods which approximate the benefit provided by the utilization of the assets. Trademarks, trade names, customer relationships and license and marketing related intangibles are amortized on a straight line basis.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"> </div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company had no intangible assets a s of December 31, 2009.  The following schedule shows the balance of intangible assets as of September 30, 2010 (in thousands):</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="b ottom" width="34%" colspan="8"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30, 2010</font></div></td></tr><tr><td valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" width="10%" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gross</fo nt></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" width="10%" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net</font></div></td></tr><tr><td valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&# 160; </font></td><td valign="bottom" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Estimated</font></div></td><td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" width="10%" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Carrying</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" width="10%" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accumulated</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" width="10%" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Carrying</font></div></td></tr><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Useful Life</font></div></td><td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amount</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0p t; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amortization</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amount</font></div></td></tr><tr><td valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" align="left" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" width="10%" colspan="2"& gt;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Indefinite Useful Life</font></div></td><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" align="left" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Certificates of need</font></div>< ;/td><td valign="bottom" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">indefinite</font></div></td><td valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,600</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" vali gn="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,600</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT : 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nursing trademarks</font></div></td><td style="PADDING-BOTTOM: 2px" valign="bottom" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">indefinite</font></div></td><td style="PADDING-BOTTOM: 2px" valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,800</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style ="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,800</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td>< td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,400</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,400</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" align="left" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><fo nt style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </fon t></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Finite Useful Life</font></div></td><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" align="left" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> < ;/font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font st yle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Customer list</font></div></td><td valign="bottom" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6 months</font></div></td><td valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">283</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(95</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLA Y: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">188</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Transitional services contract</font></div></td><td valign="bottom" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1 year</font>&l t;/div></td><td valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,161</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(194</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">967</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Infusion trademarks</font></div></td><td valign="bottom" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3 years</font></div></td><td valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,600</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(450</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,150</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ti mes new roman">Infusion customer relationships</font></div></td><td valign="bottom" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3 years</font></div></td><td valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,200</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times n ew roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,246</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,954</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign= "bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">License and marketing related intangibles</font></div></td><td style="PADDING-BOTTOM: 2px" valign="bottom" width="12%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6 years</font></div></td><td style="PADDING-BOTTOM: 2px" valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER- BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,655</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(213</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td& gt;<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,442</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font s tyle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">18,899</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,198</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>< td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,701</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid ; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><t d style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="PADDING-BOTTOM: 4px" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&# 160; </font></td><td style="PADDING-BOTTOM: 4px" valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">34,299</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new ro man">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,198</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32,101</font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"& gt;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">        Total amortization of intangible assets was $1.3 million and $2.2 million for the three and nine months ended September 30, 2010, respectively.  There was no amortization expense recorded in 2009.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The estimated amortization expense for the next five years is expected to be the following (in thousands):</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div align="left"><table style="FONT-SIZE: 10pt; FON T-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="90%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010 (three month period ending December 31, 2010)</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,576</font></td></tr><tr bgcolor="white"><td style="TEXT-ALIGN: left" valign="bottom" width="90%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10 pt; FONT-FAMILY: times new roman">2011</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,276</font></td></tr><tr bgcolor="#cceeff"><td style="TEXT-ALIGN: left" valign="bottom" width="90%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2012</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DI SPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,552</font></td></tr><tr bgcolor="white"><td style="TEXT-ALIGN: left" valign="bottom" width="90%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2013</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,002</font></td></tr><tr bgcolor="#cceeff"><td style="TEXT-ALIGN: left" valign="bottom" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2014</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,276</font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="90%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2015 and thereafter</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-S IZE: 10pt; FONT-FAMILY: times new roman">2,019</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="90%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,701</font></td></tr></table></div> NOTE 4 – GOODWILL AND INTANGIBLE ASSETSThe Company follows ASC Topic 350, Intangibles—Goodwill and Other (“ASC 350”) in accounting for false false false us-types:textBlockItemType textblock Discloses the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subjec t to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain or loss on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each g oodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. This element may be used as a single block of text to include the entire intangible asset disclosure including data and tables. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 42, 43, 44, 45, 46, 47 false 1 2 false UnKnown UnKnown UnKnown false true ZIP 15 0001014739-10-000029-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001014739-10-000029-xbrl.zip M4$L#!!0````(``^"8SUBKVW"G&P``"#L!0`1`!P`8FEOP]%,=7@+``$$)0X```0Y`0``[#UK<^,VDM^OZOX#SCN3 MFE3I13ULR_;,EOR:>#.QO;9SR=XWBH0DQ"2A!4@_\NNONP'P(5&V-3.)[>QL MI79L$FQT-_J-!KSW][LX8C=<:2&3]QM>J[/!>!+(4"33]QL_7QTWMS?^_F'O M?YK-H\./HPOQ.U>_[C!VDNC43P+.0AED,4]2-N4)5W[*0S:^9\78AH/->JU! MJ]?J-)L?]N[&*F(P;Z+?;\S2=+[3;M_>WK;P<4NJ:;O;Z?3:PDZQ84;N1"*Y M?F`XOA[[.A]^MS3^MD>CO>%PV*:W^5`MZ@8"6*_]ZT^?+H,9C_WF(CXXO5@# M?[\TRUA('2@Q;P4RAM%>Q_,ZO3+@L!A;AKK9-B_=4*%EO^MM/82%&>$^R'1S MZOOS*O!,M^US_&;8['C-GN>^0%17X]T9]CIN9,C%$EQX5H;YX;__B[$]Y/V. M)JY>\`FCM=A)[^?\_886\3Q"EM&SF>*3]QLX:=--UKK3X4;;P`EDDO*[E(GP M_4;0P?^9">`52*1([^UO\+L(\9!:RIOV@G2!` M7:6'H-E&4HQ@_@?*O M8F"WGYWR0GV+I?P"]1V^+(+@O^[V.@1EB3#49.5`)N:^SA3_8..XG9\O#_?: M[J&!@A\N@_"60%#`NJ-GON+Z:3`*)QR*&V!'02J..H7`'R)^J?+'3\'7L*'^ M>P)[R!,9BV05X-54%)"70>RU2Q24R87$YM"E,,="!W[$SFF)V#$\UI"MT#"( M8W?<.#/,C*)!S*[C!4:KSI7\L[?7?O"K?/XC$BKVOS+*$E#[>\`C@IRI/+49 MDH\P`VJG/95FVMHO"I*/]J\'1Z?NB1USE5\Y+[[M^VNY^TR9!9.WL;9'2;MIY&_2&Q.R5BQ]IJP'F&EM_VU>;D6 MXT::R0F[Y/.4QV.PM+U.@Z$A;+!TQMF!C.=^^W(DQG[S<@BWY; MS*?8>!K(2*KW&W\+`LXGD^)=R&XLCF.9IC+>J*#LX&UO%^#^,#-08=(7R.TB MTQ#D)4^$5"Q+(`X`NQ>R1*9$?AFJW.VB`*WD(X7:JZN3T=B92_I\JI4Y&)Z#G$?CW M5RFFQ@EXFYW=UR.OPUZCM^5]AKC6F%6+U?GH\/#D]&-S_^SJZNRG'=:=WRT3 M]I<4Y@-_+E((M",(WC_'U.Z?71P>7>2,&T<^A*G`/J9E)$)+Y^N2\75(>C:; MW1\\A[W^PU:&K6]^7HDTO01IZ7G;C4UO\YO)_"K<_,2U9LU*(A3[::8P.[H5 MZ0R2(IEP=L]]]OA)[VFML;_:_AD5=H1W]_QSMD*`&126A":]3K")`L*RP ML#>7"G7F*VD&\)6%,H-4_46HQA.SOK5(>3ZGT6]L#;I/5(HVU4N^5>165.1. MP">HD"N62C81";7K8%W-#_Z="2U0(U!)#GZXK-3H&&@,QR13)/"A3RL4P.\B MS=/.ABO647%N`H-(^2+I)\Q/0OA=\1L9W>#KI4]Q@-`Z@QD6BBZMDI7/?[HJ M8>9'&C"";V/X!.',?8'E0E,O)-UW!(DDB#(L?C&1:C97F#VO1&KEQ$B6=O7( M&D8P7\&\0@>9UMCYQ"-YVWH))IVEP-7?27/8F^U!J\-B$44X>J5BL'>N8M_M[.;+XAYYN]]3\(D`_#XJF3="&%BC10,BU(K!FRH\6!KF(!?$F:I%3 M0/$]&(N`4G/S0<-P#=+V?3^Y-I,#U*9KF*X,_7C$7%'T0"I(5^S;A[Y9;62! M8XLTY#P`>^N^E,U^,5;C1BL*J^5"#5.`T,?GQ,C.&,WD>A%&BV%,M4("74BI M34#YQNMT6IU"^IUAUM6-D"+N+%S6@L1?X9!/,*0BXR9,?3/HE(S^`NP'O.+" M%![D0$.SR-T_-W6X&V#@3.'_]^BGST@Z2U!]O`EF\-B^DF2Q4Y9(1A. M`C%'R8YE!C.*A%#25$)*9["@TQEAV@"T]!S][@V/0/USUVM=(@LST*'4EJ(@ MCB::'3=`%IA_XXN(=K51%G+JX<4DY:K.C9=LL"/@BRR&H7"`*,#T%@EM&E!0,*Q^RM$ M#@:H?5-.PLG!`0@D2?&`BQNDSIB!_(5(;CB:/&!9-F=DF&/_3L1F#4CHEB2[ MQ4XL`^KH+<6J14'QGL-(9Q'F!0#F%#X!@:K/BYB/$0H.6C\*0U@\TS*F,L#6I-Q-,4 M/246M*Q[!\8\_?N2:0<"`*$3BAETBGHQEE:E"PH1>B7^+1;L"5J&+%:4!RAV ME"D9HA-2YM$\RC1Q;SZ/P%FBJL2^F@K"N^?,5I^,V4K+X^#CT,4)9C[9ZTDD MI6%8#K2[!!3Y0"`Y*BMQ#B0@Y!,_BZQ8", M!7$PH,#7,K\B#530`'=JXJ:$[#2(.=BA6*3D#2:<,JI.:PMM.X@C`2Z\`HJC M4FA2&[@`B$669(B=+7HZ97%SOH8TYIEC[_TZ@5\5MJ#\0[C[&X@5KC?`"+'O M%%+.PJ5G<[LT,C`EZ8`6->`J]=$2H0#JUNU*O]EW!!E-6M;'4Q`BI% M4\9N@EKH&6KR;2FJHA`35!06-G3P5J+DH1/)T*![:#:8VG5[G.S8GSKP_#-TF#78UDV`ILLZ!0[ M=.%SF:D**C;`!=CDBFKSL8?#\=Q1865'Q39?`J`)GYI?`K![D`.DANX`=!(T M"&8PXHQ8Y<845NV6`S+PKZE$"[)R[GO%,1!#VLJA4BI-DPBL#H1>C'(B&[=C M$H=#)N(.<`YFX$0,/L7(RJ3HF!&E).<6VFF9?9((5-M$\E,2#@:)'G]?@[2Y/(I`E1+40'<6YB'.6@^>!/ M0&B6',57-K,P*=`*_'>9+4P=**EUT]$`XF#PCC&-%3EG,;E4V3P-3*%")!IU M.`D@4,A'_I:%4V*QD\N^!/0>BG%/_7)'*>RV*VMW??NA+,PL8@U1G.@E2BHG@T_<`F8ED" ML/'8@**L'2N#8.W`@F+P1!;D`FLI7K\_(D-PP: MMQ%`(@;E1:9@`SV#MN:Q:)J8GC+A:JP^`G9$S".T5O"EM*YI?6`?`:2 MY/']RH"%W]E]800WR=#!@H]3&!@:6VU_*4V=<40J>!.,/N1!P-C19>#CNA'FOM:,*-"8/G['`XE=B MV8K?23)D/\B.W/Y0Z&.SMSADUL-F4J]JE9C M'1D6`?)`*]:J7`2RBF+<%`Z+YR0I`"^@D#*U9?0@4)EM@\L2ZF_)Q=O*Y2:50SP.H.6UQV\ M=60NI@+&?;T;5X%4@]X^@NFT.A1]L!.W!;#@=366YY1DG/,OU5/'N=AT:M$@7`R!?6C9B#: M)G8U7JI6FNC-9''<;+KZ(80@N$6BN;HAVPY*!X%!%MAS/0N5F$I!N\@'C1[C MC@G6WFUU'0N^B4$#RZ&Q30K+;51C)<(IM[TS[JM'6S&OJ"9/V4&^/Q60\%`@ M939%J]E7J34<7,:;[=9641F"UU1"&7/7WH)AC-M.I2]EJ;G;-N!@TD4B:MHZ M8<9B)4P=RM2^0_9FL]+E6L&PNA>4[P/=S@0DF;?8L."@Y_-3?4M5=NI*,VNS M,6&R53/T@2K-!/&G:10/L$\_=#6),`M<;%CR%XY5Z!`X;7^;LA**@MWJI6T! M66HBT=3!(,)R2X:9N(9Q6`+`31%MXGQ;[,,@LF!GK\1.S`6*/8A"G`D^=2AT M6[U5S*^5OFKKPM)VH8W(!86OH#58>BOW/[M&(A?V+'83O0*#]N+3*L/W69,Y8UH9?#\%\FRJ1+>Z2K\#^ M4E+P!\[NG)FPSK1E-MBG-&PUG`7S=7Y4IEJ#M)M@2U7_A0;Z5?&>S0N7JQ7& MIEA%950^BZ*'M<[]O-=^Y!:J_.:J`PI7<::P\)+F4C7*4EQPO'B[E>MY.H=/ M3R'LQ1O`Z$HKNFT-S'L@8O`=[S>:O8W:*Z\&G=XV_%1@N@#QF3'T-CYX_5[W M21@B=%M`0%%`?*E,BC]@U'_C1[AQNH@@$C9*0OSGJ!AE;C0[L4U1(,KT[^?P M=[@UK*"_SGPOF#98F2\E"C4,'+,I&9GZ.O4*-$TA-RB_QC+3$GF7>%W>/@Y> M`+7F(G6WNIN5-:H'_,(0AQ7H]K8'ZR!^**(,PI5%='[A6%?DXG!LU-4()^URLAN>9TSXK]UL:'?L?;[K].[$&V^\-N MK_LZL04&G=9 MR-4UF+FKMMQ2OTA,_LDE?O&%QF"[0L`CH%\,UKW/PGH4\R0T=_=&_K1\8V[^ M!E_42NX$<.'FLMS*X&H@3Z?20ML[8L)Z#.(KB1?CODJ:P"F'`/[%"HKT#LI? M8QA^+)7YU'QY!!\"7>NK7=.COW("$;&]UO)NR2^UIBL\P);:,L7X6/ M8W_$H6ZD&5@K;__"/Q3PZ*>%T)V='AR=7EV,KD[.3MG9,3NX.#H\N6(7)Y<_ M+DM@@CT2QC=="'V]Y@7Z?YEM`KPU?UBY-?\A-G[;27B,H>4F<[MKK*E+B[N3 M)*FDW@IS[`J/!PO7>:YB.ER5*4W;8&.;PJQH7^-L#@XQ]H-[M`^W4EV7#JF8 MDIW94+CQE9"9Z6-C>@Y1&9ZQI8X^KFYPER,(<-.14PC9B_+=GX>QED!=_6N1MF7/&X;>D17+5,OK;R;I"28)#,K/ MB9^!^0$E+"00V_?S4YV%Q#$]H\;[,;8X^*'==OPM2Q;V'4=/!;AX0MHT!*3N MZB"ZMX#:ET1")QM3TZ9@FQ>L/1J9(_87')LF-#\$2W`OI"7^`UZH=&7^JW=K3=TS8LQ6`L[O)WA$J`MGZ"UN;^*;*K*BQ. M2A*VYL_"TG&7`#NY"S]!_<:FOP5/MY9Q_C@:G2^QU+4R%0>(2\M#J-CY M4S!`YTOR&II;GM]^55@^R50B]"RW#&OJ@.*3",(!32OJAXC\DI&RL9A"":*H MIC+.A%6@/7FL).YNPM!_8 M<-$<7,J`E:NMIK55%?L!:Q0([MK0>;C"4BBR]K0"&*^*6."5,=0W)K6YP15B M(R,*U/+4M8C7GNUZLHPL^I[]_:W#:.K/W]5)W_@),S4V]2AT[$BV[) MSE0YMI/QGL3VL3VSM1\I$K*X0Y%:7NQX?OW;#9`4*5$2)>M"RKU5L[$D$F@T M'C2Z&]T-6JZ5ENLZZS$5L-$4(5GEWGR:(QI-3R.`R_.)3-!.VS:F MEOT&%K(H6GCGN[&L6IN__G-Y@[K*/B6$G]!4%NHE5C M('D>TK.]8U\K(\T_ISFJCMAL'QW^5&295,7L),,DW::"Y?2Q+SY)(XZJ7O)=X93+M;35NN@TMO&..T M?D#(IN=O%0A;1LR2(/3HR:](8Z+NL)'_M'#Y62.'#W-MH<-8V"-C\T^1KHF3 M&"Y\/=414$:F===!N?*M3$_QX\#*2JZ&H&X('6!:QV91*O8TTU\&C"?1F';F M$IF.3TCG+'YP)5]*>[SE2;:N6/G=@O-AJG?=9=`$BL9^4-!.:4]8N2><)7EJ MA2E-\QZFFR\HWRZ`15;RA#F!K1>YG"4-)!GP0NW,Z]1@:&/EK.GKEIG;USU_ M6FE(YNNFE3]*4W\1^GX2VK=@.O)())LL$K`!S^$0 M$)-K*]][8NV+/"#0,J7V$N2D4ZHUKF?X3SW1V_8;9U[KR[3.[7PL>S&2^=)+ M'T5C;9-HEYY>/%A)F[9@$59\Y@E_>P<%)+D9.UIQ8#)57^XWBK[H)?]/+[=G]\X3G3^G3 M'_#[!4$@)_\G3^7SC\Z&!-R(>A3LB^N;T7P0@/Q5_+AXL&7!ABWH7VNW#+6K MJ_G0@%R#Q3"YLA02,.BFU;DP5U-N&/_#EKW!/7OZ;+4DE-/H+"D7](>HZ;-V M5,;*[).9'HYEZ-KK'7JO>C[5D7+`>,'D?S9#QZJ8P#$7FRQ>7C_Q1S>TU>D; MY9T=C&[8DO5>OZ,VC>[*R3XUHQO3?'J]5O>E=.-),5YW4@CTEZG*\P%N^&@N M"O\RO;EOO8R$=J>C:[VNF@^/*6WY8$3"1FEHW4['Z/:J$SF7-3$QD])[RY,E M;LS@.A`VEBU$3QJ6O#C*V5B0Z8'5D-1%B1.+NJD)_?J+Z4_4Q+/$B9.YG\7! M4!S.JXS)D]F#\KDJ8:/E;\Y1(B*^7';IV?P'^U_^7$*"?$0\`0^4]HU,::E& M5^\72"B^N4;&N87>Y,C\,6]#7(K?[O&GC5/CU5ZK&*4\WV@]:`4!VC74JJ1> MY:IC80"F",=X&\MCXG?YLB5X-B0B1&8IAB9PP#=)`Y^??X>W+[TOZ:NGV9L; M<+W=TF:2"JIWUXA!HF.E;[2[+QWCC:R"D^42YB+%9('@U=ZAI(GS1#I=R)9` MI13ULC;U$9QT.NIL48E->J[Y2%7AP5-7.?#6'6EIOJ(91R,_P#I25=(53[.G MU]=H6C.Y(\O;KPGA^N:$I_-2+IO37T&2RIG"=9ILRVO;KFI?^,YR-"YI?N\$ M8J*+UE?UM0E,N_OBA!B5\$\\3TB>DX_A4_`0/E,N0TY4[21U M8RUZ3VE^/(4^>FU)K*R65F.TAST MY=5!X1<_N$E*5'X)_#'\+8JD/6[LG>UTC>*V4K&G^@T&A*O1UK07#6;6YVRG M*VFZ_8LB?\L=T-D6O&$I`57K%H>QK/DZT;[,=;Z`:JEVRJB4Z>GN7,)'&BP@ M'__FAYL<]``XBEMO2;-[)ZR+I2,Z:NWH0ASV#:U^A&&!KP[L.Y4)DZ4ZA9(Q M\EV\?_?_)35]YXHLY9ZYD%5_UT]5[;1[ZDR)I;EF#T&;2$MM=_OZ>K2YCJQ# M66+O?)O^M#Z?C&ZOU2D>#.;:VP<1R!!=-;3N2B(RA6I!_G7Z>Y(OO;&ZI[=G MB"EO>+]T%0_.5E!TFD8!)Q=TSFTVR>]))`U;N3:Y+_X8O7`]J@#V2H>&6D;47W'74##@Y*F'B:7P."5H?+:E4>^L*J8\#0E#7R5KY]Z]FGA MY:3;#6K9R6)V>?6M>G!6M&2SO2X>$J,CK];N](QX>"S=!G=O!-AO<5 M[V]%?\AP7@J+WV[$3^LOGFY;[Q6MV%QS.^X>2YNJQDPXW_ZZ%R=LH/>U#]0_ M6IYJN]==S?[2,_LE%03GCM=?4O2PK7=Z/5U?=GI?5D+P<#3K6+6UTVWW.NTU M:3[%9%<1A"[NZO/C032,W2P7<4[)3Q__X@?GR<.I>GZ;U4#9W%O?,5I%P;A6 MAW4Q7-9=6F)G@PE1NU+1 M6-KPP4C$4)M^4DV_&H5??=_&VT_FA%KR_08^!TWO]HNH31O;5:\P;,TP5G6: MV6UHSHB;%!:8[GFS(V_LB:NO$ZM[`W-8TV:4U"K]U()Z=::$["9D5S`F"X;U M"PU?O=7I%SVZ"UL_**VJJ-K8FSTT6TUL:7A)+JMRW:"2S.']DLB9=J]?A'CU MSFH\,)PC?3;F>X.13;>R4)2,%#7D3%O>@)68)JO#2'*M;)3OU>ZL"A?)]5`; MVM%M,1L94(WR0Y?:,Y53:_^<5 MLW23%CPH4;XV<,7HK>(Z6=;\(6C$:KU@D->:1G%D#U97K8G$%6G,.Y=7TYB[ M,0^CTD[$;4+"?3YGB&1/8@3II9=XV7.6W`;J::?3;Q67[>INZD`[*KEMH]/M M;DJ[O(#4`RF4IN8O.045#^>.+J]\S]KX%+([(Z<6-WY@8M%QH&G&NL3B*=") MN%,3UUZV/Z8T))=(SATT)V='>#';B]BK&MUVT3]_JZ@X.36^[E_6F1<'`K.)':8FOSS[\ M4ZBN]>7T[G.AN%=R`VG)Z^SWB;@IMUB7T@.AS34O6.4;A@D5T MYRIC20J+E_F8H%IA#:Z,[[*8'!LCQ2<\(3=]UYR2G12<$\E9OBPV*E("9?4Y MO"\[Z1HZ&:15VD)Y3HC5F"S^OC@C>"4W#[%P%M9;Q7)<(P=("JR1K&AJ<]SE M'2]-!RNT5:@-GQ],"-(+1S1.9H`M&5(H*X<6&Q9)3M@_-ZU1ONWL3O)L=-"@ M[0*T$Q?_`O61"0KFURW%I.X%]@C?\ M/D\;@$?P/5BQHIYJ[G&L#Y:5@RT4E@*NBG+Z`A!>RH'"(^+PZ,1T?6]V_-"A MQQVQOXN./5&&M8RR<$I-4H(UO3`KN78`GDC@*B8[K6@DRAL5`0.$%JDH@>F` MIT7=T*TFYB">X%UP,_,T4SW.E:?GQ>:Q:).(I2Q=)`J#?T>BT#.0F53P"C@\ M@#7"QSP:^7:^>M<$<1J)`KIYA,/P91$P['\2^-.+`@2^R@#).%81%1$U0**8 M85E.#-X9B\J-LEKH4.:*8'FR,%]W092(,H?PCKQR6FVG)7(OS`"K;=N^O,,+ M:,NH5M@@%B7NO'2*D&_1E&"\HL%UIE.%-0QSI29%D+.H@94O`"%+4V5D2H2< MI9=7X*VN.`N"H`+7H(N_FUZ,=8UE?5]U42&MZ6A$=TXX+8"5+I>LF#!T)8IN MF=,";0Z0LKQ`V[2R%L##KER`;479[51'R84=;U77S&GNXC=A[D^/!O`^;W?& MAA(*/BQ*+.E5C9Q#'4Z[<7!U;FVJ[K(!9'4Y81?U8T2A$S M1:J7F:F;!T[W9KSD):T>DD0TY%IZKU^91AGV7FYM9KXD\>WF/#-:VLPE5846 M]T:++FJ$:3VU`BT7I[=78%3=L9N+6W;WV^GMQ:IK\W9ID&[?4MJ*1=HI6*3S M+",;M$JU3%E)7ZCB2:5;6:(V*3QMP>X93V\=&(@J-N@HLI-[&I,(X8FXC$V& M5HG*(&^%H@AJ%#P<*K!?"T-F*$NW)L\DU5O??:S#5)6W-5502EI*9LGEPVG/ M"1=E'\NG)!)3@O68`S$ES`)5-@3=!69#AI#!YXEIV^GG)\>.1K^\`0GR\[2_ M(/O+1KM-4#3PH\@?ORDE\`48FB6XR"$V/XN1O80XR\?!PA?M-R]?22N<9I90 MOWKCTQ,X1P+/?\I,">_ MO)'_[G%X,^N")EUN2QB"#>GY^>PMYU\OKZ_O_[^D6F3'_-8 MJ-5:3_K\?'U[?G&;T3UP35!0@'HF:A+/C^&HT5&X3&=]:5`"@F3`#1<1A)4M M8>5U2I'B(DAF:C%:M)VAI920_4$&O8$D50@[FV&GU2?L$'9([A!VZBIW"MH- M&SP`=_S@ES?_;5F<#X=O8+;?`\W2606QG MVEZUA;-#&;`?#P?QE_A+_-TRG0N$_]/(B?B;^4F8U2Z,5:9NZEIO:S\W?(O@ M47HD\];UP_#=^JI9J>H"'!0IVBZOHJ:E!Q4_[VJ8/[U`"ULTE`#O5E@XEO[. MQJ(J_4Z[VGA*<+V!UKS[Z=F*MDR0V]E8VDK7Z!+D"'+[@]Q;36EUCTS,E6RN M!+7#0TW5%:/,K[!M7\+1*(WGW//'CH>>!7;"Q.51ZW@8*EL^M=L$ZH#6G1N8 M]68[(8600DBI$SLZE?Z47>3)3WN3)/'&5IZAWD(NB+E2F/$Y/ MWD[M]H/Y5\`"T8[,V#U&!\M1@D_O*?V.2N`C\!T`?$9?T72-P$?@.XSDZ[66 MGFM4=_R]>E567EA?.$N>R_([3I7TF'SAK??*]?+LTQE0?4@FI-1H"+4FF9!2 MHR'4FN1Z(X7B\&I\>DS(W_G9+\G'0Y/IA7NIBX9IK)8N;R@AU0RZ+`$:7+S2>\U6-] MQ6R=VB(-64;K#.E0RZS;V_!<:[/:-LV>),+=UL:D*IJF$_((>7M'W@FACE!W M``=*;SL^PUOM$@K]5-&28,C#]J&HI7566QRD,LQQE4=)?B,EJ+VCBS" MBL#7%/!11@F![V"NU;ZB&UL)^7OURNAY\<(HRBAIZ)(XOF#K8Y3&QX4XE1!' MB*.,$LHH.3JDM=[K2X&64R\_B*LER_2B@]Z0N5E;];\8=>7-IXD_%:\TQ9M2 M(W'C(S[@0:\,-%J\!I#C-8"L<)V7N+<=U6`WMN%]?/=I-J!37B^?WK9N3B:! M_\/!"\[=9Z;J[U4V=ES7F09Z.F$8X^O0>S[\P/'P.F`/+WN'9Y^><1ID(1X1[0[M2&$?$>^8`04XS)">2$AX(:/W9M-D#V1,Z)8"`TM_QN>5J6 MY.+ZSYPGI")'N1=*EDYH+M'0)Z\OT+'X] M%'V'OP-/@TL/KPX"\D\]6WS]V0RY?99K^`;;O10R#TB_PXZO$Q:M=XUZ^\VO M6A]OF,]=HKY3^EX#4]4WOZJ&T3L`4V\"6!C.Q'39Q'P>RQ`ZC[F^]W`2\6`, MA`^B6<[=\O39Z^$W>/(>'CR'Y]9'DJJUBTA:U'0=Z(5)6H=24;]EEI19T2&+ MO.3IT/)T:"5D=(`,L(X6BR/1YL[)Z"(9:OO09`"(3NK`#@3'>[TR.VX"/N1! M@!LGKDJ%_?0>&P%0!V@#Q;`]MQ7X!O]+]U8SCD9^X/S%[4]@OLYHGK#OYA3/ M>5F7="=DP!_8P9K@[Q7`7])>F5Q[:N6_%N.093*KCVWC'.#L'HR"ER>;. MQ_09^0@\@0^4;Z.@>)^T^B> MIJJ?V#P;2>U?Q<9+T)$MRP]L5$&D+7=Z=\;N_0E(2:T'2GS%3N__^0UZ=2(@ MVQ(M)Y!E&6:+-U*_36=.:WW"'J&O[!OUTSM%&`4#U'I0"4#;P3,CP'MJMZ,N M9'K/V?QW/X4LY,$CF*LA6JUHK/@+[%(EWP(;.2#,P,PU71<^F#:+GGRP,?`V M2*1:)A;@&-!%!'V(884?66X`=V"F.*8;/;,;$&]CTWH&2TC2DAN4:"KWUGU@ MVH(LT'B6O;?079`?&;;M@`!X",R\!3X"(PGD;>S*XT%F,FMD>@\\94X9&U>. MO92@"V':@8DV#T.T(P?PESUU8:7/2M>#(^Z#?5:8'0>B]S&W44P( M']1$T)&78N??+_(23)`^PM&-Y.C2?G%\@\@4/3M2M`E?V70Q+USPV5ARDLY_ M=.RT)2?,.)3Y0`4)LTPH###C#%(,HRCM_G*NZZ0',0!8*FB9IC-FVF/'@_F! M=03?P!QE_4N);@?Q0ZBPIY%C`>.?)XGP#9"Q(.)-.Y.+7AQDK5H`.,%_`)+Y MP,4P4VJ4W*2`:)L2(%>L#UH?K%[;#]$#C(U-`%_BX0!F`GL`7@'X@3AXW1DC M7WGV$.BH&%A1+OCN1X$?/T@`Y>=[Y1P5I6/R%/SZI^.Z\'1^Z.D,/2)"8+`@ M81]1][1CV'/2!Z>\"/C('#BND_CRIC^,?)AU2W(@17/HX]XU)1?&GXQ;;*1C M$Z3Y9P@20>6H$C7$=BQ_-C),,,;$0D:!/CL*!;`#"S7@;K2(O1Y0;^IGXLY#$'`?'`:(I,W*\V?N%8:)QH/`K MGKW(GV%+XV'$^`_<;[F2OA"9/Z;?V1Q6-@J< MB)^`%,"&89`<]D&0GR`OG_",5BKH&`P@I>?IC7"+!":J[CP0)1.3L]R-<>$\$1@3'PP@QV>B?&5YHX0=(GP1R8D*JD?"O$'`GJ0 MTQ;+3-]X#!NU$'4H+)TA;.W03`E)35C^*[Q->#;"@STZF^9]&:`.X[I&P&S* MSX;QX*U`GQ^'@.`55Y_7.6:F+!H[68JRE_7BC)C%73><@#+E/?SRIB4_3W"# M3CZG$5NMUC3.*1?6OKSZVLY#)-G\/!;"O6:)LWP<+'S1WGW`_$X17IK2*0(; MOLMXA@N,9UB*\NU4"CIT%.RKFN$K#%AY31-R0W"'LD-PY#':VM<]+2T M_D7)N!&HL.NK]NR\K@?-+QV@H@W8YS&%U!ZROZIL5)Z68F MPMY+5)%^1^ETEMXT2M@C[.UD3'U-!S6X0]@C[.T=>[U>2]&KWM9^7-BCV_:V MKGM7_4OWU%*V]H2)$L"/8;63Y];I*OWMDU_'L+S:O3+_>V6`JI@;68(6\Y%CJ M4"MAYW$]]68[(8600DBI$5;HL$!X&CC-2N8F@E M)<:."ALO#H^CU!1*33F6,%FUI73U5QDE2]`[-/1T1=,H*8J@=Q`=6*VJYQ#T M"'K;A)ZAM+57N>&2CW77B2=LT:5Z3?3%-C'<0FLKG>ZQ%W8@E+Q4\6TKO;)" M[H22.I)\*)1T-*6GD9^64+(\DU%5^D9%=;*Q*-E=]4A*JF@DZE]-6"LAI79L M)J004@@I=2"9D$(>N_UY[,[F$B;(K;:G!?>VJW0:'++TCJ3Q+L'147K]Y@8[ M$CAV"@ZL0&@0.@@=I>A0^TJO:O13T]!!3C-"^^LT6P@IM6,S(8600DBI`\F$ M%'*:[<]I=HFWW/,P8OS'A'LA5^#WB/QF^[)O>HK:X!`2,GYW"@[#J'@K"$'C MM4%#[2MMM;G7UQ$Z=HL.Q>B2T^QUJ&\6EG:)S!^I`D>ZV]Y.+A15I0V:P%&N MNU6]T8V@\=J@H2K]WI'NS@2.EX-#,YI[:?DFJMOK]+N=\TG`+<>,'-\CE6U_ M*IM1]9;?IJTN`L?+1:_>ID`D`L>"&$9-):6-P%$*#EUI'VN`*_G;BM58=AOT+7Z=#Y&X"B/B21H$#06J7)=,@0)'(O`H?>. M-"22O'!%+YSU[]@)'=3=%&@FX@^!5.1,#Z:8/_+`]"R>JG7-O.FLD4L0]#JC MN75323Z3J4V.ND,6$5+U(XU](G"0]-B*HRZAZ_7>>/;9M)G-!UG"*@NX:^)- M"I'/+.@J,*V(13P8.]Z&I[1T[TJ=5_AQ7;E"J"/4-66*"'7;-)2-7L5K:)H" MO8KZ+R&.Y-R!E>KJ%PD;KT:MON(1O"V2B=^Z?AB^^[@EQ1E8R&P_'KB\%FN[ MXE7?:PWE8-=4*?U.Q0./$F`W>%T3Y`X%N;;2K5J4AB!'D-O2N6ZK>V1B[B6Z M,D%M=QNJKABMBB<038':8>-$=S88JD1-M4#IT):04LLAU)ID0DJ-AE!KD@DI MM?%/-M4'^8\+V<3`=^U-^'@73R8N'W,O,EUV/>$8Y^D]L',S,M?W3])RI.5( M@IN00D@AI-1Q"+4FF9#24!=<753!M5AV9DX<5/DN,,C3=J(XX.$&)]*TYFC- MD70FI!!2""EU'$*M22:DD/MOGSI?CFE+_[KTAG'H^-Z'WS!:\3=NNM&(W?'@ MT;$:FNM=,8:B#HNSWVUN<98&RN\&(MF["Q2VSHW>:6 M.JQ8!X8XJ8#1EB@AU6[2GC2[).T+>03PY>D7GZG$A[X6E-%]/S9^J^G;5 MO^[]R'2WI(=3E8,=GL<9K2.KIT$U7.H-N79_PV*'!#@"W"9CZ5"=*H+4PD;A(VR5-BC3Y0@ MSQYE+S7*_NJWCWU)$D1>2'.O358`061E6@HEK!-(5O@3^NU7FKM$EY)3YM)K MC*C6-XWO:'8\->'NT$XHK:(+BG!'N-NFJ:02[@AW^\==UWB5^RS=5DZ92]MG MU3&%6&/FTH;)M,T.L2;('<[-H[4HCC7',J$%L],PY!&%+%#(.)TX$E)J/X1:DTQ(J=$0:DTR(:4VSM57H>J] MWI0E6J4U7J6$E-JQF9!R5$DKAMY3NE7+OQ$Z7ADZVIIR_"D4Y/.CG";:TNNW M+@DIM6,S(>4XD:(:NJ*V*]9D)9@T87QO37"U MQCB:HC$<5\`U`8V`5H?`-LHHV;DBT]&4EK;A'02$/<+>2\)Y.XI:];[DXX(> M7<34K'2F!@J`E='(355XFAU639AJQ$`:BBG*#MEW/K:N]*JZ`0ET!+JMY/H: M+47M5:RP=5R@HUC5`M.^^K[]Y+BO0Z&MP]*CJ]10DKMV$Q(.:J4$ZW?5_36L5=2)W1L1NK)D>."8D_KF*E$X8`U MTPJ.*RZ&@$9`J\/I)<7^[?X04S'Z%>\;(^@1]`AZ%'9:/XV:PDXK8*8>JYY" M!`E3M1](0S%%$8#[Q9VNZ4IW4Q6&0$>@V[?:W&S,Y=3F#Y$)$U*JP"5__^U# M')X\F.;DXQU_&',ONN43/X@<[^'<"2W7#^.`W_,?T6?4@7_]S_]@[&__=7+R M]?KZ_!^7W[ZQTZMS=GEU?WKU]?+SMPMV>G=W<7]WJ^;_B,'*&SVO,VC\N9"L#W[57 M3>2]F,@KF,C;;"*OKN\OF,'D?/8T5?W$EK-TJ3*^A#&S;,C&.`C8AS7;6L%D MM;=M+J_%TOL19V?^>&)ZSVSHNZ[_%`+OSMB]/W$LIK=;"JO8Z_T_OT&W#IA` MCB6:GH(VS&9,RZ*9F>G9[#H:\:`P2>QM^JS6^H2$``G9-^JG=]`I,RW+CSU< M;$!R`%V&["'?JH^MPH-9]\P4J^9]F='VNV?#PTE/RK0A!Z2('S%SC,OZ+VZS M01SAEV$\^!>W(A;YS(Q`PIDA/`0T>5YLNJ*C,$2!($D#QCJ!^#AX9N9DXCXC MU28;PMN8#%TW(QF$XN69EO^XS@]Z>1MSCCS`: M'#]'8H&PW+..9SN6&?E!:4>(!&L$+,,./&R#66802(+'R'#F#Z?\@?'X$QZ8 M8AJ0ZX&0@"@X62AEHF`!MN,!3-@89G@4,@[\MMD=GT1\/`!:=6"ZUE);S`22 MS3`#X5M!@Q^'T';X[F,=5O)&;97Y,1(NR5[6V\^8Q5TWG)@6L/V7-RWY>6+: M=OHYW4U;K>E^FG,(+0^GV_D&S%9H%K/$63X.%K[0=N]JL@"R/-@5#PJ!>[MP M$LVH58?6WX]W)M,#]E"1#+AS;%,G5!,.HD][C[PB`-0+`!N>!![![&\W=[MC-/R(^;/IFIXE M#%LPGL^YE1B]*AJ]K?XN5,BZN+OKX,T^]O!IPL7N3SD('`2.XP/'-I-O&[]+ MWP3<=<:.9P;/4P>W\,[;R;F$ZI MMPQ%[='U7003TOL(("1'ZI)=V7@5X-3&0`L\M0[Q:#_3`D`SP+L[\+L7[_F4 M"7*0M?[64'I5EWI3,D'>;7]Z"''[5C^:`C;*>&L$ZEZ=G-M7HEOCE9OB*<1\ M[-V65!D*RZ]'E:#CBLLGT#7!$4Z8(\Q1TMON$Y#J'.K>R`28\SC`#(:J:0J* M//Y),F9,X35"]Q!\B3D=\M0(M2R9(WDVI M%CG'TH+L#"=D`0]C-Y(O86J'9P7<#'DN)P:?L;CS*!(,@(J?6N_;;.RX+K2K MS+XC\V2L.`C2[)(H3%[2_5X!)^'/$!.1N:/N=<[[XWT]5+VG4+?"?O2([P\H?@YFSG'!G8X M0T?P$'N6HY4S+[+\@,:DD4D<6"-L9!(XJ&"G=_T6?(A/)DZ+'5O"Z!RT]2 MH]B$!XYORRDTH_S[BL3>PB[Q!\#A?+_A"*9>)(SENRR%XN5,TZ',?,K(C$.4 M1V,>C7P[9&#,6B/,'`O\'\X83Z!Q!`/N`141H,Y_=%!0#9[%]W$$B^(O,X_0 M)/6-W0>FS<=F\"<"&?]FG@G,5V#]A[`K`FN$JQO>#$?.)$SDE87K5OR-KW*1 M[)6ZQ`L)=H4AX!H&1`0F*A$,@8!9;DZX9?07=]5CP'X^&W-DV@"H.22&BV() M%R;UR8PZG+G0&H$8PM2S$:;8"20EK@&4>PMZ*LG5.V1R7NT2ZEYZ=I:OHW3H MW(V-!Z$V;1`U4?HWCY9/!J`;/^AYVSLZ2*#.U?QS>WIY85CV-WS15)T]N0Z5UWZ6Z[I$6M=M67V>E' ML/G^+AW>WYSA!@6,7I53YLC$P*DH_[:5.6_P^3RA8@X5>-YC;I8,0=@X@\%=&]I*3V\.OWPJD4G./V([L;W>J:1-O3IHG>+DY05>L\B@S0PEVD1> MW[(B:49L?SULWV;1H3IN(>OY5GF`4<88+BS"[#R^E5.MYKL9IR&V+V!'\C%) M8ZG/FJTL=NJ2-52'I*"^TJF:^]AD>4[8V(!4*O5$N-A(9NRO.%+C596K.!!) M*5&60[+&SKS)^=\K56(V`%I=%1RJ`7,0J==6>IM6B7@=!W"$O,/J880Z0MT^ MY=VN7$ZU\<0WX)2@KCI*`]=D'=: M=3OCIU57+S:3?":D$%+J0'*]D7+LP1\OC1_\0K&#=5M0)`-HMR"DU(AF0@HA M97]>@KIH%NN%E:;E/%TG7"=E]WA#,3I)3><7,(,.,HY1OF@]G;8@@LC2.Y7Z MS;TCLN(=<82,S8XO>DLOJ3AV;\=:O+H/3$_>;6"Z+.3!HV/!,Q9T$I@6*2D" M3NR9FP&I*#4E^6!21E$[:F-W(`+)?I04M6\T%B.DI>PT"Z;3)=_)&B42#.5`H+Y=`LE([,=K-Q0AI)[N5'^IR;)`7I4P[ M*;^QC305TE1(TBR@N:MHI*D02%;Y413-Z#06):2K[#;3M-]>ZF6C>B*5>?FM MZKVR:^SCZS#U>/2=SMKZS@;@JZLN1#GW!]*E.NV*41%4[8&0MTT%35,K1FPU M!7@5=3;"VX$DG6%HA_!/[6QNCC`_N:[:20/79!W6G-I3>OU^8XUP0LF>-`%% M[2\-P*PU2LA5LU,1TE&ZK:51#<@PEPM?#5-P=Q+SFT(:KL3;P"URIZ?#Y$) MA&>?OCAW7Q<#30JW,.[9W&9W?!+Q\8`'3&\I3&NI\/\!#R?\J"C?\5AY`R?=P4H M8"KCT,-8Q&N5UA-NS.(NWN%J`8]^>=.2GR>F;:>?TVVB MU9H*URVD=/9SS34RU!#%!'LKQ8J0)FS"`\>W4:8@WLZYE<@45[58+8DN):SNAME*J[4)5K3'(-AU!:.E@@]).8PXNM4GZ.SW`,+3W7I(_7K$=)9[]O_V(0Y/'DQS\O&K[]M/CNN>>O9EYKX^%=[KT7#^, M`W[/?T2?$;V__N=_,/:W_SHYN>(1L\QPQ.)0NHL=[Q'=H-X#,]$'[40.#T]. MY/-I7_#2&;QS$_B/CLWMS\^_P\N7WF7ZZFGV)HL])[KEPU_>Q*U6ZPVSN>6, M33?\YG\U'9<*XS+:FO;24>'S MV'H(+P32.3TQ'>%U/K]C-R,S&)O6.''_&5L_P;-_#"O7\>ID]O,$5& MO],70ZG60YW(AYE8G^Y3RPIB@%%R$!`*'<-')8.YCCEPW`*:1./)*Q?)&[`J MK_'Y;]/'-^![OZ-/V;ZZAUK1#XQ76T9O4_K]V(M"0,LS2L'9=7OI6:#NA?R< MRW\OO?2-&_G"/=8^7)_A7;55%$35.CHLW2AK5*.E=5]"^2U_Y%X\1W#R];IS MWWGSJV&H:ELOD)0VMJ-.NV]^U77=Z';VV2F`1E5[/:VM[K-7F/)^K]OO&LL[ M/?/'8Q"Y800*@,)^>H]O`C0#U'QBT&!4K:W`=_@?"T$&HJ"(HY$?.']QL!*2 MKYPPA&7[D;%V1^GHFM+KJD*>&)K2[704H]LK'F%G+_IQ%()B@D=4GUA;5SJ] MGJ+K/7QYE@^2TCLD]`^D;4U^]-[\6ISUV?9>'TMT6(+56')W7]/]GE MU?W%[<7=/3N].F??+N[ATQV[_L+.;B_.+^]GZ;NS1MR.77X]_!J;@0G=\^L! M*-2RF%NF>)8NF9T:6NO'#:QSZV%9*,'5]?T%4U4FS?2>IJJ?6$6NUB$VH-YQ M&M<>^VX&UHC!RDP"9D"[!U1YN+I@+3\YT4@$8)S]=@>Z_K]C1U[3H,@O_?'$ M])[%\G1P9PY@U03/S`[B!_8T\ET>FB[H1:+"C2S.!'\#:-R,9 M,>(ZH`EA_!%^2`G+T23"2+(A9.CJ?@J%=0.4PO/0KFSG02Q"&^0$Z+?BQ3ON M.4#C';=B'-H7TT)%JSS&"-C\]]CC3.VF7,YS;Q@'0GL47.'"W\9@@-"Y@J$S MP!6I748CX%`(W]FVG(Z$ZS!R4+L=,T`]$BA.WQ>^.S_'C'00@^="_\D<+)@\ MBG9:N8HN/9R39%TDN))8!':"7AB$'($XB$/H(`R+L^\/(A.^MIG%`_R+N3R" MU2*@"]HE-,O>YI#_[:P`_&'@CZ&+\9@'EF.Z;&!Z?R*`V=!\!'1"&X^`"S]& MK3E`,Z`4GZ=1:>Q7W%8.JO[F9WWZF+YWJ(TP3TBH9O9?VQ,S^,PCO4.3Z# M[F^#RH\RZI"[\@XO(EZX)?>*._)2!C=`A-1.[_GL^'=6X$S8!6RZT3,#FQ-0 MAG&2-Z[I+2_H5@^6'E@J_YYMU65[_&FRV:(4NN5@-^#&J(&U4\YO!45>ND'/ M:B/B-7RJJ)/DA/S8?)9V3?F.[F1]"=N)^1,AQPJ"__+N.LRWKS#/]T[^'0,S MAPZWE[QY]7]SK\J'S0D(9=@VA*8G_/:A,*VBP!'AMXDA-^$!2'A@J\4SLPVX MEO\:S2>A>_#QQ/6?>?*([4#[H$B5[SK3"P[R%5!PEM0@_X%O2$5IHW8$IHC/B/TGA`F0;A_EJ%"0XMU.O/"H!.$ MEP\\1=%_]%>N"_(7ZOPS(EDV'>L5`N0"')36!JN`^%"I.Z M#ICY:#JN"(4NS#"HK;JB==MY=$`W':77SG]7KN&(7I8H.?A_&K2N*JVND;6. MLQ#PL530BF0)4!6G2`Z]'.L3.1V,#X?2<<%LM%02^R2W`/)BPT+V8074/]$V M2F!<@HI%B0VY^4@.\G-(0@7-M,>.!Z:7L,Z*9D$!`=]-SWR0IM@Y?^2N/Q%_ M8Z-Y!0D_C!U07_G<>BE_K"B53);Z;P0>9$,)AS[[L"Z:8(O45I'X@#9CLKD) MP55_7AY8@[C(UFJ,RQ=M`L1F@LB<-P2_`NXJF:<$5EFG7)$0YI00T/.&."XG M,(1`JLJUFEL^A4E%;3JW_RX= M26I&BM[!H'H$ZSCU(.F*VNHHNMK.T9*IRU;!"8TLE=H`.F_$])F8@V2-3.\! M#%241V#5#H6`3Z8#;.D'=,>DWJ?%`CW;:&<]*JG`0LK.4R6HX."9FPWTJW:45J^3=2-@;/,01BA3XL+\T@PPNPT0GE^^R9N+ M%B;F)29O%3N1QR>I0A;Y$YE*EN7 MJ:(](O5.9J?*<9(=;V7B7.S9N_T(DY"$.8K4\6%'^>NO&P"?HB123]+&IS@B M"30:W8U&X]>-^`N^B'&A204D0[WKA6*GF^X';7$FDK:1[HDM+W+LC,@6]L@Y M-5SX]"(YJ%E(-;1YIY[K+,6W?-\'TL'LB#@!GB,(HX!DI<$!("")#60U2Q<* M"+1/F,.XT?#3\XUE_M6%CP.\#1("L/ZW:`N7D+6J>$S8HGBS#+ MK5C%6L"]!IBPV-/$$Y:IRVV5E=UAI[4+Q)4IJ"6Y`"'HPNO.Y4@K5%[H:J= MRUYCU;KF0,8G4O#TJ'G/P^`J<&V^&W,IWW&(4#[Z,CY=@:TEK7M7XHWW$E)` M@R\T!/K@8_G$KH^U')N]01[65J>_M@Q48-;W&N'5M@I'Q>%<)>=1GSP_]W7M M23*-<1Z-N;;M\Y.;9_5V0J\=PN9K\=UWT6+A\(`<[`1N7-!(W)7=N/P0$MN) MP>Y+:/]3A,=K7SV'6EBWJ/]9&"H]>_=KK MCT>YZ3@!E:WE%X?-#L['+YX2P8_-\XBC(N?X>R+;ZXOGQN_6E@W3*`#72]L] M"W5=1-:/>S6H^T`GU$=K&Y+OJ[E>\=-[\EVV0,-]6&<,>T:>NLT]G(-,X*$Y M&(Z[.Y'I61$_0?T$W@5QM']3XFN?X,>$9)NRM_%;XB5\A[]2OBZ`E_;+SQN^ M2OJ^^7)]^_M'[?[J?SZN(-]N7/#7*!!?DN7X^U&9$[# MF6=[CC==QE%'&RL+/O!HO+<>^IV4'I24BMX0,$7"2$#")<7B+`[_!QL8^/^4 M9_&%L%3]$*`<["(&W_X9^2RPF26"%_!0'&XR\(07E+?6AEA#@T0K01:3#>+! M-Y'FI;%FS[AESXMB@B%OG&+VB:B5OK&Y>AO)4*=$4_M/H?]2<0> M6A-?@W"2!^]1@*52:>,OX2D;[ELC)SF4LF7FH=";=,V+2ZS:$17G7H[W!&-: MP"[U`LA_P/P(?M`4\C.!F(Q"Q4T"/AFS>*#[:4;E$5Y)+P+CC2=ZU"X.=L.T MU)B&SEC@SSN9T![/24&S4LK.X67_;UE:;ERY\<_C,7$3)&+Z/#M-<(5@D5%^ MUD.F\#0(44-+!EYM8I$23OT#A68K3"S^;4DHIO4'@(9(3R$Q2=H0Q M2K9]H"FXYQ+_X9MP;GK0VCK(/C'B)R*DAC M66\U+0YN3&PAGF@7"OE@24C/PGB8.!<\H>W1WGL@]()2K"U,).`&W@G!3DK$ MA0U.K4_1V0`&!Y=5S525N&)"5^B@0IS##2 M*S*^&**U-ENA,HLC5YAMAH;3JXS-H8Q-:<[?A#DT([HP?V'D(QX(1?`3Q3"L MHTNUPP9@T.#:YGS2;2']W`(4N7&N&O;&,\($ELK/A?;QH:CIG3E%SZ)FZ'/B=!0($"`1<%3^Q!^6L2J5P_/S+2%TPIU6RJ/;M-_?$F84 M55_X(UGTHGXPF]>P2"K(9-LZ=N>\KD>G8V[K_H9G+@=A?'3%CR]6HR;B)1EW MK%_/8V04JAD56CPE.4,L+U(L=W(V:K`$R+AO])M"#Q;>Z0V-2N3DRV&L%+S8 M4)."GR<&5RD.+4NDD26RLR9^:O8[A6H[&YH_.\7=5[\.#T!P4FID`Z%?B7_K MW_%T/UZIXROU>>LY@LTLP;UR%G=X>9-2#95Z<[&%8=Q=7U?_UQ#V>PKYR4Q6N`ZW=Z^Y).3;N[@),NX%NSR M&L?2K;UP\C]\O+[]QFLMO!6H9'S&O[_&G01N"'X#']_"Q>+.@&&"$%-L/N< M3*B/[_(Z,<2*Y$;1@JVJRRPT3*)N3?F&%RC.[#0+=,7E;.*!I'MBFP7H"8MD M.SM),O8S""39QD(4!Z41%U201MB*K?SF1J$OQB,2),5:G@P8?Z3`\46OB,*L9J%B'"'C3[:^P&$,*HG.>]V**J(&H/>%$7""- M@4;F#^B0\'-.C)MREEJ\?%<@LCVZW60L&&T0C)%QP/(#U31A)$103QL"?HU; M"G*5=5O`P`9$3-,;`^6M>GAH``(H#\?R`%6P36X@SQC6%,`K4S994X%,ISZ= MHJ['&7^H_!;/*)0Z@@8!OLHO&^HNPV;<9=BT+(Q:=>\_$2;#!RA@5.32YZ1[ MLUSE*_YOO-$!N`NS`O\USWL71]4K7*I<3S$:M?QZBJJW\Y;G2,ML\3=&-P.3 M$?MT=<_ED6^L&!OZ8/-M4-5O:5&B7B;J3\07:2OOYC)U MO'G>829S,%<&<+Z$JUN MHCN/DS/6!^9!+F1\$4+/+YLK!"=XT:0E/9`>-$#.6^2CF[S07.<\3OK1S(M6 M?P):8A*;(#,JB+''6H]G2+(`8WS2D]P8P$0>)2_4B$=3;;1];11HHZ?W![NL MX7S)H]CXB;JE-%N85RC*@71$WV-]9%:-]Y5?R;Q%FL]^ M\OE,\`57,J<.%J3LI;1QY:.-NM8,EC8?<3#)'=1RW(#D>HP7XRD\&?83=!5$ MZF(Q&[,$C7`R,$%^'5=0@,:LH'P7Q>%]^`="`6"HB#`[PDZIZ:&A(]$WU(W! M1G>OSF;3]9Y\LOC[*_'OV?WN5F`_VLK?0X1[6FV_IXK+RGQLE`\_FKO*=W7WU,D0R7^41,9:2.$'OJ])07U3@9:#Y_ M]SR"WHK-:+7Y$A[6KI[5WKB+A@CT_F"+(PW$U(?#C4?(&^6VRIE^DS1U'X!4 M\ZSD,YB0PX)[AX.68W2JIB1E:E<(5$_^I/L(SF'S\&M-@.`*:5,\8E-L:F;_?9Z/;[-PB*L% M"\\-O)9FV[=1]=Z,=&.D[+(2#F67E8N<"5CX4;8>``(.O!Q`*I,]I6SUR<(9 M>`NABF_8-2#FI044'@16P&EYXW4<^6MG-M;Z??TX>8J1.V3O8WN MB@KG[[)X$'?*L$Q-`:K([Q!^$0M($Y3UQ40+&B4I+:K';'3TX=$*\#1%.%3< M?R<3?N.&:XRXLM_*?C]C^]U&23'[NMEI[PF_`M8%6 MDE(QGE*AYGFCY627V(D*R^]NS__A>?83LG>J6T%:O\J\B`OQ]K7#O>>RH*P,I%5*K:Z::?`UC<]5Z)IT MA4[S[VBAWRT:!/$M*HO(MV8D@#]\9E&-7Z)=?E5+>K+@VAJL1"X0ROBU)FSM MJ\(X7![C(;SR$=6TJ=TV7I8?5\'6.O/AMO$[.IP'>^<%_ M%R_A7]?>?$'<)4^>L/"IISU0S?(I[_!A"8OJ_(&Y_/8:_J'/O`@8M9"+;A!? M,_/$Y'TVLD5!U<@TAN^RK^LP2LN)[+A!P84E]FOY7A!V^Q\/PP.,S,%@PZ7/B3\6L@&K#5*WE.G(@.V\LD.-, MI[6,+S>2GI]_0^I^H\2!(=S%@PSH%$MF7FJW*[-I>7ZVZ7SONO;:-"X-;0[O M2F+@Y0A8B-*(-VDBQ!J$?.$%.*9-KI&R$-#D#0B,A2PG+I@#+F=7=]?:O;=@ MEC;J]'6M8J?W__X,O3)P79G%6WX/T^^BY;GF:B9T)#OYSH'7H\'!WV1N.2. MGUR&HB_",+!.*_:&N!H;!0I)\%&5'ARTC9@@GV9@U#WZ&99W:4N>HQ[J/Z^O<-.8)O M??%`]'I:8FN-=UH<;N0=9R`!\HH[M(KQX*2@6,3WESAIR0#2SIMO,K?LS4]_ MEV`I(.-J>WW59K"S`3[JRCV"T1S\$_:#"I^NJO=YU/L`6W`'8&;C5RE2UCO! M1D[;LD-=%P3HG2"*9X%84?]8//@(:C-'XUXC0%=EVLZ]_:Y*)HAF8RKTYH+/ MASS2;((*53K_6!]N:[^F_1'02>1HG]EDASIBE>:^.:JWYV2O4D/K$IK`_^-\`&`-_:BZ9URJF M\'Q70AG$WM_CE,=:S5':YAQ=MRAW:*3W-H--#@K7;KM=B8\L-"L*8)04SV<< M$9R=L84R,-AD5UM24@MSH@S,2\!(#[?EMIP09MQV.W1-?8QVXL$`/\MQZ2YI M(;7VM>TW3,RUZ82YL&X=B54-MUL*T'L6NS?6!X?QL/:&O38A`%!G$$T*7.S` M_%;9`87#/&-6;Y/@BB_YE/YFOB!6B`[5518:Y")D@OILKGUB+G$M1AQU:E_I MU#Z&("R`GS&$I$(GE/+@0[<.J"5@_38+?!G(T,&8OFL[*!GI` MSKH@K348:W2'EZ-RS@[ZE_W-G#7&E\/:K+U-7I)-(>4H_[:'*X<7QM250!LM MSU]X/B(+DW+OX8R$VA/U$=U&'S&RZRRQA8B#XQZ6`AX+U,X(0H@98C@?*'6U MT"=N$&/H/.T]\^XLGRW*^B!X!Y.?$8603F76$?U.K0C_:@,J[,P&\4,*(:TB MI7H.HIY,Z>M!1I\Y?#)=J7@P$MZQO"!<"]<.J'@>2PU#'!4(3?PQ"(-#I\31 M-1+94M13]^!G_&P#JG:MB6^N#W`1DDB<>Z)2Y M/+L"IC2_6JP5F14()#_+W2^U>`*$E`:EB9Z'H MR5+DTPFBM>-5,9,QPN15(ZC"P)A'F!'0Y!FS<@MY-K/&IP@WIQPL+:3[60C@&E/@N9RW(JQ8`#^AIS5:K4*MG#Q(5B4O0(?T&QL[K M;)9+,19\#_.[T*./J$?UP^JU$TQ/-[R=L4+/>M*_H.U\X7-^:*3PVVBMVG34JUM/\$0-S_2H M75("_HRAW!/'ZML_D\EYIYI'-8]J'M4\GKUR3JO6]%S"3%.J.K15(A1_%7\5 M?Q5_3U.MIF^V/)O[FT!7'L-/:$JB7A/R\'H]0S?ZW2,I5//R/)5TU"I;,N[I M_5Y)H$Y)AY*.=X9N]L9ZI_O<+^=5\K&K?!C#OM[K&L]Y0R8:2C3*[8;3W2FXE&4>5#!,\^A?JK;W4 M.-M[$C`K3HK&A%KX8^ZY(J]6N7#'5;C.9:?WS-5-B<:NHE'UEEHE&B].-#97 MSE.B\8)%PWSN"XJ*MF58]H$Y44AMY;\I_TU9XH:)AO+?E&@H_TV)1DW_[;EC M<5I1UWL[9_:^_'I;+YRV#Q^O;[]=W=_W& MM4I*X*US_%093VCRUM7^&3E+S1R7599-[L8.>=5$&F`98%[;<"&9KCU$`70= MB(J/\DIM;Z*MS(OV)J[<;':RLY;\:KS[2=>(]C3S'&=YX3UA5@B8S;". M)K1I^]$T"#V?7H)SCW4MK;6E0+-E&!>^]\AL&N1&QDO2$EXMEO`ZCS@ZBA60 ML5BS>\&+QR:#Y&/3`O:=WU^E.8?$D>[H_XCD!UH5U.? M\I*K-U.G1><)+BQ8IZ-XXYY$62KKF+97L<+>-76E>J= M>H'8)^8X\=QHR"7*B\8&DISU4QN3"5QU`H^7P7XJSH.\@HT7%P6F0LL1Q;\] M'XR'*$&>9651[R--Q:>A"/`+"Z7:?.BQF[%XOY70*0U M0\8%<6W86IU-/>05T/E$?#E]#S0=]O]%Q`>](5[&!-'#K3^=8.Q]6LB/K>YRV]S&UD6ZGN7WW^`_;H=`>:OXDH<:^/X)8TY52G6<=H1Z\4T6RVJW/6K?E1O8V9<\=VNUZ< M;<3+@@]F%'=T$QJGLEO'T1;S>1B_K7D3M/?&H-U#.I?XC?7.>&/4H;J#ND9` M>R_&0-][(5Y0FP;70_X#WD7*;'E@\2+"J#>LSO&NW$Y0,2W"6*R^`'XU=VU=N\MF*6-.GU= MJ]CI_;\_0Z\,K#VS>,OO8\#:-;_[69Q5YP0@!U7#7J&_/$R-'_PYP,?DWF4. MD(M\:T8"C@800+(M>*[B@2$+$/'V)]ZJC`"9Y`+H+%QG3DD0^1*G)=`Z9!)2 M/X>^PH-Y[4T.V/>3]C2C.NT`"X\]6;I=/(1/G!#LT M`VQ0]T"@?P*?LVZI\WADW1/L]XY;9/\C*,X<\6DUMG55IJT!.X5*9()H-O,D M[9!QXR:H4*6(TOI-6OLU[8^`3B)'^\PF.R1:5YK[YJC>GI.]1BE;.O&?T+/] M%WJV5>=]E^M`&J7L%;2X,;2IU:N1.)!^RT/IUS*W"G:N01V4V?-=``/V3EGM9;DUR.:IS[R5,V?6(I\X)-&CS15AF7 MAI)\QFL%!AN+U.X-#]AI']Y**_19)O1C0#Y-18]3.=.H9YTE?I<-;ON-U4!4 M!3@2GQINR110ZBR6<*@/^L?$L5:'234A1%%G$$T*7^S`_%;9`87A:012LAS# M\\O/47`Q)63Q-H:'9-`A'UB`P(K(I_?T>_@>%^%?__H73?OE/RXN[K"S;60?.>`A9GGX"'BQ87X_H%YP=NDA=O)'7Y_ M[]V)KW\7']^3[_^=?JI%+@N_T59E.+S8D3_/W51?<5WS_7ACF"/[ZY><=>FO+,`T8YG#_47[V$)WB:C8+%EX`&U*.5/E.X\)6 M\8!B6?D'82Y^<^O>$8?>3N),S*\.<<./<29F_2DSS#X?2[U^FC4,F)+=1Y#> MGJ6]`\-QDH(4P.\.S MLP/DQ>CV.N,*=-QD:=`>Z,3S:4P8F""Z(N!I&Y]@T;CV>#TP4/RT5LU[WHAX M[QZ;`$/A^2QY4W8E7LP,WL@/OE(Q[].I7$X8]'G3389B[RNDA>;S@P*I+WU:<3 MRNO)Y>EC01!1NTA>\G:FJ1O^9FTF9J1F?:MG)K-;E\PKR_*QEZ3X7%H>CU?M MRQ1E9*FRVKRL+IH?LQA M=Y]A?44T/[4#44T5-^06S"X+M0FQ>/*`#C_R,FD3"@3R`JFP9^0RYZ^8ZK@U MM%F?/7=Z3_WY9]R(WTZN1;.UEZRN@<7!$^\^"&B]Q[NT>[$2SM,0J=O9*2LO-EST6=P^JJ3E\TB M+4ZQ+-Q8V[P,>]W1R,A)J6CJ>+WB*C<:FF9G4Z\?XB4#4W5N@1K=:^Y6]\@"[$KP;^ MVAGK6,$2*TJS1^HLBYS)4`2$2OM??PZ-$?A1^2U#::&\<&7.,XX.N$!WF2_$1NH@]GU;)\T;1_F*47D<*U5ON/.TNEN/WQ)+$:C& MQ^^6$V&(_A^>9_-\R]K\[YI&)\_^*OV?RXU";"AH@Z M&'B:VV#$/<1F$`4Y@]%DN;$U]D-L:9M^OMN)[ZE+)[4W+P,P)H8Q[*R&OE9: M/CEM0]SO-Y,T/!<&UL550)``,>P]%,'L/13'5X M"P`!!"4.```$.0$``.U=W7/CMA%_;F?Z/ZC.LT[V72^-;^)F9/M\]8SOY+%\ M3=XR%`E92$A``4#;ZE]?@`0I?@`@2'T0O/3%'^3N8A?[([A8+,`??WJ-PM$S M(!1B='%R]N;T9`20CP.(GBY.OC[>C'\X^>E??_OKCW\?CT>?``+$8R`8+3:C MF_@WR&@\^N5G#P6CR].SM]^/QF-!&D+T^P?Q8^%1,.+R$?WP2N'%R8JQ]8?) MY.7EY8/$W>GIZ>37[Y?#?W5R#RQA!1YB$?G(PX_0>:7+S#OL<2Y0KL MKPL29@+>3?*VM!3BOW%&-A:7QF=OQ^_.WKS2X$2JN("8YHV(?WP"UV]\''$1 M9Z>GY^].,THAR$*=C/RU1B^M/SL_/Y\D=W-2+@@:1.<=Q/OY+VE'$QR"![`< MB=]?'V[5%HB;DRN,*`YA(#QXZ85"SGP%`*.\]404VZS!Q0F%T3H$V;45`Z<\9\10(S.EE<>7=V$^*63LBVD'T;[ MV5H\.!S%AU&_(+Z@OT?\S`3Y9]&*'%@0L4D`HXFDF00X\B`:1R!:`-*LK@:K M[Y,&`B8>MO>)%66Y!3U]+_3C,-'_CO]?:A&\,H`"$&1M"@T[05PT)]L+L5]J M(Q0C#"9*LYCWBA&.(*"I=3&=Q'3\Y'EK8>3Y!(0LOR),/1^?GLEQY3MY^=Q81P:"EUKMPKJ9[=*UI0<.^4E(WAD,O$ M2/09QKX,GS2.HD3:F#\24<:_)#BJ]2HVZUS0[,,H)1PQ/*JP8!(`(E^-+P`^ MK5CZ3Y]>$N/5%`7BU\<_8OCLA6(@F+(KCY`-?W7_QPMC4/%>*Q[90W8\_7J[ MZEO<\Z=!<;,;RXQJ[[USR7O7 M8`FX]L&C]YH:HWU<+2AE%YDHG7.UO5EFSQOEJ('P#Q>!<`.1"&BO,,W-JS_8 M=L05.&B(G46$E7%VH-")4N/B_S#X^+H&B`+*0XT96P$B M-5+.(-JPR"Y!X.56]+9SCNU@B]F]=@+53O[>I8?_GF`^N6>;>SZ99=P,$7VN M(^6C;T,J.\](ZL[DK85%FKF<6<(`8CC5R^L+1KYU(%`G-L0"!6)W4-#**@T. MFF0,(![\A''P`L.PXO/J9=D/^65W_*C15..Q+?4`0K1;Q#ST!/D<,4?7QU<_ MC,4RBL9O;5CRF9D%BSO^[F"A!@MVD@X5LATXE-\.0W;1O)+>$-"7Z=V!1UO; M&D9V@Y@!A'E)="K!K7N[&VED)ZEIW'&ZC0T:1VM8U<[]ITO.O8/>`H:0P60B M,F?8_WV%0ZXG%>$HVU3\;$LNNZN1W!'3]5;J#>H-N=8^P"9+2DAN$BDP7A+E MXNI!04%U+E)/4/=NWYE'E>.PA0DZMU8\Z/0*XAU$0!0^\#22UE`,M^=Q@]/0(278.%SMUZBLS;"@I'G=UHBXVO54(& MD#*:^CZ.$:/WWD:L6FIJ.8Q$65&'FLA-GUM99.%VG9P!I(CF*TR8@.PE)@2_ M\-EQ->HR4,@>4E&XZ?!F6RR\K10R@(S3/%ZOPZ3^SR.;6T1C(F:_MVB)221+ MZ5)S-S>8W,0L)N`>A]#?7`($EI#1.\RG4O0J]&`DXE'QKUPM>0`4D.=:P'[$ M%C,H'J%%1Z%]]+ZV>52.H=21UUVG43+67\?@$8LUHOE:5)"26K5F`UGVOM21 MN8DR2ZMLWIE:28?*O>G\Z?LD!KIU7WTVHC7?-D*RY',4`AWMMHNC;$4/((>7 MI9D?P#-`L2:HSHBY,CH&-V%@H;CSLUIMWMQ,I)C;.I`YUZ6F;$PQIJ,LJF%,)+7JR'4Y(XAH:5Y)DPTBQK`U%>^;6Z1CR/`+3$@PX:T_'I7 MDSJ&B!9FF=!@%C.`F7$29=B,$,V$Q47508P*UB:9$&`2,H`:B\;UU<85U88U M5%?7(1OM:KT]^W7:1#`-":X]R"/':^\-61>6`!E-0:W9L@B\68&-W'0VE(+ M7-C(=#$T?P#,@P@$'SV"Q$H;GVO$D;`5!'P2"GU8WXALRY#O2FYDJ;)I(JL._[_04X[:7,N3(_N_`)8FDT0"WX5;RCO2827[_6[O2-3 MXX8_RKRW&40Q1\"V?R_!$A-02)I\A@B3!%`2)"@H2TGQ]AFP%0[$WG3*$J=5 M^J>'EO/-)L=KN:\A68T^W&>WEX;UDG[I1I@CZN7B;%`:*@9?S8ABH,C2>0J* MOA#8!]"P32>5<'A$+9,$I$H[%]'XB7#5[@E>U@)7Q9UL8V;A3E^H,[D?FY0O MH4(A)=FX6>1VT6MR8;LZ<%0OYS,*>;DO9ZF\@;7JECQ48$WG`QF+BVX1._=F M2ZEC+G^(KW'/.227&3JRI\JEQ>[TF?9)UH#I*Y4'HT;,A'^6D0003% MC(C!9R"K?U0K;^TXBTMQEIR.CJ[=C;<9?5M)MZCZZ!UE_)EXAN)TXAM,KG&\ M8,LXS$KT:XL\S:3;`U#TI(X"IX5Y-D@QB[,H^>@=&I@?8-!)9P/\FALR6 MU5,HJDL:5L3;2G$3L:/@:66B#6":!%J4FW0#B:9\/#M,))FM9LK<1FL/DJA> M0&1)73F11T?MJ,_;&6DU06R2:+%GH/>A(T"@>*)\4;0"KD'ZNYK(ZP]KG\RF.%^9*)O,K[OK+S5[$Z.QSOT26DH:-.Z&"G:M.IB+G7_2^Y'?@FT]3DV MVU5]+UB*EU`HBAW`42_78$V`#Q-K^=\A2)R&@N)DJX*)-BSYABD+EF$AJ$,O M[``LN]8&L3%O:X@!5P;\#!@GA\'#,+;3I!A/#X-)(EY?XZNB&!0]; M>W?`BJ&)0^W0^W_&;$=8[)!(:P>.CODUITJ`LSW)=KD.2^K*5F\'Y2:9$/G*\\`B[YQ"^XPI&P*%V-:)RM[T66=,MN MLH8%V'WVVPYPWE&-`1Q9H[:F@F(S47XFH))H6+BSLG0'0.GDJY'R@TM(^1/5 MV'3#3M?2FW8(ZE*1<^X2CJJIU%M4^'AF?7VJF7:[2F6@'1:4VMB]`Y8:FM&D M,9W*8]9-R+[A60_&K&BU:"K2#AU->KOWBJ92,QHT.96EK)L@OQ&8S6OD="8[ MIU!9X[6;$"W^K(0,'9@=>FJOB+5K7P-EIQ*OGSR(Q&K4#,V]$,R6I8\6C%E&3@[IF%!LU-/[)*/LVQ/`SVG3G"H/U:5X_(?B1?4J^':,&E'2273 ML*#7J2?V.@JJV]-`[V#';J=G@$L=JB5"JGM9#5#IWK!\;[)K!Q=7Q&H\>;@# MM]4G?U>7`,U4YN/3!^9G.UMW6?S3-:#Q_>Y)R7:'K;<^9;WU\>HNG*O>$1QM M>V`7G%BTI8&,4]G)\B:1]#N?W%C5QBXCZ<"08F'U7L820RNZ6H(S=\"A,3[;^WZ@S)A'G&RV)2#; MA@O$A]+3/2/R3J`!81O6"A*M6(<)QPZ]L@=,VK4ZA*,;-/;G44;;=[.!T?QN M5C%^(^_FYCXYQ+M9V:J+-X7F MR5>D>!NS97+R^B.><]WH%A9W MZID=P->VW0%L.RJ&%+>4QN(#U]PZ\431K\)4/D?B[PV1($*!^D$3*W(T_XQ` MTC&SQ&9%)?7AVU)$E?MO:UB/RS'[?4_1[0'4',!FK5*85OAN;>4Y*G[00\LR M+(A:F>1V,KIAH;9HH99EN$[3]X*33BMB;,K'FDA\(,CZ02MR#-=EVCYPTF/V MJ_P6GT'J(,Q!VQ6^[FZ[29BP?0\ED+Q5<T+`[ZO,7,J[$G''"V M*O26G]J\$PNDLT4(GSS5W+X#IRJ-W\`Y/`1TZ9<"$+0GL"B^%7_@=0 M2P,$%`````@`#X)C/:+:SM[%-0``67L"`!4`'`!B:6]S+3(P,3`P.3,P7VQA M8BYX;6Q55`D``Q[#T4P>P]%,=7@+``$$)0X```0Y`0``[7U[<]M&LN_?]U3= M[S#'=ZM.4B79EI5XXYP-3E$4Y;`BBXI(;S:U= MP#PQ0P"V4[4;BT!WSV#ZUSW/GO[+_SQO??`(P\A#P4\OSEZ^?@%@L$)K+[C_ MZ<7'Q=7I#R_^Q_F___&7_SP]!>]A`$,WAFNP/("K_3^\.-J#O_WF!FMP\?KL MS5MP>DI(?2_XYX_D/TLW@@#+#Z(?GR/OIQGET_G+U%X_^K- MZ]=GK_[VX7J^>H!;]]0+HM@-5O`%P/0_1O3A-5JY,:U5E< M"O+K-",[)8].S]ZP0T@_WZ\F^;, ME'$?O=I'I_>NNWM%WK_RW27T7P7PGF@1%THEQ(<=_.E%Y&UW/LR>/81PPZZ' M'X:)K%0*:Q& M#Z-@3?Z9_&OO/;H^#.)H%(_=,#Q@D_FKZ^_S-J2?_=,++9[8BTDKJ/&\*K<$ M*:S2%B&,T#YT"< MT8K\`0O*O[PJ&J#>9*.PBB`W7&5?@?^4?'E*\6J%L$WNXM-*(VQ"M-75/FJE MGW)S_PB46$&,@$Y)QX;:IS>R&\77?N,,UYR,/G((EO/>"`%,# MM`%)Q;]4/!9*_!(0>:Z/R$FP[A^/YV(\XC[W*T#B>5](['A`<@=7$-=KZSMR7>O?Z#F]:>SLY/O7W\'W!C,,>O*\@T$$(]Q#S.('&*:('D41 MC*.:Q@/X-,7^H5;U[*D!B&J"S?!3".-#)Z-QTE8`,&T&ZN\0:0BP2DW?I4W1 M)ZKJ[8XX[5;%4OJR@)$]1>E-=-9HM=_BEJ0K8*8J(S.5^7Y+.C&L)>!NDSZ- M*M$+@+M^S'N^E;OS8M?W_@WQ&!)%F"I^P)W$*3J7R-'\0/5-@.J]J] MAU2VM\7_AO0Q6B506-$W+HA#[_X>CSSQ;`@2PSRAH,G$KA[<\!Y+=>]=LM`% MH!N2B5-$B\$U1`$$!_PPDQZ@<.OZ`.W(JB21N3JL?'@"O`WP48#+.<&5WRZ] MH%Q3]_X^I$M4^".345S:$K@N4=8V2]>G;1$]0.Q-UICZA+RJXAJ7'X,(&P%9 M$_4/8(?UC]_BPJ`?P2=L")"T:T/>2S"NRG'#I$E7A!=C#C=%"-/6)\I`0811 ML&XTPS>J[?#MRR';(&_:J&:%'0\9$N_.'F@SWZ7?5'UGX$>8A9BY_;I(OB>I M4CH+A)W$@+P]6P%(V'15S%5("N0=1WMZ?4%,&IN_O-!2B:13^)S5R',>^HKL MV)'QF80TYZV--"0IW3]C3[N M$XE"[2"5!JUBE$59(%:NZ*Y[H'0C]-8]D'T\SC*8D"CKH=A$)LY26*R2ZX1A M!`6NDU>`P)6R69SL.=@E+WIUKF)U(;7VK;E>)FW)%7>D?;VN4S""L:5ZTJOF MRD]?9=L!GR\(N#VP!1AT[.'F^]W.AW3/+3Q,@V@?DHV;:;`A>RQD%^[:> M[\6'*Q1>[>-]"&^1[ZT.%S"`&R^.KA$>9D1CW_6V9&>8_$PWBN]@!,-'6!_` M=UABJITN2C0PY0X;Q,PK=%-1OHOIHGPG>9MU5"?`3V5B*^O3875I-:@'9%8= M:0<%%U[Y#_>@.>,6#QN_`B]!S\!7_,0?KN&8J/R:G(/!.;U1Z$W3 MB#B:2'&>O6T<"#)2D0PD=H[I"4H13"%Y3$X6@``>:<""Z.`:>8.6OG=/*Q*O(U'#A;29:V(GCW,IL1A?D8< M?.-6\9L+_38Y-9B]IO7?N@=<<2^"]-42@C6$Y,@/"7X*/4?:9 M&Q^N8MJ(V6;B#H6DS;*V+8U\P3=$,.-88OJ(?RIO8(?R&$8H,XC:%)]#79KD M\^19<_.K5;B'O./8UX76V'Z_T:U:/.RK%4,F=?PJ?I^$?Z4-(CJ9/9!97%,% MC<.AG$BN8QS1U@:2I;Y!HUCA>J.B%"N]1\GCGY!@PMCU:)`K<=3%@7'2ET3X MT_Y3D)#7=TR=OZ0GK8`UQZ6V[ M@&.=+2^W=NV`^=J+5CXBM64=*\_Z23P,AZ'GDB$X/3KNK6D'A/\:0H?#,G5M MNVNL,JNQ5Q:>%4OL=[TC)#;"N6A4+R\`*1?&M0,KL9!0`*[1?,U!6+]+50M5`9%R% MN1P'01GZ\4]I":T6`#EP^*1J=I^2KZ?<;TH(P?1E[P(*CL\%-II-CT(\!$XN MM^OY\!09=$X#/'&`"V*F7!>I0EHA9MMRC@V@#O=7:A;/VUR?6)G*(,KXEM2A7GK\Y^>'/9W2CX;LW)W]^^_;DNS__4+V^+>.`:"9\@_5X&@8&A M\(LS,Q6F7+ZQ,,B=[%EF,)E)Q'3W[D?P?/+\3/]/\?_FY.UW?SYY>W8^G-L+ M!:I$\O:OPKM)5P#\V(C@C&4U;F^WB@PZM)5@`Z/A^Q].WKT]_[*PP1L*X_3JYQ*SGI^CJ3,D.VVB1G,%ES4JZ.X`M>3]$+"47XB M97T)-][*:UZYK,J0W[\L93"ZC%FU.J8W,RN4([JF6^:UD/3UU'61*3?D#^&H81N70J/M1PRR?(8AB;!"8Q1=SB#",$ M67(%H3I-\G2A,2J]^2]ZCUGB;&[%DH/'^MJ=&P5KJMU3)FQM9;'([&R;"JEC;\N*5HK2GPF9N;K/0.>?0 MK$-9ZZQ-&16<-/=IF%S,S9O.@76L[3G[^&)NY'TE"%/8"[2*LRHY5L9^6;FWTH;E ML(NQ<8^EDC742)W1?#Y9S/N_0Y&/7J%>LB6]"DW]9L4!82]+Q2."((>&E:_! M'B`YA=K`95.T8@J``J75O"3]HY6G(G8J`!7LUD@YB0$&@639\(H#;ETVQ9FH M#1/0K=IQ9Z9*AJ(LQ+F>CBZFU]/%=#('HYM+,%_,QK_\/+N^G-S-_PM,?OTX M7?P^Y!D$W\A:(DIQ/M$TQ790[#TV4VZ/8C\E(+0:S72\TO,.U MTOY(6=E-X^#V3*JXZ'T+9QJL_#TY`G>;!,V/XCCTEON8!&`L$`DW($'^R,?U MN9\&,<2XY1G-<81SMXZ,A%O=C[#QF;:WK`SKI+,!8E24,Q_8HMV14"S8<+%H M)=RM&I,R1-L\]HRPZREGEC3Z"H67:;O9%"!:R9CU8_ M).*KFB`5C;+,1:WO$3`PS6.HO4Y2KRD-GY:91)6*9PXIE4U3J!9LV0QR MX1HFD/*PX9_$H@\*^C7-\6'/5#$/\@FQ`.XL*/0-]5D1\2_#.X.4!_HRJ4WD M,ZI@&?[5$C1LH,S(-H2!W#VBI%>^2?!1P+.+$H?`.+B0Z?/RA:1J-6P**%C7 M+Z04MJ+MJP5:O(`A%ZP89Y_22\+L!Q,_7U,4.X">J)L4R(G_:O?"-I:TR)>R]2C89.WY9A7 MEC8Z'RA$\6R35J4Q,F"\RX<"Y7=&?3^C$-/.OBI2U+N7*1WRDQST#_N'&;OM MD;#5ZOUSB:3<(7,5US'TWHRCMT"S6PR MA_3?H[SGK0J1KGNU+*UF)LIO6.7 ME1U:9P^V.6_3[ZV_-0`OIR`S%]44RD=KG=;)'F3=[@D(8*_S09XND*0-J^"L M$17`%"JSVPSL]Q?7,`-"F$I<RD:%VWD"F3J#+"HL<3'?UR#K9)95( M_0^O4JVFU3'Q5^A<2F/X;WQ,^NT?7J8? M+\.;?GQ=?J:7D2FN?SI,OH`!;&YM2J@J([XFE;$?Y19L8R3%$BYS3$V>4D+, M(:QKRA2&%!N898D-XKK52!#0,<)O8,Q=O62^2[^Y^LX`P\Q"S)!;%\G':Y72 MP3_3?JU/=+*;'0D;K(K$"DF!O^/HS.H(JZ7JR"BE4%XZ4OE<=,CKV8^GQ7+N MZHJXIYH+AU<#MCZ1(TVD.S>29WRNUDY%QM)J"K# ME2:5\7"%6["-X0I+N&RXTN3)ABO%3<'#N!-8ICFDV-*L<4N#N#YND4"A8ZAG M266RV$P.UF5D:4MPR0S0+BO:#.X"Z7R\:D&D6J# M5U'/HRY@KP:*GG%_X4;>2@+Z"@T'\0F-1;A7"K6+]4RT.M`3#H?^,R0P5S7# M13)+@1P84U(^AAEJ[AG`EYZ_CQL!NQ(J#H@S*HLPKA5L%\B%<'4H9SQ.^L>0 MX%S7$A?0;'5R()T2\T'-5'O'L/X->OR_'4K MWK3-]'@-#*-5)[?2#D#(2+55 MF]4245CR,-&KN:)57@89#(C)BMA7A4O>*EKWR!QHS\.9(;=EU^Q_;,RHVU:U MFUY(:0:N+:SHB]RT+RI/S`=S,45K%&D;NWA6KRM%W^`'L0K`J6PZ$);=#M.2 M6VSQ7&[[!B^KZ%'L75"HMKES9>F./`!<-_^Y`F4PC6HRW)J_!O^KQF(SHL M:8LJL1@8K$Z5S/H6\E$;_52-4(6SL#Q]G'5N M;LFET&K'%16IG(ONUZ#4 M=(PT=5$W(R%3V8(T0-1U$K%T7PRNQVA+:L7JG<1$65(O-I%)V'0%8K($FC$^D+ M\$U&0HZ1X__E5%\*?@0A@)81U+MOO0WASO76V;PAG2[@.3>]+6T419!UEX.! M$*XW5A)BU?QTJFW;*A7+UC%7)9%.2I5?(DB7IQ"A`"XE&981:T%+8-TM(,HU M>A59(F^@C_3>W41V#=RM>Z`I>D-WW;S32(>)ZP:83%;-7E0MVV;.*4O'K)DB MG/SVOEWR>%A6*]2\P$H5$,.U2A:OR`KE0%.QNJ6'(FQ&9]B0SE]3(R)//HU] MU]MFHFNX#.#3-(;;3^>U+TN?FX`]$_V='3QG-1(!MBC223YZ"(AL-C'B-E$5 M5^GK`C@6M,($@XIFUFBU)X%@W`6QAFC!;?T52F?Q`.GZR"I96%_O0[H'BI_B MSHGLMN!?.QAZ:(T?^&YZ+)R\=[?$;)*;_B,8/N(A!,F>O=G'^Q""'?*]U0&L M*E"@8PP2\52,.K"P);W;A"2"7K\<*%B8FJME"BB3E#(%5#AMN17LL\)]/F*( MLB'#M>LSUC< M!J/*:';MB&;UC.^142]/>%.)JAAZ%<8*$Y.$))0:+`\E*W5STIZOR-"%"6JO MP\:E*(K\E1M3!H5.VS?F=`O2[*Z=/V!:4V9_0.TZ$XA[H%?S7:$05W4%X9I> MX(?_7N])#2%S?5Z3*\L/HLAEDBI$KV)F?8IZ88($(HHRG%O\S0\N&47B$24V M58RC^$"G)/!?>V]'A.3'$=9>M$.1Z_=JLKH802UU6$M#HL9>]W[04PFFW&(5PW(DZD=$4R M0`Z=629`<>&&`WJ!>&$.0`Z725'(`VD5$9S?%$'W-4S2NS-H[^K+&@VL@#&23?P5TZKI]M1,Y,2I>" MFT]GX,RDA9LY,Y%XOC/C80&+1SC>=G^$X^T+)V\5@D(:QDAT$B4M`[9)T]!,)D]%XPQA,_S[ M)BX;+7G\$QWM0&7G=(=VV8)05SU1SH(/>1?,(4/PCHAD:P9H>PWY)H?DSF[\G7T`^> M[>@I,L$2T-'*8BPCV2_+TE+4T1K!WG+6,:JHMB1FOV2Z2KU+BTBZ8_@,PQ4Y MX4B.6VYW/CI`F/J^8=U8T8WM,%?OCFVJC!5`ZT6R5Q&/[!B&L<-[Y07X&UOL M\`H8Q3N\+$;[^VB"ZAUEAY==GO8&&DM,<_MLDU$->_M,!!'9]ID<7N+-,P:_ M=/.L-V1VL<-[/(!RCWM^D^+UVZ\4L)K[O4>!;,>]#*DC[AG)/R1;\Z/KD^7) M6QI44H]DK1E-&]:T7;583>(A6U31K+?1+%$01:DC*#'G_.9":MCD:![]`Q;L M?9IP*[@@$TW6PB(5*N]3R^`S7N@/R!;5VF_H.WZHLXL`>EL0RI[ MY:.GB)/41(4TN[131&JRDJQ0!<,+/,4E"):'18Q.D?06;2BD`"482`I<)KM*$687%1QQ$\VW:V/ MDHLNB`,L5J%DH`Z]89F"`.V` MO",.RQ2JVU6`GLFP3"2N,2QC!4,-<5BF`J4645&MAF4".6UBI(;L`AA+_'HN M0$&`]H[M$5V`0G6[VL$U<0$B<0T7P-H?&Z(+4(%2BXVR5BY`(*?-MMD@7$"> M_0A&MZZWQK6O60Z?H+B7N$Y@=@NT&:H7&,@@CYWMI- MLS?>DGN"TVB2V2;M,UP_7]J/+KUHY:-H'\(%?(XO<%W_64/AL<2G+6U=O(&I M'>M3S6SU"+7B&[OUPIR+T7PZ![,K<'LWF4]N%J/%=';3IVLX&J#1L7%4=4ZV M2RF\VW%MTB"8\P;%,%H@1JF<^6060?-#K0DM!G"^LV/E.@&<[UXXM"6(QO*V M*'9UA[*-W6S\1LSF.S:TU6(VNSZ:L7J`Z[T/9YL;^)1FL,"C'SPQ"_"?JQ2' MP3K)EQOE62XH#1[+>SL?@Y?3RQY'>';\PZYPDP,C1_E,PR,FMNLD.)1BMRCG M;C+&/2H8C<>SCS>+ZZR&6XR`:'1=*M8,R5LLH':TY MHD%V[!4G;AB0NWMN84B#B7@.3DJ7MCR?SL#M2`LW\R`B\7QGP.=R)J.[&VS- MFHHB'CE%?#')GFW+DW%V2KV>,HC@J M8NNRNU1YMF%)6MJVIM(,[,S2AYA9HWDE^#9K*MN9+V;C7T[QG'AR"<:S#[>3 MFSF=$(/;Z]%-K_VU+1`BRV"H>@Q#H85?L6HE7<]$X#VIS5V6\D:^B*?!DSYYW__(6T/9J(5":F-D.6-IX*N+ MJJZ#_Q`-C@\35^!%_Y2;E@Y+%NRGPF(2.J51)R&3'3O MDJYR=@7&=Y/+Z0+<3>>_]!H.I:-[U$8]M>`G!W7Q,R.M,;//>;@,7H M;Y->1XI*.FR>\5'NKT0B;Q%Q6>B:E MBMGJEV2%J?1*8AG.?#+^>#==_`ZF-XO)W62^`*.;2W`]6>!?\Z%U5FJH8'15 M.G!J=%1"9E8WI0%#DZS:-!EP=+F'"T2N'9OOR'F#L(9?"5463L>A,HF($Q=L M&-3&%2Z(2^/P..D+L-[3V#%RGQ^(DI>]QH1)-(<46[H6F<4F+@57=08%J]?C M6D0$N5!$@(E>#Q2;@H)W-\B08'&N`PN%G.X6D7'>)G_[R@W#`WG\Z/H83B[- M>DA>+%V?7#$)H@>(!:Y)AG?\IIQJ/<_N'C^$:']/LKB[*>73@[=Z`&Y(RJ7K M[DE8[-(EIYL(;&EL2?S@A6NP-#N/+=*/(V'GZ2Y%L@-0)NLJ,>$0+H/5(YW[A5@\F%?GM"R\M>T_IOW0.N M.+E:E;Q:DASR<`O7E!<%C#H#=X\+?PE(_$;RF1L?DD@/TKKT0N48T+;'W&G; M^J7$[-\0P>232&+[`((#=$.`I::/"'F`PJWKEP*#5X<5_BQO`WR$U1Q^VVL^ M>V.K/S^FU5N<6@0H2'ZMH5>?6N!'GRY3:U_@DNH[P8Q7V;9N^97)'BVC",,- MUZI$P>YIF=#)?@'RL]>=3U:C(U%[U?8D2Q2E#4:NOCJ$V@C78$UJ<>6[]>0F MS'?Y4+K\SJA[9!1B.FRNBA1U@&5*)_\)R.]^72&KZ9&PT>I.KT12=G5D):32L+4CN`S* MTNE;J<([Q_"8'FGPI\$:/O\"#TP0)XL^5UZT`O!O$R$.J/Z3:W+7#8!SJT@$P)4AT[L%_ M@[[_2X">@CET(Q3`-4E3!.M[?DJT%8_.HS7V[))*V/#P_")DGI['F7E\\O[T MGX0`9!0@(>G?]3X,ZUFMA#05 MPZC3&!L$IU`;AM`4+3.`.D<&_/PY2%[T#W>>KI!2Z[+@72.MPUJH^.Y'[DEW ME!_^)Q<6[-FH%I-6Q_%L4O/AO+`*5D;UO!*D@WLV8S[&3P="^7N0$/1O`!*U MUD?\*B"H#OR9'(WQOP)B.C<.:J%C/#B[1R%[4LNDJ)A"E<+8`I@%V@!^7;`, M[U7Z#.;T*<@>]P]NMGZ00INRH%PAK"-8H.C.@7N[7_K>ZLI';OWR'>[["FC+ M[XTARRC,!F"K8F5P+5-G8$V>`?JP?ZBR=(*D+*#M%@4T MCVV2!W>VCZ/8#=(<\XSAAP)#=1`B8C`?BBA4Q\J`1%R.=%@B8L\')Y0(4*H3 MD-"!$F'_QJ&D_/I011TPU0&+@*\Q;%'&6,=A$K=8("0'_$IUH_/G=0W3&Y;$[^+LG9?@*BQ&`\^K[??.U272+UAJ_:!I^^ MG.9<#2(#L`5^;Z-(+;`*2_V,8D7LVX=J#R/CY5H*&D;7HJIIH05,#R2(RQ`<#!'P.=D M+_N_65Y%@4BCL6L'=/@,I6,ZJL@8@!7!%*TV1^$:AC^].'OYNM_\!O$##*^+2"BN%Y03IN`7 M$)ID#Y`6;Y@'0"1?<*,_G\VA[P!91,LLOA1QUNL=_7)5(O5VK_H\/GWI!GQ% MA'1^/=EVZ\7Y[<"(W@@,@Q462CAJL%2DSLZ/2:B-[B-3JHCI562R0D2WD(EY MG1(!#?>LD/1[`YF:CI&F+FI'S<1,Y2O'-$#4=<[H+=GN_7>:N6(:X+GNO;?T M8=+YU8"K1ASG%T^(B,VBRQ6J87P-A;@,882YB-4IORWAA#R)E2:OE&TI2BY:J04\N:HJ1" M7AA?Q3)>AR34IAG7[P/OWY"5NXY>ZX!;8X\[D^SB"0B>0B^&IVMR?A9[L/L< M/9L8#YU7")>0R\$0\LDU$QM<:'I/!F8I;M38!UY<2*#74U2NUDCNET@N?W`+ MRI<@QZR'AQ_8,43D"@E,X4,WBC&0@[WK^X8ZJM%FI\&&`F&>)I"D!5EGNEA)C$2J['QC<8<'?5YE M%)YO(S9?Y9N&I5=&6X3-(DRWR"L213M_)4*G_*O?O1M&FR-1<]5W\`J*\GX= M3UU=+[JM_[&/Z(+@%0K+:QWU]3897;;4QJ4S6663%6ZXP"80+UA;XW()EM62 M.5>_BVM232+E=J\MJ?'(2ZMI:O#HV`ANW)CFF9HE%S.BH+[:S"=(6X!!8(!W M?G%F0&?*Y2.<0>[-\"@KWEH9CO MEQ'\UQ[W;Y-'*,@HJL&16:("AY7<$](*&=J@4D$J.2?X_-CZ+N:37S^2W-N3 MO_:>[D]#UXRL$JH`R8US?R;_VWHY>*RNUZ#:L>6R6!JM1H)9^ M%4VCMK1*%(5P:0AR;N](4MW%[]2.<5\[O25Y=?L-X6J!#F2BN'IPE[J$-LSRDZ_6$_.VJ>;1SL7J)^O5$N6,9Q\^3!40K48N7QT92D=LAV;2Q?!_$4(7U^M`PTTO#F.2DD<^=U7B:LQ? MQ5Q6YK!*%;,UCY45IC*7%3T?SCW>]@OIB->\VHK:M\QH16!S6-2:V0 MF36QU4!;;]9W"33F_EH,9W=@-OKT#6,8^HM5R\R$E#H^NP>5H,0+??+P9?;R<8IIO^S1?35B@ M=GJK&JH:;V&=;5!H$$"3.8,%RLLC]X;"9""^).DQ5KPPFGI4G8.`HD7`W[,VZ?5<7U,#S6B:UVP\JD73]#:F^ZOK[RG4\200 MFX+O;4@@1KJ#J;!B8D%28YRG+\G*B*_U!]@:^[6I@,HH4%]N89?3*3@%N0`: M4%&(`)F,88P1VR.0,5HTA7-CW*@MD#6"-#2-CMW,Y'D%\336?4Y'O%=88?22 ML`LW@NLQVNY@$"4AJUFNX=$J]A[I70DU:[4B*SL2;R3+Y`"]C8\P/&YO6`7! MX7PCR4["3NY+`LM$0)1D\TYOG(/;G8\.$"87\]&0R4Q>KT?^K>`2645(+9S` M1&0I^,">T0S6#:5#4"MN2"!+VPVQ9'7BA@0?T94;8E?!AAMB2<[<$+F@*Q60 M1"Y3$:=+(@.4A9R`7`PHY'P>'DD$T18>28YX;8_$$-G&(PW)?JP&4@_4C$@0 M]A??GQ_?>GCAWL.SGQY"Q8MTA%?X2;V?EE#5`L3K5!9BPSD%VPD+;PJ71X37 M>8I@\'*F2_IN"%'@/,4U`L#%&DXMAD/<#/L6(J$WE"?)O^4X9]`QD5ZFLX9U M1N$VT5X5KXKW,E<#\6E>^8%AGJ5$#NKY^F;BOD3.0SX7&5VO4.]W.Y_N`;C^ MV(T>KGST5-J8X>R4:')E*\^*7":KS'H5,UQ15BY,L'JL*,.YG,['U[-Y&FTY M'LU_!E?7L]_`].9J=O>!GB/XL=?E84U(H)8JJRW[JC&7EGC;8+!CFYP&*W)* M"5["Y-]IL=(S=G<>KCG'+/49T];48#0P3OWJF=FG5GE\$]40XXP?L`R2\"=( M0_OI3D[IEN83$$!Z\9J[^M?>(U>4+_>1%^#Y0:_6VP(YJ+U:JS:LSE^8<5O` M]I05(IG7P3&*XBC-5G$#>5DAQ,2UK!`<8@M9(<35L),GA5N&/"$$A[6X^C\E M`)0B3[*+:89P];]$QXTD$4J8R,:B0IYFD@B;$&(E+&#+;[\ZIYHI@ETN+U/$ M)E]=7A&&SP,D6LT]D/P0URBX7\!P>PF7G#Q1`HH4Z2P*`Y]EC:Y0,>9?*\\O M_+'*_=G,"=B*%LX=1=@03!\K;.(9I`!-'=O21;JP-D;;):X@&4G(S]GK,:4M MI\AD8%IZU3*S+^6R^$:F*,(9C7_].)U/R>9%K_&/FEI'[=12M3,UWL+8VH"L M\]YKJ7!MCX0J[ZG85$;]D[!@TUZ))US4%[%YG,O)1:]WY\A4A!2;M-ZS,(G+ M_8F"S@V"`ADF=!NB*[+Y5]H#G+AA@/O\:!:2'$2SS2C9J8%S#[<7_1%YU/K< M&/^,]ZZOT9DH65 M1R-!JPFH8%H$0&&2@2I-)95N7T(0D;**1TF!8(U+!/@-GEH5J:JPPXF0[Y%W MY-D*;+S]Q;G7YNWZ/JT]P,>6I.MQ0L4ANB)?$+-+0DHLE/<#`J3$]O\`@U/9S,% M"TYB,^B=&Q3#".S<@[OT8:_'JP5Z00IM63LVW20L'9&6*;C_=?R2B=V14$<2 M11?%=2SK,_+747B,=OM^2?6L3QCXY6EUPSPQ3GG(G>8(AO=)RB0`GTG88[\A MW"T0(NH-U=#%[]0X_,+>20F87>?I<+V`=HS!W"6WZ50N-<]O-*\9A1Y3EI=# MC>DE`3":B= MJFJ9-I1X2QDV6@"OZ\P:[H'>[;=`Z?`T\QZ0G'N9;4CX4_IF78-^&]8LLX8. MJTEFC195-,RLH5>B(+.&CB"'_*)+Y]XZS3:(QZ/>FD!Q_/.\.#-)R+*@HE[S M;K3!#C)1:RWOAH:$4MZ-H\.V?%9?IS3VS(,X$/P4QL/48N; M^%I0::"U@<1;X)YI!>$Z(K>.9">+KTFU<85Q1;WZ.$R9ODBE)*$WRY^D5AGC MI$G28H29DB3<3D:2W'$5P">PHF_`QEV1R-!#;C$;2!<<$E/RHF@/PUX'8^IP M0-I*:R1,$K-5LB3I8*ZG0[QW\!$&>\@./MR$O79)K]/BK4\5FX#(9LQ#E4J91.-HO*J MF*RDI=SW`H]_*>N(@5LPS$-S>P5TZNIIMRO%/`LQR68SQ*JN,3:SRRJKB M]#;TL-)VK@\R:K)X,YPP4"6]F:Q3-U?).[-C0&);<%:'0K4)0TJ M&JI5R$U]F4(A1UP'5]#UFS^47>C!9,[("+:OCXM:<(I<%H>S#:[9HGIT8Y)6440XF4,F8D`BA\8PGJ*]=,6D2[1+ MOE6*>Y6V:NOPY,#HR_6Q:Z;M!+]FB-APDD<-*#][?)N7O!`049"^., M`I>%;RHZE:U.&FP[T,K*DD)MWO!,0X6Y)V/0TF]]M4V_3<1>LJWJSXU4WXS# M:ZG_?#)Z1@T9/=E*&P@H[+FJ-92:NVR)C@Z\ID;-Y,XS2LZX M4F[@$_:O`Q-,;UK^\FO\%_[Z[!'^#\GHB9_\+U!+`P04````"``/@F,]FPQZ ML?D;``"NI0$`%0`<`&)I;W,M,C`Q,#`Y,S!?<')E+GAM;%54"0`#'L/13![# MT4QU>`L``00E#@``!#D!``#M75EWXS:6?IXY9_Z#Q_WLLLO52:?JI*:/UVJ? M=DH:VY7T/.50)"2A0Q$*%]O*KQ^`F[A@N8`H$E3\DKC$BXN[?!<[+G[\^^O* M/WI&881)\/GX_;NSXR,4N,3#P>+S\;>GVY,?CO_^/__UGS_^]\G)T1<4H-") MD7L7)_".+L_>GW]_='+"2'T<_/:)_6?F1.B(\@^B3Z\1 M_GR\C./UI]/3EY>7=R\?WI%P<7I^=O;^]%\_W3^Z2[1R3G`0Q4[@HN,C2O\I M2G^\)ZX3I\)5BK_.0K]@\.&TK$M(P?YU4I"=L)].WI^??'C_[C7RCG,19YA$ M927L'VZ(U^]IE]+4LH(2UB7 M!J)V_H_,T"'QT0.:'['_?WNXXVO`/IY>.A&.)O-IB"(4Q*E1:;TIDWBS1I^/ M([Q:^ZCX;1FB^>=CQN:D,``SUU]X;$Y-Y+DB5),@#E,6D_E5B#PE$R(3D5H\C"2Y MHRW%"CTYK\C(+M7B1O7?XP`5OC81H%;>2(+)FK6(U)*/:+&B^#.R0YN)D2Q3 MZL<@7J(8NXY_[<3.$^D4QEK\C31X0"R&+UR7)`&SQS0D`?W31<:F57`TDO(1 MN4F(X\U=$"/:",87@7>/8OIWM`L6`5S-I(V)^QMMLY%W159K%$1I"SFEOC(R MJ(R=D7S?`B>ARC%^6RP]TGXE M(C].?V$U,AW//IZ&_-,`+9A3P>+6 M!H5^&&:\^V3!%P,E(JJ].G(1TS'&91'3L$1G)T^)A-EH("6T[ MX@W5BIEYS`Y'>_4 MQA`4MBXVPQ*0LV&\KE8X3L.(.H/&%V-))_.&HLK8&84KRFG$,^28MQ@ M(IN(E9FWW27R$A_=X9\=/TD[CPN?#@G8:)9J_K^)X^/YABJ?.\K,\=J5&(Y- M?>32%I7R"^G8T=_SF<,!N@PE@;R?T4(B=*PDW:^IM(5V=@),.% M2]NO"!L/UFKE#2-D9M0&I^7,9O"KM>/&DWE%]DG0]K#9]![*NR+YNK*J1&?G MO]6J1:\Q"KPM>ID&7AG,B^- M,B69P2YF41Q2*Q:5IV/&S\BXF)D)5.1T0#-<1!%UQ%42,J\)]);2Y(KR M::J:54%V$=:U=$*WX$?_K"&LO1R;4YRN4Z2=N$OLE^"\"UP_ M\=*A=YBZ+LX&E$SZ)_*5!"X;8A*?RK,H5^9$;?(^F)>M=Z?,1](:[M6D9LUH MUR+QV]\/`P?*E#)$-':]5%TZD)J$J8$\-GE!S8VG/`#T"N5>`!8:#+![`2`Q M-%83LET*Q\`-%8H/VJ%;][KTJ:C111(O28C_V$X:N&`5$7-!VB(^<'`JC-,O M*-O"6#)D9D571(@(HVS`\_+80 M;I8>82=L!?]J&]SNHBA10ZU.)8)93G7X$..:HW=X%5+DT/K.-FA-DIB=AF0J MJ_#%(16!K$IZ^$@3&Z9WN-5$R3'W_<"8J^TJ96(VH":AR`W)HS@X8*G-L&\\ M<27(8?0W"V>FW(Y132B9D1YJ]P@VRA`ST48G>?[N.^N0)NXG@=02S!UT;ZEG MGB'0Q^LSS]_]+T#!.R77[^2&$5/I%R4WYX5 M%.S#P`ODC@,4&#*DFX9]HHZY]"O'9'*]E72YNF*Z@0)8PV$$KF8]'-5UL!"3 M\%8L>?<::KP;6$-%&T<609C)*(>,KTFX<`+\1RK0]GP0DR[PJL)6-@:W5KG& MD>L3.NX4AN6^V.=6[9S]0(T`!$=D[]:L-QH2F5AKT;TL@[8JBJM2;]UY1V=0 M\H/`D_E7]"*R-CMPO72"!9U?!%4:3#5:^U0]06.S'^;%&91NF8]BM+%7@YH, M4;H6R*9QC>QNX5OSTTWSL^UW)O.JE1^0[Z3W#*,X2L>^J1^FSB857=3>=,0M M-]VNW$;1HG1K,I,F9&<);&HSVG?GWUJ*C@8JF4$?T)JM5P4+]51'HT0QI`"4 M&$54ZZMNU/E#:K$I.L596=ZBM*M=\8J%F6758:I3I-PE!Q091:`:*&\2J;!J M;`K5^VHNG+?H['JR7S7OK>-B'\<8,H\'EFM-T57E1A&LIF;8;6*MK,NFL*WF MT'J+VFZBMK2INB^%D.9*2TE'$8X:RII$H)R]34$'R-7U%HM=]Z!?$B=TJ,'1 M9.;C19;T2MU_@DJU>D]YJ5$$JYD)=NLY%379%,*M)$IO`=M-P!:&;2>^*Q06 M$A0*M@E&$7%*Q4R"B\=TV+X/EL'J+9PZZO]D5A9V?UJ%BMX/5F@4H6AD`*.^ M#UC1P"';2(KW%IQ=#TZ;)E8/3)4E6H-2<8EQQ*2VZKL-1B6U#!J-@G2B;S'9 M34QRS9OE,5(OYY@5S@VC67@40;N304SB5[?"2B@?K8L;$O>9-X56"LOTRP/$ M/S=A[EOT=W7_*3,N.S065RVLCGV3HN7-*(VBHXC['8QA$O5ZU0U\I$&<%ODM MBKN[ZB^P,>1X@TGA2CH`C<*CB.6=#&)V^$&OPD'CN9XX^BV"NYX9U^Q[N;GR MG0@P.P:5:LV0Y:5&$:QF)MAMIJRH:=#P%&7Z?PO4K@,UM_0E"N@?<7KK8MM: M`T)6LWPK>*'E1Q;&9F;9+:#!=8YO]@Q]A>*M?>BF?6C;N?+&EJA1T"N4&P)8 M:!3A;V0`DYB'5M1C'Z[_R-R>X!V0(/N7AW#KR3F$?^6((KSG!B`M+K')2/<5 MR5!5GVA-`M6JGQJJI)\&BCN0Y8E4C7IE"FBY\X&I_Z?.P'[\QJE0YVT112XE4/2]&Z59"Q.%JME MZ.L:P_Y?6("VQE,48N+=!!X=NHJ:92Y-HWVNTUCN=8AB9BUV@R/?[W\=?`1T MTWJI=B`89H((TXGQOQ9)Q!I?APJE3(X'M,!L3!S$7YU5,Y)D)#5M&B0#Q9'( M[@2D23UR&KS2%&=<'O8-NX_\?1S=@J`N9*08_@Z'@9^(G5*UPRG+3>>?-) M;74Y2#-H5R[@Q0?`/E]+@`$@!>@5[8<6).2/UK@4-7?7*6SULDP/H',;+/@^ MW>?3!3"?3I.9C]U;GSC-O2[A]YH_J]]M]:98!Z`O:PSXGOQA<$]JO*`#+U!O MJBU\34?=8)L^BB-NMJ4<^?#X:,&"Y'8Z<4M_:7;<"JK&HF23RC[OP_11NES( MIEA%.;/&L]D*J=JW'#JN=ZMTMOM7K).FAVN,"A\/=+$S/_%SA]GCDYFYBX?9 M+P)V1L;'\PUM=(JGV;LZ%E-4K',R1JM,XW28O>=CMH>NMB[@61Z0/7-W3JTS M=?JV$7J'<$,!"HSA<9V0`D\-UT(H&/B`_>[L^VEEV?&I,=00JJ(JA MLH!J%#$&4]$H^[R(\[!I-%=K*M]D7NGF)D'[<.V?O.L3*,-I)Z*-J%OLW?4 M97"W+Y0A[]+QV1+!XQ(A@S6!#OO;++%'OLLE:/FD-,7Q M5R[-H%?8G6C)+C_3_[%D!L^.GT(UOG+"D$T/V:2Q==Q%ITQQ]@549J#V1>XZ M8J9QO5G@5I&>D(&Q[O_D&P0]["T^*C)+#/45Q;EV#;1(:7);\6EL10-$(Z#W M!:S$)^',EV$&2U+.LIJ1<$/U:R"#]RDNDI!7/MF*`XG\0/?7.71X)$XP`IZ& M:.U@[^:5/::%6-:+2;Q$82%9*F;#23I% M0[=AD",;W,@&-=8Z7:8!T+L-%N*SB[KC;1([_OW@+?5U+O.3\YII*NS2`93E MXI*8TE:DP+4#XD;*L(S^88._D#&;MZ+T<<5\3^4H"EV7, M(3Z59U$^4R+8F-\+\V(ONEOFP^:6S)&3ZL2;P$LHXB)39)MBJ"WW_;B=0,S0 MV'/O5))\O-B6P,ZI?N6L('=-2/"Y6/YI?CXX,"D,L&\DM:L_H#6$6N(W'OK$ M!+GY.00'AT"E$?:-09X`XC4-$0JYM])3/Y\&:,&V!8:=)7L>SK29TIG^77#E MK#&=OE7BKSEU!A'76TC[1O+$('ZO[P(6Y./'995K]@\O'#=9)7X M+'!8OCT7MQ?HH07*U7IE@8,#J+:1]@U0B$#]W[\TFR0J)WK*R=KA`4YIA'T# MC">`^#[G.)<\R\,9DWEY8&-*LD,5PE4(>)$2KH`BPZ_\2\\U2`\T<)7H-0HU M?$(4*C7C2LUZNS>P90G+9=+[@J=R9P1DE#JOUM;(EH54<%$Q*SO3[T:Z0=Q\*Y'J=_.:SU,%+;A. MD?+T(*"(=4@R4%2%)QC+LHLXM^\,RA;]L&,H7'K)290ZO768T%41VL!(^)5H M&!8,]]B989_.L]-CE.W%*,%JA6ZQW&[@8B-9X3`T@]G:![RR_I-^:D)-?L5' M3=B&D^RR3X\`T@8$T5"W#AMH50WHB!>/!IY9MF54PD()!PM@(#G[J%1(Z'#. MH4<>,W$.P1ZG0X([$A>N&R9(=(:_HDUS,JM;KICO@LM9C1E3]76@I%%'AYE' M13A997ES$O1$V$KHXYK=7&WE"E:1%2@0D=GM=)AR6CX6LK1S8>LQ6:_]=)3D MA)N[($I"-K"N7.(NU-WB'IV!&: M9IR)*8JXX%#8C6.E2EJXXW&K+%$.NM^0I[6;.AMVX$5PJU%*M!V?\8BL]C-( M,5BNE-Z7GL;/SWE*QXOV`GE&0"#H"?^:+"*WV MJT1N2P__5G8X*RI"MHZEY.W-8S[Y\-X$K[YJJFZ^!JNNZ-#&_ODZTEW@DA6B M:DL`""&M+^3Q24<$/`V5S4$GKT0$N*%'#Z*U7_'RIEWKMR9;/_O8ZQ$OYND? M;.'O`%ANW[WF,C!W4==B]?#@%_CP+V2XH2:L'@,>_1`#K*XYHF156+*"S^YT MXCA+T1IX5Q3/%,LH<"E35J(!$2!U)>^!C'I$8-%3W!PQRGHLFO\6B#=CTY2*K\ MQ?L?(UTE]?Z=1-E`_(D\(#K1=[&/:DH_D=T:NGU64693VD,5HPR''HS=153M M1\P#RH9WC:C$+DZ-3/_V48J\P+M8L26Z/]+?6]MH\"+E5AJ@R%#WI?:)9&)D MKL;%JST(F&W5002S>R.^W/+)CQCFAQ`%&[\*ZL:^KXCZ8'&J8Z2^(*J0RO'2B=A,>L4$YC6CAIN`$6S\W(!?+/,^+"(\2&1<>YW&ANFH[,!X,H/[54%&L?L)2ATC;+_5]3. MG]$1'`?0+U@F_`07'"64C0W3!91U*C=/;#S\OGI;3]HY(?S,KKHT&UT0K1"< M5=J!\&B`*"X.Q6K7H0>OCP^Y6CUV;B&VA;X+GJD%2-CNM$&T0OQ4:4>.'[': MW>*G5L^AW6=NJSL-T=K!7K$9G^_!%PGSN,GX=V,BQ"J(R%R*YLF1+O MW"2=W-&35F?I65!GDVZ'W)*0:N,BY$5LJY?^[25,"<2=L&F6*DZ(`DO9M4X* MP1`Q-0EHD50B07KF$UJS_BW!)JRVRZ6G`5JP"]]6@/>)7+B_)SA$ETG$\D/2 M_H":,HO=_(LG0+!.T0:,045'C64#XW0):%CUE>G=2&$,MY+Q0,!X`#!.`!L; MI@OXZE1^:/NO`MW+DSRF8UL``SFT90S&.;:%FZ23L:VT.CLOEE1'0_?5O-'- ML8"*;GO#24!G5R,)00:!JPUJ$R5UYO>21'5UEKMB^&W\![3.ARZ3N0QP2KK< M\F*Z40(.JG87@)/4I9^/81_C1\&JXV.:8(Y*-)FGJ<.>R".U0S3?_(0#O$I6 M3\[K+SA>LHQB5/<&KLP*ER\M:14>)0)W,E`7L-050-`X#IU0H=J'?TA2-<>`H]_;8#M`T1EBM_4&)-43\X5Y/W7Q>GANZ]KE"'3 MI_F['FGL05Y^0'ZTOFN>:C8H6AQZUBEJ^5[<#F;0VX73J\C.!S?Y.ES0>`W##0W- MGQT_@>&L4>;7`I5*%\?"SI[WA\4^+Q@&P MN*:`"G&\H?/X79[.R8!Y$WC#P_(Q6:_]U%".7QCJ+IB3<)7A0?!:C5ZIS107$#+H*OY?7$^M>AW*_I5J+2J^%Q&/OL MJF&#K9V)[2MO&(O<+B+87DQM$HS)^0KM=O!_FW.'J1]$UTJI4.PU-3J1#;.= M2%KW$[F.IDN'"NDVG_,#TU<&)G)ZNR;QP-.^NF;HXI`OH,[]7V7E"G%+PFRW M^A_(\>/EC1,&DZ39+AB4E&%(4/)PT`0RS=YP):I=]TK97O>CJLMH7TF,!-?C MTW55C6+UJ+`+43I+R3HJ=[<+!:^ZOZO8O>Q%Y3>&[]GZV&3FXX7#.ULFVLQ1 ME#X03)IHWBTTM2383^HDN][,S6^\,WT'GU:4G\/.?ATO&(+4S$4K>RJ_`XY.=EB_*VYG?CNVZ3N:YE,VA+.];,5BM M?;/7?S(=P$YL,+$SW\"7D$01[2G:S^YQOA1IKRM?[/6A6'ZP!VLL]'>?[3[7 MF:9G>40^Y;[X@@+:S['7.2Z\%0XP,P$[DIUG0E$T(AP*>SVOU@?>*/!8 MZ9]\L[M;*G9Z^%V/X&MCV\S^+D2N!Q@1+39\-/Q@Q;88PRM;\Z)S;0KBA.)X M.[N^1',2HLHNST\X2(\5%!JF#X=5N;`C"O'F)Q0OV0$LMH:;3MFY<^)>:Z[- ML_NIV6:<#V5_C1CJ443Q=<6QMM:0%]QACY);]F([&-UZCZTKD0A^)SV]-S7P M+5?A,([[;7M7=11#-YD.8*ATZM_@L5I%5EQJ5-$ M9B]*@)J!`2/FU]W5XN'OJS6UO'0B["HP4Z,1`":C&0@M2BAPX,)3JHX5$5<> M6')NEAR':TIWC?TD;J7^5%`)'%U0C$%TLJT,4S'3DO MT-=D-4L3ZZ2Y/B9)',5.P#)X"+H(T^*Y';6+V]NE[&@)<%>C7X^@"QIZ%PNJ M"*^7,2JKB;E!>R5C-&D@4=V+Z4JA@\^\]LXR%UJ274*@?M[LMZP`P[6JM!S9 MPM*'@VV@@?:&;G']@,R(=@.Z_ISX';5>L,`SG_^F`8QX^_"/C-C>KEY+2W#' MKN):[@8:O-0N./O^A1#O!?M^NA9:U'>W6CLXY#VW#J,N#IPHJ.UUKYZ>$,I M*K:E@\\'#?CBH8`KLIKA(/,)>R@@PNS/!^0[Z=G+=OX2_8*Y"34*VHL:8^W! M`-*I87MT('\=4GQ$-__"_C-S(D1_^7]02P,$%`````@`#X)C/>NX:(K""``` M)ST``!$`'`!B:6]S+3(P,3`P.3,P+GAS9%54"0`#'L/13![#T4QU>`L``00E M#@``!#D!``#M6U]SVS82?^[-W'?@Z>7:!UF2G:2QQVZ'HFB;4YE41*I)GCH0 M"5FXD``#@+5TG_X6(*D_ID1+3M)ZCIG)3"A@`>S^=K'8!=:7ORZ2V/@37[4FP77[;>O77_[YC\M_M=O&#::8(XDC8[HTKK/_$"DR MX\-[1".CW^V=OC':[8+4XKBDLP>]"7(APCA-D2,3OL711@D6* M0GS5FDN97G0Z4$$R$EZ$K*D<]KM=;OG9XJM&">8RFO&DP&>H2R65ZW/&8K) MC."H98`<5%PLQ&J:AX>'DX>S$\;O89)NK_/A;NCKA4M:MNH**P4LO?/S\X[N;8%F?E"J090RB208@VK)F]*4T!G3 MOW^X5-07)?-C/#/T^`N%PE5+D"2-U;JZ;<[Q[*JE@&V7@/Z1:2@*I6R'>^CD@ABH\5"8:$6?QB M)8K1]%B)8`B.OYTL:HX`N#?4QV3L[-ZVFA.+4<%B$BG_TT>QV@C^'&,I6@:) MKEK[N_/UB@4C/".4Z'W05;!TC;;A@PUJ%P3?EN?ZWM`9F($],/KFT'0MV_!O M;3OP+SN/9]B<.!,X\N@O^ONQ91NA][[1*NLC00#HT89@ MN6YV=>Q7PALXDP#X`1%AS$3&,?SHF[ZCD1Z-;1]0U_NCR5B/<0@"F6'(,BHA MGQEQ1N$SS*T]A_T)FCH-G%8T,+8MP-TP+^K7P;-%D9-N(4 M\!4CS/TYG/DY_)76.L#?5`"WS;$+,/L&'`=PB,.!WV2(?GNP[T\PKH M$,THAYY'FCJ&&=L0YQACQ_^MR?##Y+B$-4=\JV4OR"K:KX`\=%Q[C6V3874H M?.(`+7#A-#8;:BRW5P75<<$KVT9@?K`;[2A\'&:HT!T80SN`7_YW9A.HH9<[B"-"W M/V>@E>K-W1/T1V6O-3FK#G-NO>$`E/9OPWXW`8TV664NDF#>WJR?"7#XHG!3 ME=:Z`Z"Z55PSF(SU$="?^'`8^,WV6%F2(+X$LR;WE,Q(B+;24]@`(2G/AP-I MZ]1136+]R=V=.?ZHS=^Y<9UKQS(?);6P6RRGX0=+-A7X'OZ:N+[L]>/T;[QO,& M[YWA4)_,<$R;[HW3'S;;K$?Y0]P2@%5'::J.R.*=9E=/G7F_KICW:*RR6(B) M%.#J,!VI@[;)<%LL28C4<0S@"@&.\MN8KCU\'4$=^-6K,L@'[IP@CVP4_A#U M*&=NNTWWY`''"#!:ZC`R1WV[J0[GZD5-,+9-?P+GIXX=FPSL0"VCWYHD)].L MO&K,(=[760=V]1IR8%]#P)@;\]CI3U97D$W&W<I)[&'&=7JH79[X]M"V53KV;F&/(>(ZO&T)/K$Z\LX\^AA>_77*U*R^MTEI564N2E'%IT$H%]$9Y\3U"Z59U<5X\ M/62AGFHU1*(%HRR!Q.!DU^@.CN6JI;V>[V0AHKS4\B"&(DR^!C.4T?P7S/=\ M9LHI*;Y7=$JZK?M[ED=8UO5JS'G^58I)FBO)SB0D[K:ZT,XT$/4KW8Y3O%P MUNZ=/I^'5QVNRF\/7%Y3JT5?M4'V7O<8%53*TP]=WL52O"4_7(E;>FF!,6!7JYW.+D/D'-1,=T@PP'3&5F?JJ>7_BFEJ@OTN>*,LK&/8*%(8P8<6XA@1-24SDZA(IE^T`XK_%#I\I9;&% MCA)VUY@7::I6C$@B1FBI)M^0ZU'[-^#]&,WX&LX(\^(--F`^T(O9\@XBIB1+ M`K1X3^16;'A\R(8KL@6/L$W41 ML4XE!B"M&R'Z\NFG5X/P%:^78EF?]A2Q[_L+=LO/-2J5=A*]?630> M3U*^R/U0WAH=NB4.I']1NT+]?80J0R%1\;IE\2OY]HUX>$CIESQ,+0.5_ M4$L!`AX#%`````@`#X)C/6*O;<*<;```(.P%`!$`&````````0```*2!```` M`&)I;W,M,C`Q,#`Y,S`N>&UL550%``,>P]%,=7@+``$$)0X```0Y`0``4$L! M`AX#%`````@`#X)C/`Q0````(``^"8SVBVL[>Q34``%E[`@`5`!@```````$```"D@3A[``!B M:6]S+3(P,3`P.3,P7VQA8BYX;6Q55`4``Q[#T4QU>`L``00E#@``!#D!``!0 M2P$"'@,4````"``/@F,]FPQZL?D;``"NI0$`%0`8```````!````I(%,L0`` M8FEO&UL550%``,>P]%,=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`#X)C/>NX:(K""```)ST``!$`&````````0```*2!E,T` M`&)I;W,M,C`Q,#`Y,S`N>'-D550%``,>P]%,=7@+``$$)0X```0Y`0``4$L% 3!@`````%``4`OP$``*'6```````` ` end XML 16 R12.xml IDEA: STOCK-BASED COMPENSATION PLANS 2.2.0.7 false STOCK-BASED COMPENSATION PLANS 006080 - Disclosure - STOCK-BASED COMPENSATION PLANS true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 Notes to Financial Statements [Abstract] 0 bios_NotesToFinancialStatementsAbstract bios false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 STOCK-BASED COMPENSATION PLANS 1 us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTE 8 – STOCK-BASED COMPENSATION PLANS</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioScrip Equity Incentive Plans</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under the Company’s Amended and Restated 2008 Equity Incentive Plan, as amended (the “2008 Pla n”) the Company may issue, among other things, incentive stock options (“ISOs”), non-qualified stock options (“NQSOs”), stock appreciation rights, restricted stock, performance shares and performance units to employees and directors.  Under the 2008 Plan, 3,580,000 shares were originally authorized for issuance (subject to adjustment for grants made under the Company’s 2001 Incentive Stock Plan (the “2001 Plan”) after January 1, 2008, as well as for forfeitures, expirations or awards that under the 2001 Plan otherwise settled in cash after the adoption thereof).  On June 10, 2010, the Company’s stockholders approved an amendment to the 2008 Plan to increase the number of authorized shares of common stock available for issuance by 3,275,000 shares to 6,855,000 shares.  As of September 30, 2010, there were 2,271,074 shares that remained available for grant under the 20 08 Plan.  Upon the effective date of the 2008 Plan, the Company ceased making grants under the 2001 Plan.  The 2008 Plan and the 2001 Plan are administered by the Company’s Management Development and Compensation Committee (the “Compensation Committee”), a standing committee of the Board.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioScrip/CHS Equity Plan</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective upon closing of the acquisition of C HS, the CHS 2006 Equity Incentive Plan was adopted by the Company and renamed the “BioScrip/CHS 2006 Equity Incentive Plan” (the “BioScrip/CHS Plan”).  There were 13,000,000 shares of CHS common stock originally authorized for issuance under the CHS 2006 Equity Incentive Plan, which were converted into 3,106,315 shares of BioScrip common stock, and adjusted using an exchange ratio defined by the merger agreement.  Upon adoption by the Company the Board of Directors amended the BioScrip/CHS Plan to have substantially the same terms and provisions as the 2008 Plan.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Of the options authorized and outstanding under the BioScrip/CHS Plan on the date of the acquisition, 716,086 options were designated as “rollover” options.  These rollover options were issued to the top five executives of CHS, and otherwise remain subject to the term of the BioScrip/CHS Plan, as amended, and were 100% vested on the date of conversion.  Under the terms of the BioScrip/CHS Plan, any shares of BioScrip common stock subject to a rollover option that expire before all or any part of the shares of BioScrip stock subject to such option have been purchased pursuant to the exercise of such option shall remain available for issuance under the BioScrip/CHS Plan.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The remaining 2,390,229 shares are authorized for issuance under the BioScrip/CHS Plan.& amp;#160; These shares may be used for awards under the BioScrip/CHS Plan, provided that awards using such available shares are not made after the date that awards or grants could have been made under the terms of the pre-existing plan, and are only made to individuals who were not employees or directors of BioScrip, or an affiliate or subsidiary of BioScrip, prior to such acquisition.  As of September 30, 2010, there were 2,286,229 shares that remained available under the Bioscrip/CHS Plan.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stock Options</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company recognized compensation expense related to stock options of $0.8 million and $2.3 million for the three and nine months ended September 30, 2010, respectively.  The Company recognized compensation expense related to stock options of $0.6 million and $1.5 million for the three and nine months ended September 30, 2009, respectively.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Restricted Stock</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company recognized compensation expense related to restricted stock awards of $0.3 million and $0.4 million for the three and nine months ended September 30, 2010, respectively.  The Company recognized compensation expense related to restricted stock awards of $0.3 million and $0.9 million for the three and nine months ended September 30, 2009, respectively.</font></div> NOTE 8 – STOCK-BASED COMPENSATION PLANSBioScrip Equity Incentive PlansUnder the Company’s Amended and Restated 2008 Equity Incentive Plan, as false false false us-types:textBlockItemType textblock Disclosure of compensation-related costs for share-based compensation which may include disclosure of policies, compensation plan details, allocation of stock compensation, incentive distributions, share-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph 64, 65, A240 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 93-6 -Paragraph 53 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 false 1 2 false UnKnown UnKnown UnKnown false true XML 17 R3.xml IDEA: UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS 2.2.0.7 false UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) 002000 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS true false In Thousands, except Share data false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ false 2 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ false 3 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ false 4 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 Income Statement [Abstract] 0 us-gaap_IncomeStatementAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false 4 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 Revenue 1 us-gaap_Revenues us-gaap true credit duration No definition available. false false false false false false false false false false false false 1 true true false false 441153000 441153 false false false 2 true true false false 333476000 333476 false false false 3 true true false false 1188251000 1188251 false false false 4 true true false false 987974000 987974 false false false xbrli:monetaryItemType monetary Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false 4 Cost of revenue 1 us-gaap_CostOfRevenue us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 365769000 365769 false false false 2 false true false false 291980000 291980 false false false 3 false true false false 1000426000 1000426 false false false 4 false true false false 872100000 872100 false false false xbrli:monetaryItemType monetary The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 2 -Article 5 false 5 Gross profit 1 us-gaap_GrossProfit us-gaap true credit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 75384000 75384 false false false 2 false true false false 41496000 41496 false false false 3 false true false false 187825000 187825 false false false 4 false true false false 115874000 115874 false false false xbrli:monetaryItemType monetary Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. No authoritative reference available. true 6 Selling, general and administrative expenses 1 us-gaap_OtherSellingGeneralAndAdministrativeExpense us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 55950000 55950 false false false 2 false true false false 32402000 32402 false false false 3 false true false false 146978000 146978 false false false 4 false true false false 94335000 94335 false false false xbrli:monetaryItemType monetary Other generally recurring costs associated with normal operations excluding those directly related to the marketing or selling of products and services not otherwise defined. No authoritative reference available. false 7 Bad debt expense 1 us-gaap_ProvisionForDoubtfulAccounts us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 5309000 5309 false false false 2 false true false false 2433000 2433 false false false 3 false true false false 12536000 12536 false false false 4 false true false false 5410000 5410 false false false xbrli:monetaryItemType monetary Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 5 -Article 5 false 8 Acquisition and integration expenses 1 us-gaap_BusinessCombinationAcquisitionRelatedCosts us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 595000 595 false false false 2 false true false false 0 0 false false false 3 false true false false 6694000 6694 false false false 4 false true false false 0 0 false false false xbrli:monetaryItemType monetary This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph 59 false 9 Amortization of intangibles 1 us-gaap_AmortizationOfIntangibleAssets us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 1326000 1326 false false false 2 false true false false 0 0 false false false 3 false true false false 2196000 2196 false false false 4 false true false false 0 0 false false false xbrli:monetaryItemType monetary The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by (used in) operations using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 45 -Subparagraph a(2) false 10 Income from operations 1 us-gaap_OperatingIncomeLoss us-gaap true credit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 12204000 12204 false false false 2 false true false false 6661000 6661 false false false 3 false true false false 19421000 19421 false false false 4 false true false false 16129000 16129 false false false xbrli:monetaryItemType monetary The net result for the period of deducting operating expenses from operating revenues. No authoritative reference available. true 11 Interest expense, net 1 us-gaap_InterestExpense us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 8122000 8122 false false false 2 false true false false 447000 447 false false false 3 false true false false 19515000 19515 false false false 4 false true false false 1471000 1471 false false false xbrli:monetaryItemType monetary The cost of borrowed funds accounted for as interest that was charged against earnings during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 34 -Paragraph 21 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher OTS -Name Federal Regulation (FR) -Number Title 12 -Chapter V -Section 563c.102 -Paragraph 9 -Subsection II Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 9 -Article 9 false 12 Income (loss) before income taxes 1 us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments us-gaap true credit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 4082000 4082 false false false 2 false true false false 6214000 6214 false false false 3 false true false false -94000 -94 false false false 4 false true false false 14658000 14658 false false false xbrli:monetaryItemType monetary Sum of operating profit and nonoperating income (expense) before income (loss) from equity method investments, income taxes, extraordinary items, cumulative effects of changes in accounting principles, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Subparagraph 1(i) -Article 4 true 13 Income tax expense 1 us-gaap_IncomeTaxExpenseBenefit us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 2117000 2117 false false false 2 false true false false 467000 467 false false false 3 false true false false 1981000 1981 false false false 4 false true false false 1249000 1249 false false false xbrli:monetaryItemType monetary The sum of the current income tax expense (benefit) and the deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 45 -Subparagraph a, b false 14 Net income (loss) 1 us-gaap_NetIncomeLoss us-gaap true credit duration No definition available. false false false false false false false false false false false totallabel false 1 true true false false 1965000 1965 false false false 2 true true false false 5747000 5747 false false false 3 true true false false -2075000 -2075 false false false 4 true true false false 13409000 13409 false false false xbrli:monetaryItemType monetary The portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 true 15 Income (loss) per common share 1 us-gaap_EarningsPerShareAbstract us-gaap true na duration No definition available. false false false false false true false false false false false label false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false 4 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 16 Basic 2 us-gaap_EarningsPerShareBasic us-gaap true na duration No definition available. false false false false false false false false false false false true 1 true true false false 0.04 0.04 false false false 2 true true false false 0.15 0.15 false false false 3 true true false false -0.04 -0.04 false false false 4 true true false false 0.35 0.35 false false false us-types:perShareItemType decimal The amount of net income or loss for the period per each share of common stock outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 36, 37, 38 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 false 17 Diluted 2 us-gaap_EarningsPerShareDiluted us-gaap true na duration No definition available. false false false false false false false false false false false true 1 true true false false 0.04 0.04 false false false 2 true true false false 0.14 0.14 false false false 3 true true false false -0.04 -0.04 false false false 4 true true false false 0.34 0.34 false false false us-types:perShareItemType decimal The amount of net income or loss for the period per each share of common stock and dilutive common stock equivalents outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 11, 12, 36 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 false 18 Weighted average common shares outstanding 1 us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false 4 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 19 Basic 2 us-gaap_WeightedAverageNumberOfSharesOutstandingBasic us-gaap true na duration No definition available. false false false false false false false false false false false terselabel false 1 false true false false 53425 53425 false false false 2 false true false false 38961 38961 false false false 3 false true false false 49232 49232 false false false 4 false true false false 38807 38807 false false false xbrli:sharesItemType shares Number of [basic] shares, after adjustment for contingently issuable shares and other shares not deemed outstanding, determined by relating the portion of time within a reporting period that common shares have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 171 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 8 false 20 Diluted 2 us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding us-gaap true na duration No definition available. false false false false false false false false false false false terselabel false 1 false true false false 54210 54210 false false false 2 false true false false 40184 40184 false false false 3 false true false false 49232 49232 false false false 4 false true false false 39345 39345 false false false xbrli:sharesItemType shares The average number of shares issued and outstanding that are used in calculating diluted EPS, determined based on the timing of issuance of shares in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 8 false 4 19 false Thousands NoRounding NoRounding false true XML 18 R14.xml IDEA: INCOME TAXES 2.2.0.7 false INCOME TAXES 006100 - Disclosure - INCOME TAXES true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 Notes to Financial Statements [Abstract] 0 bios_NotesToFinancialStatementsAbstract bios false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 INCOME TAXES 1 us-gaap_IncomeTaxDisclosureTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTE 10 – INCOME TAXES</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company uses an estimated annual effective tax rate in determining its interim provision for income taxes.  The methodology employed is based on the Company’s expected annual income, statutory tax rates and tax strategies utilized in the various jurisdictions in which it operates.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT - -INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company recorded a provision for income taxes of $2.1 million for the three months ended September 30, 2010 on pre-tax net income of $4.1 million, a 51.8% effective tax rate.  The effective tax rate of 51.8% is above the statutory rate as a result of the decrease in deferred tax assets due to a lower post-combination state tax rate expected to be applicable when the deferred tax assets are reversed.  The provision for income taxes for the three months ended September 30, 2009 was $0.5 million with an effective tax rate of 7.5%.  In 2009, the Company maintained a valuation allowance against it deferred tax assets.  The effective tax rate of 7.5% was below the statutory rate as a result of a reduction in the Company’s valuation allowance associated with the utilization of a portion of net operating losses in 2009.</font>& lt;/div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company recorded a provision for income taxes of $2.0 million for the nine months ended September 30, 2010 on pre-tax net loss of $94,000.  The effective tax rate for the nine months is above the statutory rate as a result of the non-deductible CHS acquisition related costs and a lower post-combination state tax rate expected to be applicable when the deferred tax assets are reversed. Both of these factors are treated as discrete items. The provision for income taxes for the nine months ended September 30, 2009 was $1.2 million with an effective tax rate of 8.5%.  The lower effective tax rate of 8.5% for the nine months ended September 30, 2009 compared to the statutory rate was primarily a result of a reduction in the valuation allowance due to the utilization of a portion of the net operating losses in 2009.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company and its subsidiaries file income tax returns with Federal, state and local jurisdictions.  The Company’s uncertain tax positions are related to tax years that remain subject to examination.  As of September 30, 2010, U.S. tax returns for 2007, 2008 and 2009 remain subject to examination by Federal tax authorities.  Tax returns for the years 2006 through 2009 remain subject to examination by state and local tax authorities for a majority of the Company’s state and local filings.</font></div> NOTE 10 – INCOME TAXESThe Company uses an estimated annual effective tax rate in determining its interim provision for income taxes.  The false false false us-types:textBlockItemType textblock Description containing the entire income tax disclosure. Examples include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. This element may be used as a single block of text to encapsulate the entire disclosure including data and tables. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 136, 172 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 43, 44, 45, 46, 47, 48, 49 false 1 2 false UnKnown UnKnown UnKnown false true XML 19 R15.xml IDEA: SECURITY INTEREST AND LETTERS OF CREDIT 2.2.0.7 false SECURITY INTEREST AND LETTERS OF CREDIT 006110 - Disclosure - SECURITY INTEREST AND LETTERS OF CREDIT true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 Notes to Financial Statements [Abstract] 0 bios_NotesToFinancialStatementsAbstract bios false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 SECURITY INTEREST AND LETTERS OF CREDIT 1 us-gaap_ScheduleOfGuaranteeObligationsTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTE 11 – SECURITY INTEREST AND LETTERS OF CREDIT</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 25, 2010, in connection with the CHS acquisition, the Company and its primary drug wholesaler entered into an amendment to its existing Prime Vendor Agreement (the “PVA”) to subordinate the liens of the primary wholesaler in the Company’s inventory to liens granted under the Senior Secured Facility.  On June 17, 2010, the Company further amended the PVA to, among other things, add CHS and its subsidiaries to the PVA and to the liens granted by the Company to its primary drug wholesaler.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition, in the ordinary course of business, the Company obtained certain letters of credit (“LC”) from commercial banks in favor of various parties.  At September 30, 2010, there was $3.4 on deposit as collateral for these LCs, which are recorded in prepaid expenses and other current assets.</font></div> NOTE 11 – SECURITY INTEREST AND LETTERS OF CREDITOn March 25, 2010, in connection with the CHS acquisition, the Company and its primary drug wholesaler false false false us-types:textBlockItemType textblock Provides pertinent information about each guarantee obligation, or each group of similar guarantee obligations, including (a) the nature of the guarantee, including its term, how it arose, and the events or circumstances that would require the guarantor to perform under the guarantee; (b) the maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee; (c) the current carrying amount of the liability, if any, for the guarantor's obligations under the guarantee; and (d) the nature of any recourse provisions under the guarantee, and any assets held either as collateral or by third parties, and any relevant related party disclosure. Excludes disclosures about product warranties. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 9, 10, 11, 12 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 45 -Paragraph 13, 16 false 1 2 false UnKnown UnKnown UnKnown false true XML 20 R4.xml IDEA: UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS 2.2.0.7 false UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) 003000 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS true false In Thousands false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ false 2 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 3 Cash flows from operating activities: 1 us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities include all transactions and events that are not defined as investing or financing activities. Operating activities generally involve producing and delivering goods and providing services. Cash flows from operating activities are generally the cash effects of transactions and other events that enter into the determination of net income. false 4 Net (loss) income 2 us-gaap_NetIncomeLoss us-gaap true credit duration No definition available. false false false false false false false false false false false terselabel false 1 true true false false -2075000 -2075 false false false 2 true true false false 13409000 13409 false false false xbrli:monetaryItemType monetary The portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 false 5 Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: 2 us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract us-gaap true na duration No definition available. false false false false false true false false false false false label false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 6 Depreciation 3 us-gaap_Depreciation us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 6211000 6211 false false false 2 false true false false 3596000 3596 false false false xbrli:monetaryItemType monetary The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 5 false 7 Amortization of intangible assets 3 us-gaap_AdjustmentForAmortization us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 2196000 2196 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of intangible assets over their estimated remaining economic lives. No authoritative reference available. false 8 Amortization of deferred financing costs 3 us-gaap_AmortizationOfFinancingCosts us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 1272000 1272 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary The component of interest expense comprised of the periodic charge against earnings over the life of the financing arrangement to which such costs relate. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 8 -Article 9 false 9 Change in deferred income tax 3 us-gaap_DeferredIncomeTaxExpenseBenefit us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 1197000 1197 false false false 2 false true false false 562000 562 false false false xbrli:monetaryItemType monetary The component of income tax expense for the period representing the net change in the entity's deferred tax assets and liabilities pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section I -Subsection 7 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 45 -Subparagraph b Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 289 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 false 10 Compensation under stock-based compensation plans 3 us-gaap_ShareBasedCompensation us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 2726000 2726 false false false 2 false true false false 2385000 2385 false false false xbrli:monetaryItemType monetary The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock options, amortization of restricted stock, and adjustment for officers compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 11 Loss on disposal of fixed assets 3 us-gaap_GainLossOnSaleOfPropertyPlantEquipment us-gaap true credit duration No definition available. false false false false false false false false false false false false 1 false true false false 125000 125 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 12 Bad debt expense 3 us-gaap_ProvisionForDoubtfulAccounts us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 12536000 12536 false false false 2 false true false false 5410000 5410 false false false xbrli:monetaryItemType monetary Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 5 -Article 5 false 13 Changes in assets and liabilities, net of acquired business: 2 us-gaap_IncreaseDecreaseInOperatingCapitalAbstract us-gaap true na duration No definition available. false false false false false true false false false false false label false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 14 Receivables, net of bad debt expense 3 us-gaap_IncreaseDecreaseInReceivables us-gaap true credit duration No definition available. false false false false false false false false false false false false 1 false true false false -10564000 -10564 false false false 2 false true false false 5913000 5913 false false false xbrli:monetaryItemType monetary The net change during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 15 Inventory 3 us-gaap_IncreaseDecreaseInInventories us-gaap true credit duration No definition available. false false false false false false false false false false false terselabel false 1 false true false false -10834000 -10834 false false false 2 false true false false -2606000 -2606 false false false xbrli:monetaryItemType monetary The net change during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 16 Prepaid expenses and other assets 3 us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets us-gaap true credit duration No definition available. false false false false false false false false false false false false 1 false true false false -6618000 -6618 false false false 2 false true false false -1014000 -1014 false false false xbrli:monetaryItemType monetary The net change during the reporting period in the value of this group of assets within the working capital section. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 17 Accounts payable 3 us-gaap_IncreaseDecreaseInAccountsPayableTrade us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 7100000 7100 false false false 2 false true false false -14027000 -14027 false false false xbrli:monetaryItemType monetary Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 18 Claims payable 3 bios_ClaimsPayable bios false na duration The net change during the reporting period related to the amount of reserves for future policy claims payable and loss... false false false false false false false false false false false false 1 false true false false 530000 530 false false false 2 false true false false -1002000 -1002 false false false xbrli:monetaryItemType monetary The net change during the reporting period related to the amount of reserves for future policy claims payable and loss expenses to be incurred. No authoritative reference available. false 19 Amounts due to plan sponsors 3 bios_AmountsDueToPlanSponsor bios false credit duration The net change during the reporting period in the carrying value as of the balance sheet date of obligations incurred through... false false false false false false false false false false false terselabel false 1 false true false false 3051000 3051 false false false 2 false true false false 305000 305 false false false xbrli:monetaryItemType monetary The net change during the reporting period in the carrying value as of the balance sheet date of obligations incurred through that date which are related to rebates due from third party vendors and payable to customers, combined with reclassified credits in accounts receivable (amounts due to customers), and amounts that may arise and be deemed due on third party vendor audit. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). No authoritative reference available. false 20 Accrued expenses and other liabilities 3 bios_AccruedExpensesAndOtherLiabilities bios false debit duration The net change during the reporting period in the aggregate amount of expenses incurred but not yet paid, combined with the... false false false false false false false false false false false false 1 false true false false -963000 -963 false false false 2 false true false false 1048000 1048 false false false xbrli:monetaryItemType monetary The net change during the reporting period in the aggregate amount of expenses incurred but not yet paid, combined with the net change during the reporting period in other operating obligations not otherwise defined in the taxonomy. No authoritative reference available. false 21 Net cash provided by operating activities 2 us-gaap_NetCashProvidedByUsedInOperatingActivities us-gaap true na duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 5890000 5890 false false false 2 false true false false 13979000 13979 false false false xbrli:monetaryItemType monetary The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 22 Cash flows from investing activities: 1 us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 23 Purchases of property and equipment 2 us-gaap_PaymentsForProceedsFromProductiveAssets us-gaap true credit duration No definition available. false false false false false false false false false false true negated false 1 false true false false -6747000 -6747 false false false 2 false true false false -4522000 -4522 false false false xbrli:monetaryItemType monetary The net cash inflow (outflow) from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15 false 24 Cash consideration paid for Option Health earn-out 2 bios_CashConsiderationPaidForOptionHealthEarnOut bios false credit duration Cash consideration paid for Option Health earn-out false false false false false false false false false false false false 1 false true false false -1000000 -1000 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary Cash consideration paid for Option Health earn-out No authoritative reference available. false 25 Cash consideration paid to CHS, net of cash acquired 2 us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired us-gaap true credit duration No definition available. false false false false false false false false false false true negated false 1 false true false false -92464000 -92464 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15, 17 false 26 Cash consideration paid to DS Pharmacy 2 bios_CashConsiderationPaidToDsPharmacy bios false credit duration Cash consideration paid to DS Pharmacy false false false false false false false false false false false false 1 false true false false -4969000 -4969 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary Cash consideration paid to DS Pharmacy No authoritative reference available. false 27 Net cash used in investing activities 2 us-gaap_NetCashProvidedByUsedInInvestingActivities us-gaap true debit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false -105180000 -105180 false false false 2 false true false false -4522000 -4522 false false false xbrli:monetaryItemType monetary The net cash inflow (outflow) from investing activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 28 Cash flows from financing activities: 1 us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 29 Proceeds from new credit facility, net of fees paid to issuers 2 us-gaap_ProceedsFromLongTermLinesOfCredit us-gaap true debit duration No definition available. false false false false false false false false false false false label false 1 false true false false 319000000 319000 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 19 -Subparagraph b false 30 Borrowings on line of credit 2 us-gaap_ProceedsFromLinesOfCredit us-gaap true debit duration No definition available. false false false false false false false false false false false label false 1 false true false false 300310000 300310 false false false 2 false true false false 997920000 997920 false false false xbrli:monetaryItemType monetary The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 19 -Subparagraph b false 31 Repayments on line of credit 2 us-gaap_RepaymentsOfLinesOfCredit us-gaap true credit duration No definition available. false false false false false false false false false false true negated false 1 false true false false -330699000 -330699 false false false 2 false true false false -1008747000 -1008747 false false false xbrli:monetaryItemType monetary The cash outflow to pay off an obligation from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 20 -Subparagraph b false 32 Repayments of capital leases 2 us-gaap_RepaymentsOfLongTermCapitalLeaseObligations us-gaap true credit duration No definition available. false false false false false false false false false false false terselabel false 1 false true false false -72000 -72 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary The cash outflow for the obligation for lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26, 31 false 33 Principal payments on CHS long-term debt, paid at closing 2 us-gaap_RepaymentsOfAssumedDebt us-gaap true credit duration No definition available. false false false false false false false false false false true negated false 1 false true false false -128952000 -128952 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary The cash outflow from the repayments of debt originally issued by another party but is assumed by the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 20 -Subparagraph b false 34 Principal payments on long-term debt 2 us-gaap_RepaymentsOfLongTermDebt us-gaap true credit duration No definition available. false false false false false false false false false false true negated false 1 false true false false -1250000 -1250 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 20 -Subparagraph b false 35 Repayment of note payable 2 us-gaap_ProceedsFromRepaymentsOfNotesPayable us-gaap true debit duration No definition available. false false false false false false false false false false false terselabel false 1 false true false false -2250000 -2250 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary The net cash inflow (outflow) from a borrowing supported by a written promise to pay an obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 false 36 Deferred financing costs 2 us-gaap_PaymentsOfFinancingCosts us-gaap true credit duration No definition available. false false false false false false false false false false true negated false 1 false true false false -8680000 -8680 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18, 19, 20 false 37 Net proceeds from exercise of employee stock compensation plans 2 us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions us-gaap true debit duration No definition available. false false false false false false false false false false false false 1 false true false false 2990000 2990 false false false 2 false true false false 1448000 1448 false false false xbrli:monetaryItemType monetary The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph i Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 19 -Subparagraph a false 38 Surrender of stock to satisfy minimum tax withholding 2 bios_SurrenderOfStockToSatisfyMinimumTaxWithholding bios false debit duration Treasury Stock shares withheld from vested Preferred Shares to cover taxes false false false false false false false false false false false false 1 false true false false -128000 -128 false false false 2 false true false false -78000 -78 false false false xbrli:monetaryItemType monetary Treasury Stock shares withheld from vested Preferred Shares to cover taxes No authoritative reference available. false 39 Net cash provided by (used in) financing activities 2 us-gaap_NetCashProvidedByUsedInFinancingActivities us-gaap true debit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 150269000 150269 false false false 2 false true false false -9457000 -9457 false false false xbrli:monetaryItemType monetary The net cash inflow (outflow) from financing activity for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 40 Net change in cash and cash equivalents 1 us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false true false false 50979000 50979 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary The net change between the beginning and ending balance of cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 false 41 Cash and cash equivalents - beginning of period 1 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant No definition available. false false false false false false false false true false false periodstartlabel false 1 false true false false 0 0 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased th ree years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 false 42 Cash and cash equivalents - end of period 1 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant No definition available. false false false false false false false false false true false periodendlabel false 1 false true false false 50979000 50979 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased th ree years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 false 43 DISCLOSURE OF CASH FLOW INFORMATION: 1 us-gaap_SupplementalCashFlowInformationAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 44 Cash paid during the period for interest 2 us-gaap_InterestPaidNet us-gaap true credit duration No definition available. false false false false false false false false false false false false 1 false true false false 5038000 5038 false false false 2 false true false false 1432000 1432 false false false xbrli:monetaryItemType monetary The amount of cash paid during the current period for interest owed on money borrowed, net of interest capitalized. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 29 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 27 -Subparagraph e false 45 Cash paid during the period for income taxes 2 us-gaap_IncomeTaxesPaidNet us-gaap true credit duration No definition available. false false false false false false false false false false false false 1 true true false false 1803000 1803 false false false 2 true true false false 741000 741 false false false xbrli:monetaryItemType monetary The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 29 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 27 -Subparagraph f false 2 43 false Thousands UnKnown UnKnown false true XML 21 R16.xml IDEA: Document Information 2.2.0.7 false Document Information 995200 - Document - Document Information true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 3 Document Type 1 dei_DocumentType dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 10-Q 10-Q false false false us-types:SECReportItemType na The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type should be limited to the same value as the supporting SEC submission type. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, NCSR, N-Q, and Other. No authoritative reference available. false 4 Amendment Flag 1 dei_AmendmentFlag dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 false false false false false xbrli:booleanItemType na If the value is true, then the document as an amendment to previously-filed/accepted document. No authoritative reference available. false 5 Document Period End Date 1 dei_DocumentPeriodEndDate dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 2010-09-30 2010-09-30 false false false xbrli:dateItemType date The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements this will be the filing date. The format of the date is CCYY-MM-DD. No authoritative reference available. false 1 3 false UnKnown UnKnown UnKnown false true XML 22 R9.xml IDEA: DEBT 2.2.0.7 false DEBT 006040 - Disclosure - DEBT true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 Notes to Financial Statements [Abstract] 0 bios_NotesToFinancialStatementsAbstract bios false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 DEBT 1 us-gaap_DebtDisclosureTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTE 5 – DEBT</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of September 30, 2010, the Company’s long-term debt consisted of the following obligations (in thousands):</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr bgcolor="#cceeff"><t d valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Senior unsecured notes</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">225,000</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Senior secured facility</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width=" 1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">93,371</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Capital leases</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: t imes new roman">245</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">318,616</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Less - obligations maturing within one year</font></div></td><td style="BORDER-BOTTOM: blac k 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,864</font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Long term debt - net of current portion</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">314,752</font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In order to finance the acquisition of CHS, the Company entered into a new credit facility, consisting of a term loan and a revolving credit facility, and issued unsecured notes.  The Company also assumed and paid off the debt of CHS, including its prior revolving credit facility.  The terms of the new credit facility are discussed below.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align=" justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prior Credit Facility</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prior to the acquisition of CHS, the Company utilized an $85.0 million revolving credit facility (“Facility”) with an affiliate of Healthcare Finance Group, Inc. (“HFG”).  In connection with the closing of the CHS acquisition, the Company paid off the Facility’s $27.0 million outstanding balance.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: in line; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Senior Secured Facility</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 25, 2010, the Company entered into a credit agreement (the “Senior Secured Facility”) by and among the Company, as borrower, all of its subsidiaries as subsidiary guarantors thereto, the lenders party thereto, Jefferies Finance LLC (“Jefferies”), as lead arranger, as book manager, as administrative agent for the lenders, as collateral agent for the secured parties and as syndication agent, Compass Bank, as a co-documentation agent, GE Capital Corporation as a co-documentation agent, Healthcare Finance Group, LLC, as collateral manager, HFG Healthco-4, LLC, as swingline l ender for the lenders, and Healthcare Finance Group, LLC, as issuing bank for the lenders. The Senior Secured Facility consists of a $100.0 million senior secured term loan facility (the “Term Loan”) and a $50.0 million senior secured revolving credit facility (the “Revolver”). The Term Loan has a five year term and has a repayment schedule with quarterly amortization equal to 2.5%, 5.0%, 7.5%, 10.0% and 12.5% per annum of its principal amount in years one through five, respectively, with the balance due at maturity. The Revolver is available for five years after the closing of the acquisition. The amount of borrowings that may be made under the Revolver are based on a borrowing base calculation and are comprised of specified percentages of eligible receivables and eligible inventory, up to a maximum of $50.0 million. If the amount of borrowings outstanding under the Revolver exceeds the borrowing base then in effect, the Company is required to repay such borrowings in an amount sufficient to eliminate such excess. Additionally, if there are no borrowings outstanding under the Revolver and the principal amount of the Term Loan then outstanding exceeds the borrowing base then in effect, the Company is required to repay the Term Loan in an amount sufficient to eliminate such excess. The Revolver includes $5.0 million of availability for letters of credit and $5.0 million of availability for swingline loans. Interest on both the Term Loan and outstanding borrowings under the Revolver are based on a base rate or Eurodollar rate plus an applicable margin of 3.0% and 4.0%, respectively, with the base rate and Eurodollar rate having floors of 3.0% and 2.0%, respectively. In the event of any default, the interest rate may be increased to 2.0% over the rate applicable to base rate loans. The Revolver also carries an annual commitment fee of 0.75%, payable quarterly in arrears, on the unused portion of the Revolver.</font></div><di v style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Borrowings under the Senior Secured Facility are subject to mandatory prepayment upon the occurrence of certain events, including the issuance of certain equity securities, the incurrence of certain debt and the sale or other disposition of assets. In addition, borrowings under the Senior Secured Facility are subject to mandatory prepayment in the event the Company has “excess cash flow”, as defined in the Senior Secured Facility agreement. Both the Term Loan and the Revolver have been guaranteed by all of the Company’s subsidiaries and secured by first priority security interests in all of the Company’s assets (including the capital stock of our subsidiaries) and all such subsidiary guarantors. The Senior Secured Facility includes affirmative and negative covenants and customary events of default, as well as financial covenants relating to a maximum total leverage ratio and a minimum fixed charge coverage ratio, as well as limits on capital expenditures. Negative covenants include, among other limitations, limitations on additional debt, liens, negative pledges, investments, dividends, stock repurchases, asset sales and affiliate transactions. Events of default include, among other events, non-performance of covenants, breach </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of representations, cross-default to other material debt, bankruptcy and insolvency, material judgments and changes in control.  The Company was in compliance with all covenants contained in the Senior Secured Facility credit agreement as of September 30, 2010.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Senior Unsecured Notes</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with the acquisition of CHS, on March 25, 2010, the Company also issued $225.0 million aggregate principal amount of 10¼% senior unsecured notes due October 1, 2015 in an unregistered offering pursuant to Rule 144A and Regulation S under the Securities Act of 1933.  The Company will pay interest on the notes semi-annually, in arrears, on April 1 and October 1 of each year, beginning October 1, 2010.  These notes are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured basis by the Company’s existing and future direct and indirect subsidiaries.  As of September 30, 2010, the Company does not have any independent assets or operations and, as a result, its direct and indirect subsidiaries (other than minor subsidiaries), each being 100% owned by the Company, are fully and unconditionally, jointly and severally, providing guarantees on a senior unsecured basis to the new notes. As noted above, the Company and each of its guarantor subsidiaries are subject to restrictive covenants under the Senior Secured Facility. The Senior Secured Facility ranks senior in priority to each subsidiary’s guarantee of the notes and could restrict the Company’s ability to obtain funds from the guarantor subsidiaries.  As of September 30, 2010, the carrying amount of the Company’s senior unsecured notes was $225.0 million, and the fair value of the long-term debt, based on current market rates for debt of the same risk and maturities, was estimated at $228.2 million.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 22, 2010, the Company filed an Offer to Exchange (the “Exchange Offer”) the original unregistered notes with new registered notes, as contemplated in the original note offering.  The new notes are substantially identical to the original notes except some of the transfer restrictions, registration rights and additional interest provision relating to the original notes do not apply.  On July 13, 2010, the Company’s planned registration of the notes became effective.  The Exchange Offer expired on August 12, 2010 and the new registered notes commenced tradin g publicly on August 16, 2010.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On or after April 1, 2013, the Company may redeem some or all of the notes at the redemption prices set plus accrued and unpaid interest to the date of redemption.  The redemption premium percentages for notes redeemed are as follows: (a) on or after April 1, 2013, 105.125% of the principal amount, and (b) on or after October 1, 2014, 100.000% of the principal amount.  Prior to April 1, 2013, the Company may redeem up to 35% of the aggregate principal amount of the notes at the premium of 110.250% of the principal amount thereof,  plus accrued and unpaid interest and liquidated damages, if any, to the redemption date, with the net cash proce eds of certain equity offerings.  In addition, the Company may, at its option, redeem some or all of the notes at any time prior to April 1, 2013, by paying a premium.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Debt Issuance Costs and Other Fees</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Jefferies was engaged as an investment banker to provide both advisory services in structuring the acquisition, as well as providing the necessary financing on an interim basis (“bridge loan finan cing”).  Total debt issuance costs related to the notes and term loan are $8.7 million and will be amortized over the term of the debt facilities. Fees paid to Jefferies also included $6.0 million related to the Term Loan and Revolver which were paid to the debt issuers, including Jefferies as a minority issuer.  These fees were recorded as a reduction of principal and will accrete annually proportionate to the amounts repaid. Additional fees paid to Jefferies and expensed in March 2010 included $3.0 million in transaction advisory fees and $2.3 million related to the bridge loan financing availability in the event the notes did not sell prior to the closing date of the acquisition.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY : Times New Roman">Note Payable</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In June 2009 CHS issued a $2.25 million 8% note due on December 31, 2010 to partially finance the acquisition of Option Health, Ltd., which was assumed by the Company in connection with the CHS acquisition.  In August 2010, the Company paid the note in full.</font></div></div> NOTE 5 – DEBTAs of September 30, 2010, the Company’s long-term debt consisted of the following obligations (in thousands):Senior unsecured false false false us-types:textBlockItemType textblock Information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20, 22 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 4 false 1 2 false UnKnown UnKnown UnKnown false true XML 23 R6.xml IDEA: RECENT ACCOUNTING PRONOUNCEMENTS 2.2.0.7 false RECENT ACCOUNTING PRONOUNCEMENTS 006020 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 Notes to Financial Statements [Abstract] 0 bios_NotesToFinancialStatementsAbstract bios false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 RECENT ACCOUNTING PRONOUNCEMENTS 1 us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTE 2 – RECENT ACCOUNTING PRONOUNCEMENTS</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In October 2009, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2009-13, <font style="DISPLAY: inline; FONT-STYLE: italic">Multiple-Deliverable Revenue Arrangements </font>(“ASU 2009-13”).  ASU 2009-13 amends ASC Topic 605-25, <font style="DISPLAY: inline; FONT-STYLE: italic">Revenue Recognition—Multiple- Element Arrangements</font> (“ASC 605”).  The update replaces the concept of allocating revenue consideration among deliverables in a multi-element revenue arrangement according to fair value with an allocation based on selling price. ASU 2009-13 also establishes a hierarchy for determining the selling price of revenue deliverables sold in multiple element revenue arrangements. The selling price used for each deliverable will be based on vendor-specific objective evidence (“VSOE”), if available, third-party evidence if VSOE is not available, or management’s estimate of an element’s stand-alone selling price if neither VSOE nor third-party evidence is available. The amendments in this update also require that an allocation of selling price among deliverables be performed based upon each deliverable’s relative selling price to total revenue consideration, rather than on the residual method previously permitted. ASU 2009-13 is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. Early adoption is permitted, but then requires retrospective application of its provisions from the beginning of the fiscal year. The Company plans to adopt ASU 2009-13 on January 1, 2011.  The adoption of this statement is not expected to have a material impact on the Company’s financial condition, results of operations or cash flows.</font></div><br /> NOTE 2 – RECENT ACCOUNTING PRONOUNCEMENTSIn October 2009, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update false false false us-types:textBlockItemType textblock Represents disclosure of any changes in an accounting principle, including a change from one generally accepted accounting principle to another generally accepted accounting principle when there are two or more generally accepted accounting principles that apply or when the accounting principle formerly used is no longer generally accepted. Also disclose any change in the method of applying an accounting principle, or any change in an accounting principle required by a new pronouncement in the unusual instance that a new pronouncement does not include specific transition provisions. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 154 -Paragraph 2, 17, 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 28 -Paragraph 23, 24 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 01 -Paragraph b -Subparagraph 6 -Article 10 false 1 2 false UnKnown UnKnown UnKnown false true XML 24 R5.xml IDEA: BASIS OF PRESENTATION 2.2.0.7 false BASIS OF PRESENTATION 006010 - Disclosure - BASIS OF PRESENTATION true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 Notes to Financial Statements [Abstract] 0 bios_NotesToFinancialStatementsAbstract bios false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 BASIS OF PRESENTATION 1 us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTE 1 – BASIS OF PRESENTATION</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and subsidiaries (the “Company”) for the year ended December 31, 2009 (the “Form 10-K”) filed with the U.S. Securities and Exchange Commission (“SEC”) on M arch 2, 2010. These Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The information furnished in these Unaudited Consolidated Financial Statements reflects all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods present ed. Operating results for the three and nine months ended September 30, 2010 are not necessarily indicative of the results that may be expected for the full year ended December 31, 2010. The accounting policies followed for interim financial reporting are similar to those disclosed in Note 2 of the  Audited Consolidated Financial Statements included in the Form 10-K.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Unaudited Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries.  All significant intercompany accounts and transactions have been eliminated in the consolidation.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div st yle="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As a result of the Company’s acquisition of Critical Homecare Solutions Holdings, Inc. (including its subsidiaries, collectively “CHS”) on March 25, 2010 (see Note 3 - Acquisitions), the Company reevaluated its segments in accordance with the provisions of Accounting Standards Codification (“ASC”) Topic 280, <font style="DISPLAY: inline; FONT-STYLE: italic">Segment Reporting</font> (“ASC 280”).  Based on its review, the Company changed its operating and reportable segments from “Specialty Pharmacy Services” and “Traditional Pharmacy Services” to its new operating and reportable segments “Infusion/Home Health Services” and “Pharmacy Services”. & ;#160;These two new operating and reportable segments reflect how the Company’s chief operating decision maker reviews the Company’s results in terms of allocating resources and assessing performance.  As a result, prior period disclosures reflect the change in operating and reportable segments.  Refer to Note 7 – Operating Segments for more information.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certain prior period amounts have been reclassified to conform to the current year presentation. Such reclassifications have no material effect on the Company’s previously reported consolidated financial position, results of operations or cash flow.</font></div><div style="DISPLAY: blo ck; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has evaluated events that occurred during the period subsequent to the balance sheet date.  There have been no subsequent events that require recognition or disclosure in the financial statements.</font></div> NOTE 1 – BASIS OF PRESENTATIONThese Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial false false false us-types:textBlockItemType textblock Description containing the entire organization, consolidation and basis of presentation of financial statements disclosure. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Staff Position (FSP) -Number FAS140-4 and FIN46(R)-8 -Paragraph 8, C1, C7 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 2-6 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 94-6 -Paragraph 10 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 46R -Paragraph 4, 14, 15 false 1 2 false UnKnown UnKnown UnKnown false true XML 25 defnref.xml IDEA: XBRL DOCUMENT No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities, combined with the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The net change during the reporting period in the carrying value as of the balance sheet date of obligations incurred through that date which are related to rebates due from third party vendors and payable to customers, combined with reclassified credits in accounts receivable (amounts due to customers), and amounts that may arise and be deemed due on third party vendor audit. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Sum of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, combined with the aggregate carrying amount, as of the balance sheet date, of current assets not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer). No authoritative reference available. Cash consideration paid for Option Health earn-out No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The net change during the reporting period related to the amount of reserves for future policy claims payable and loss expenses to be incurred. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The net change during the reporting period in the aggregate amount of expenses incurred but not yet paid, combined with the net change during the reporting period in other operating obligations not otherwise defined in the taxonomy. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Carrying value as of the balance sheet date of obligations incurred through that date which are related to rebates due from third party vendors and payable to customers, combined with reclassified credits in accounts receivable (amounts due to customers), and amounts that may arise and be deemed due on third party vendor audit. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Treasury Stock shares withheld from vested Preferred Shares to cover taxes No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Cash consideration paid to DS Pharmacy No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. XML 26 R13.xml IDEA: CONCENTRATION OF CREDIT RISK 2.2.0.7 false CONCENTRATION OF CREDIT RISK 006090 - Disclosure - CONCENTRATION OF CREDIT RISK true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 Notes to Financial Statements [Abstract] 0 bios_NotesToFinancialStatementsAbstract bios false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 CONCENTRATION OF CREDIT RISK 1 us-gaap_ConcentrationRiskDisclosureTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTE 9 – CONCENTRATION OF CREDIT RISK</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company provides trade credit to its customers in the normal course of business.  One pharmacy network agreement under which various plan sponsors are served accounted for, in the aggregate, approximately 12% and 14% of revenue during the nine month periods ended September 30, 2010 and 2009, respectively, and 14% and 23% of accounts receivable as of September 30, 2010 and 2009, respectively.</font></div> NOTE 9 – CONCENTRATION OF CREDIT RISKThe Company provides trade credit to its customers in the normal course of business.  One pharmacy network false false false us-types:textBlockItemType textblock Description of any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. The entity should inform financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. Disclosure of any financial instrument credit risk concentration also should indicate the maximum amount of loss that would be incurred upon complete failure of the counterparty to perform and the entity's collateral policies or other policies that limit the loss exposure. This element may be used as a single block of text to encapsulate the entire disclosure including data and tables. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 107 -Paragraph 15A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 94-6 -Paragraph 21, 22, 24 false 1 2 false UnKnown UnKnown UnKnown false true XML 27 R1.xml IDEA: CONSOLIDATED BALANCE SHEETS 2.2.0.7 false CONSOLIDATED BALANCE SHEETS (USD $) 001000 - Statement - CONSOLIDATED BALANCE SHEETS true false In Thousands false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ false 2 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 4 Current assets 2 us-gaap_AssetsCurrentAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 5 Cash and cash equivalents 3 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 true true false false 50979000 50979 false false false 2 true true false false 0 0 false false false xbrli:monetaryItemType monetary Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased th ree years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 false 6 Receivables, less allowance for doubtful accounts of $16,408 and $11,504 at September 30, 2010 and December 31, 2009, respectively 3 us-gaap_ReceivablesNetCurrent us-gaap true debit instant No definition available. false false false false false false false false false false false label false 1 false true false false 186474000 186474 false false false 2 false true false false 151113000 151113 false false false xbrli:monetaryItemType monetary The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a -Article 5 false 7 Inventory 3 us-gaap_InventoryNet us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 false true false false 66322000 66322 false false false 2 false true false false 51256000 51256 false false false xbrli:monetaryItemType monetary Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer). No authoritative reference available. false 8 Deferred taxes 3 us-gaap_DeferredTaxAssetsNetCurrent us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 false true false false 19960000 19960 false false false 2 false true false false 12913000 12913 false false false xbrli:monetaryItemType monetary The current portion of the aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference. An unrecognized tax benefit that is directly related to a position taken in a tax year that results in a net operating los s carryforward should be presented as a reduction of the related deferred tax asset. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 41, 42, 43 false 9 Prepaid expenses and other current assets 3 bios_PrepaidExpensesAndOtherCurrentAssets bios false debit instant Sum of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of... false false false false false false false false false false false false 1 false true false false 16519000 16519 false false false 2 false true false false 3999000 3999 false false false xbrli:monetaryItemType monetary Sum of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, combined with the aggregate carrying amount, as of the balance sheet date, of current assets not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer). No authoritative reference available. false 10 Total current assets 3 us-gaap_AssetsCurrent us-gaap true debit instant No definition available. false false false false false false false false false false false totallabel false 1 false true false false 340254000 340254 false false false 2 false true false false 219281000 219281 false false false xbrli:monetaryItemType monetary Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 9 -Article 5 true 11 Property and equipment, net 2 us-gaap_PropertyPlantAndEquipmentNet us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 false true false false 22723000 22723 false false false 2 false true false false 15454000 15454 false false false xbrli:monetaryItemType monetary Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, and production equipment. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 12 -Paragraph 5 -Subparagraph b, c Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7 false 12 Deferred taxes 2 us-gaap_DeferredTaxAssetsNetNoncurrent us-gaap true debit instant No definition available. false false false false false false false false false false false terselabel false 1 false true false false 17414000 17414 false false false 2 false true false false 26793000 26793 false false false xbrli:monetaryItemType monetary The noncurrent portion as of the balance sheet date of the aggregate carrying amount of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after the valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 41, 42, 43 false 13 Goodwill 2 us-gaap_Goodwill us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 false true false false 323798000 323798 false false false 2 false true false false 24498000 24498 false false false xbrli:monetaryItemType monetary Carrying amount as of the balance sheet date, which is the cumulative amount paid, adjusted for any amortization recognized prior to adoption of FAS 142 and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 43 false 14 Intangible assets, net 2 us-gaap_IntangibleAssetsNetExcludingGoodwill us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 false true false false 32101000 32101 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 42, 45 false 15 Deferred financing costs 2 us-gaap_DeferredFinanceCostsNoncurrentNet us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 false true false false 5440000 5440 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary Net amount of long-term deferred finance costs capitalized at the end of the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 21 -Paragraph 16 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 17 -Article 5 false 16 Other non-current assets 2 us-gaap_OtherAssetsNoncurrent us-gaap true debit instant No definition available. false false false false false false false false false false false false 1 false true false false 2151000 2151 false false false 2 false true false false 1194000 1194 false false false xbrli:monetaryItemType monetary Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 17 -Article 5 false 17 Total assets 2 us-gaap_Assets us-gaap true debit instant No definition available. false false false false false false false false false false false totallabel false 1 false true false false 743881000 743881 false false false 2 false true false false 287220000 287220 false false false xbrli:monetaryItemType monetary Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Concepts (CON) -Number 6 -Paragraph 25 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7 true 19 Current liabilities 2 us-gaap_LiabilitiesCurrentAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 20 Current portion of long-term debt 3 us-gaap_LongTermDebtCurrent us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false 3864000 3864 false false false 2 false true false false 30389000 30389 false false false xbrli:monetaryItemType monetary Total of the portions of the carrying amounts as of the balance sheet date of long-term debt, which may include notes payable, bonds payable, debentures, mortgage loans, and commercial paper, which are scheduled to be repaid within one year or the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Article 5 false 21 Accounts payable 3 us-gaap_AccountsPayableCurrent us-gaap true credit instant No definition available. false false false false false false false false false false false terselabel false 1 false true false false 84782000 84782 false false false 2 false true false false 74535000 74535 false false false xbrli:monetaryItemType monetary Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 false 22 Claims payable 3 us-gaap_SupplementaryInsuranceInformationLiabilityForFuturePolicyBenefitsLossesClaimsAndLossExpenseReserves us-gaap true credit instant No definition available. false false false false false false false false false false false terselabel false 1 false true false false 4598000 4598 false false false 2 false true false false 4068000 4068 false false false xbrli:monetaryItemType monetary Amount of reserves for future policy claims payable and loss expenses to be incurred. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 16 -Article 12 false 23 Amounts due to plan sponsors 3 bios_AmountsDueToPlanSponsors bios false credit instant Carrying value as of the balance sheet date of obligations incurred through that date which are related to rebates due from... false false false false false false false false false false false false 1 false true false false 16170000 16170 false false false 2 false true false false 4938000 4938 false false false xbrli:monetaryItemType monetary Carrying value as of the balance sheet date of obligations incurred through that date which are related to rebates due from third party vendors and payable to customers, combined with reclassified credits in accounts receivable (amounts due to customers), and amounts that may arise and be deemed due on third party vendor audit. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). No authoritative reference available. false 24 Deferred revenue 3 us-gaap_DeferredRevenueCurrent us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false 3527000 3527 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Chapter 3 -Section A -Paragraph 7, 8 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A false 25 Accrued expenses and other current liabilities 3 bios_AccruedExpensesAndOtherCurrentLiabilities bios false credit instant Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in... false false false false false false false false false false false false 1 false true false false 46577000 46577 false false false 2 false true false false 14273000 14273 false false false xbrli:monetaryItemType monetary Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities, combined with the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations. No authoritative reference available. false 26 Total current liabilities 3 us-gaap_LiabilitiesCurrent us-gaap true credit instant No definition available. false false false false false false false false false false false totallabel false 1 false true false false 159518000 159518 false false false 2 false true false false 128203000 128203 false false false xbrli:monetaryItemType monetary Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 21 -Article 5 true 27 Long-term debt, net of current portion 2 us-gaap_LongTermDebtNoncurrent us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false 314752000 314752 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary Sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year (current maturities) or the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 false 28 Other non-current liabilities 2 us-gaap_OtherLiabilitiesNoncurrent us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false 3796000 3796 false false false 2 false true false false 3224000 3224 false false false xbrli:monetaryItemType monetary Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet due to materiality considerations. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 24 -Article 5 false 29 Total liabilities 2 us-gaap_Liabilities us-gaap true credit instant No definition available. false false false false false false false false false false false totallabel false 1 false true false false 478066000 478066 false false false 2 false true false false 131427000 131427 false false false xbrli:monetaryItemType monetary Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. No authoritative reference available. true 30 Stockholders' equity 2 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 31 Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued or outstanding 3 us-gaap_PreferredStockValue us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false 0 0 false false false 2 false true false false 0 0 false false false xbrli:monetaryItemType monetary Dollar value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) whether issued at par value, no par or stated value. This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false 32 Common stock, $.0001 par value; 125,000,000 shares authorized; shares issued: 56,632,871 and 42,766,478, respectively; shares outstanding; 53,688,338 and 3 us-gaap_CommonStockValue us-gaap true credit instant No definition available. false false false false false false false false false false false label false 1 false true false false 6000 6 false false false 2 false true false false 4000 4 false false false xbrli:monetaryItemType monetary Dollar value of issued common stock whether issued at par value, no par or stated value. This item includes treasury stock repurchased by the entity. Note: elements for number of common shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 33 Treasury stock, shares at cost: 2,658,963 and 2,647,613, respectively 3 us-gaap_TreasuryStockValue us-gaap true debit instant No definition available. false false false false false false false false false false true negated false 1 false true false false -10496000 -10496 false false false 2 false true false false -10367000 -10367 false false false xbrli:monetaryItemType monetary Value of common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. Treasury stock is issued but is not outstanding. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Note: number of treasury shares concept is in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Technical Bulletin (FTB) -Number 85-6 -Paragraph 3 false 34 Additional paid-in capital 3 us-gaap_AdditionalPaidInCapitalCommonStock us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false 366901000 366901 false false false 2 false true false false 254677000 254677 false false false xbrli:monetaryItemType monetary Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 false 35 Accumulated deficit 3 us-gaap_RetainedEarningsAccumulatedDeficit us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 false true false false -90596000 -90596 false false false 2 false true false false -88521000 -88521 false false false xbrli:monetaryItemType monetary The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 false 36 Total stockholders' equity 3 us-gaap_StockholdersEquity us-gaap true credit instant No definition available. false false false false false false false false false false false totallabel false 1 false true false false 265815000 265815 false false false 2 false true false false 155793000 155793 false false false xbrli:monetaryItemType monetary Total of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 true 37 Total liabilities and stockholders' equity 2 us-gaap_LiabilitiesAndStockholdersEquity us-gaap true credit instant No definition available. false false false false false false false false false false false totallabel false 1 true true false false 743881000 743881 false false false 2 true true false false 287220000 287220 false false false xbrli:monetaryItemType monetary Total of all Liabilities and Stockholders' Equity items. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 32 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7 true 2 33 false Thousands UnKnown UnKnown false true XML 28 R2.xml IDEA: PARENTHETICAL DATA TO CONSOLIDATED BALANCE SHEETS 2.2.0.7 false PARENTHETICAL DATA TO CONSOLIDATED BALANCE SHEETS (USD $) 001100 - Statement - PARENTHETICAL DATA TO CONSOLIDATED BALANCE SHEETS true false In Thousands, except Share data false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ false 2 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 3 Current assets 1 us-gaap_AssetsCurrentAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 4 Allowance for doubtful accounts 2 us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent us-gaap true credit instant No definition available. false false false false false false false false false false false false 1 true true false false 16408000 16408 false false false 2 true true false false 11504000 11504 false false false xbrli:monetaryItemType monetary A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 false 5 Stockholders' equity 1 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 6 Preferred stock, par value 2 us-gaap_PreferredStockParOrStatedValuePerShare us-gaap true na instant No definition available. false false false false false false false false false false false true 1 true true false false 0.0001 0.0001 false false false 2 true true false false 0.0001 0.0001 false false false us-types:perShareItemType decimal Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 false 7 Preferred stock, shares authorized 2 us-gaap_PreferredStockSharesAuthorized us-gaap true na instant No definition available. false false false false false false false false false false false false 1 false true false false 5000000 5000000 false false false 2 false true false false 5000000 5000000 false false false xbrli:sharesItemType shares The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 false 8 Preferred stock, shares issued 2 us-gaap_PreferredStockSharesIssued us-gaap true na instant No definition available. false false false false false false false false false false false false 1 false true false false 0 0 false false false 2 false true false false 0 0 false false false xbrli:sharesItemType shares Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false 9 Preferred stock, shares outstanding 2 us-gaap_PreferredStockSharesOutstanding us-gaap true na instant No definition available. false false false false false false false false false false false false 1 false true false false 0 0 false false false 2 false true false false 0 0 false false false xbrli:sharesItemType shares Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false 10 Common stock, par value 2 us-gaap_CommonStockParOrStatedValuePerShare us-gaap true na instant No definition available. false false false false false false false false false false false true 1 true true false false 0.0001 0.0001 false false false 2 true true false false 0.0001 0.0001 false false false us-types:perShareItemType decimal Face amount or stated value of common stock per share; generally not indicative of the fair market value per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 4 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 11 Common stock, shares authorized 2 us-gaap_CommonStockSharesAuthorized us-gaap true na instant No definition available. false false false false false false false false false false false false 1 false true false false 125000000 125000000 false false false 2 false true false false 75000000 75000000 false false false xbrli:sharesItemType shares The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 12 Common stock, shares issued 2 us-gaap_CommonStockSharesIssued us-gaap true na instant No definition available. false false false false false false false false false false false false 1 false true false false 56632871 56632871 false false false 2 false true false false 42766478 42766478 false false false xbrli:sharesItemType shares Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 13 Common stock, shares outstanding 2 us-gaap_CommonStockSharesOutstanding us-gaap true na instant No definition available. false false false false false false false false false false false false 1 false true false false 53688338 53688338 false false false 2 false true false false 39675865 39675865 false false false xbrli:sharesItemType shares Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Excludes common shares repurchased by the entity and held as Treasury shares. Shares outstanding equals shares issued minus shares held in treasury. Does not include common shares that have been repurchased. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 14 Treasury stock, shares at cost 2 us-gaap_TreasuryStockShares us-gaap true na instant No definition available. false false false false false false false false false false false false 1 false true false false 2658963 2658963 false false false 2 false true false false 2647613 2647613 false false false xbrli:sharesItemType shares Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false 2 12 false Thousands NoRounding NoRounding false true XML 29 FilingSummary.xml IDEA: XBRL DOCUMENT 2.2.0.7 true Sheet 001000 - Statement - CONSOLIDATED BALANCE SHEETS CONSOLIDATED BALANCE SHEETS http://bioscrip.com/role/ConsolidatedBalanceSheets false R1.xml false Sheet 001100 - Statement - PARENTHETICAL DATA TO CONSOLIDATED BALANCE SHEETS PARENTHETICAL DATA TO CONSOLIDATED BALANCE SHEETS http://bioscrip.com/role/ParentheticalDataToConsolidatedBalanceSheets false R2.xml false Sheet 002000 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS http://bioscrip.com/role/UnauditedConsolidatedStatementsOfOperations false R3.xml false Sheet 003000 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS http://bioscrip.com/role/UnauditedConsolidatedStatementsOfCashFlows false R4.xml false Sheet 006010 - Disclosure - BASIS OF PRESENTATION BASIS OF PRESENTATION http://bioscrip.com/role/BasisOfPresentation false R5.xml false Sheet 006020 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTS http://bioscrip.com/role/RecentAccountingPronouncements false R6.xml false Sheet 006030 - Disclosure - ACQUISITIONS ACQUISITIONS http://bioscrip.com/role/Acquisitions false R7.xml false Sheet 006035 - Disclosure - GOODWILL AND INTANGIBLES GOODWILL AND INTANGIBLES http://bioscrip.com/role/GoodwillAndIntangibles false R8.xml false Sheet 006040 - Disclosure - DEBT DEBT http://bioscrip.com/role/Debt false R9.xml false Sheet 006060 - Disclosure - EARNINGS PER SHARE EARNINGS PER SHARE http://bioscrip.com/role/EarningsPerShare false R10.xml false Sheet 006070 - Disclosure - OPERATING SEGMENTS OPERATING SEGMENTS http://bioscrip.com/role/OperatingSegments false R11.xml false Sheet 006080 - Disclosure - STOCK-BASED COMPENSATION PLANS STOCK-BASED COMPENSATION PLANS http://bioscrip.com/role/StockBasedCompensationPlans false R12.xml false Sheet 006090 - Disclosure - CONCENTRATION OF CREDIT RISK CONCENTRATION OF CREDIT RISK http://bioscrip.com/role/ConcentrationOfCreditRisk false R13.xml false Sheet 006100 - Disclosure - INCOME TAXES INCOME TAXES http://bioscrip.com/role/IncomeTaxes false R14.xml false Sheet 006110 - Disclosure - SECURITY INTEREST AND LETTERS OF CREDIT SECURITY INTEREST AND LETTERS OF CREDIT http://bioscrip.com/role/SecurityInterestAndLettersOfCredit false R15.xml false Sheet 995200 - Document - Document Information Document Information http://xbrl.us/us-gaap/role/document/DocumentInformation false R16.xml false Sheet 995400 - Document - Entity Information Entity Information http://xbrl.us/us-gaap/role/document/EntityInformation false R17.xml false Book All Reports All Reports false 1 10 0 0 3 114 false false c00003 40 c00004 1 c00000 1 c00006 16 c00007 16 c00008 40 c00005 72 c00002 1 c00001 49 c00009 1 true true EXCEL 30 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\T-C(X.3,Q,E\V-3,P7S0U-S%?.&5C8U]C960R M-&4U.#5C8C0B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D)!4TE37T]&7U!215-%3E1!5$E/3CPO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E)%0T5.5%]!0T-/54Y424Y' M7U!23TY/54Y#14U%3CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%#455)4TE424].4SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D=/3T1724Q,7T%.1%])3E1!3D=)0DQ%4SPO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1%0E0\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D-%3E12051)3TY? M3T9?0U)%1$E47U))4TL\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D5N=&ET>5]);F9O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I!8W1I=F53:&5E M=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF M72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U M;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T M7S0V,C@Y,S$R7S8U,S!?-#4W,5\X96-C7V-E9#(T934X-6-B-`T*0V]N=&5N M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\T-C(X.3,Q,E\V-3,P7S0U-S%?.&5C M8U]C960R-&4U.#5C8C0O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E;G-E2!A;F0@97%U:7!M96YT+"!N M970\+W1D/@T*("`@("`@("`\=&0@8VQA'!E;G-EF5D.R!S:&%R97,@ M:7-S=65D.B`U-BPV,S(L.#2!S=&]C:RP@ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\2!S=&]C:RP@ M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M&-E<'0@4VAA7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA2!O<&5R871I;F<@86-T:79I=&EEF%T M:6]N(&]F(&1E9F5R#PO=&0^#0H@("`@("`@(#QT9"!C;&%S3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'!E;G-E M6%B;&4\+W1D/@T*("`@ M("`@("`\=&0@8VQA6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA2!O<&5R M871I;F<@86-T:79I=&EE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE M;G1S(&]N(&QI;F4@;V8@8W)E9&ET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M/B@S,S`L-CDY*3QS<&%N/CPO2!M M:6YI;75M('1A>"!W:71H:&]L9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T M-C(X.3,Q,E\V-3,P7S0U-S%?.&5C8U]C960R-&4U.#5C8C0-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#8R.#DS,3)?-C4S,%\T-3'0O:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$&-H86YG92!#;VUM M:7-S:6]N("@F(S@R,C`[4T5#)B,X,C(Q.RD@;VX@36%R8V@@,BP@,C`Q,"X@ M5&AE&-H86YG92!!8W0@;V8@,3DS-"P@87,@ M86UE;F1E9"X@06-C;W)D:6YG;'DL('1H97D@9&\@;F]T(&EN8VQU9&4@86QL M(&]F('1H92!I;F9O6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E. M1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^5&AE(&EN9F]R;6%T:6]N(&9U2!B92!E>'!E8W1E9"!F;W(@=&AE(&9U;&P@>65A M2!A;F0@:71S('=H;VQL>2UO=VYE9"!S=6)S:61I M87)I97,N)B,Q-C`[)B,Q-C`[06QL('-I9VYI9FEC86YT(&EN=&5R8V]M<&%N M>2!A8V-O=6YT6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@ M+SX\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<^07,@82!R97-U;'0@;V8@=&AE($-O;7!A;GDF(S@R,3<[6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U35%E,13H@:71A;&EC)SY396=M M96YT(%)E<&]R=&EN9SPO9F]N=#X@*"8C.#(R,#M!4T,@,C@P)B,X,C(Q.RDN M)B,Q-C`[)B,Q-C`[0F%S960@;VX@:71S(')E=FEE=RP@=&AE($-O;7!A;GD@ M8VAA;F=E9"!I=',@;W!E2!0:&%R;6%C>2!397)V:6-E2!397)V:6-E28C.#(Q-SMS(&-H M:65F(&]P97)A=&EN9R!D96-I28C M.#(Q-SMS('!R979I;W5S;'D@7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/&1I=B!S='EL93TS1"=$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T-C(X.3,Q,E\V-3,P7S0U M-S%?.&5C8U]C960R-&4U.#5C8C0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-#8R.#DS,3)?-C4S,%\T-3'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@5$585"U$14-/4D%424]..B!U;F1E2!A8W%U:7)E9"`Q,#`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M":6]38W)I<"!C;VUM;VX@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`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`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY#87-H('!A:60@=&\@0TA3 M('-T;V-K:&]L9&5R6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SY4;W1A;"!C;VYS:61E65D('1O($-(4R!S=&]C:VAO;&1E6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXR,#8L,S$P/"]F;VYT/CPO=&0^/"]T M6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`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`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SY4;W1A;"!A;6]U;G1S('!A:60@=&\@ M97AE8W5T92!T:&4@;65R9V5R(&]F($-(4SPO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!4 M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB3X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SY#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB M6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXW+#$V,CPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!C;VQS<&%N M/3-$,CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@ M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SY296-E:79A8FQE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXS-RPS,S,\+V9O;G0^ M/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY$969E6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXV+#$X,CPO9F]N=#X\+W1D/CQT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F M="!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SY/=&AE6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXT+#DY,SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!C;VQS<&%N/3-$ M,CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F M;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S M;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXR+#6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@"<@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$;&5F="!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE M/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXV-2PT.3`\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^/"]T9#X\+W1R/CQT6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^*#,L,30W/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*3PO9F]N M=#X\+W1D/CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*#(L,C4P/"]F;VYT/CPO=&0^ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/"]T6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXI/"]F;VYT/CPO=&0^/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@ M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M$96)T(&%S6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^*#$R."PY-3(\+V9O;G0^/"]T9#X\=&0@ M6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXI/"]F;VYT/CPO=&0^/"]T6QE/3-$)U!!1$1)3D#L@5$585"U!3$E'3CH@;&5F M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXR,#8L M,S$P/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U!!1$1)3D28C.#(Q-SMS($EN M9G5S:6]N+TAO;64@2&5A;'1H(%-E"!P=7)P;W-E MFEN9R!I=',@=F%L M=6%T:6]N(&]F(&-E&5S+B8C,38P.R8C,38P.T%C8V]R9&EN9VQY+"!T:&4@<')O=FES:6]N M86P@;65A6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX\ M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^ M5&AE(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S('1H92!I9&5N=&EF:6%B M;&4@:6YT86YG:6)L92!A6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SY%6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!W:61T:#TS M1#$P)2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T6QE/3-$ M)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SY56QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O M;'-P86X],T0R/CQD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L@/"]F M;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)3X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1L969T('=I9'1H/3-$ M,24^/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SY46QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^ M/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/CPO=&0^/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M."PT,#`\+V9O;G0^/"]T9#X\+W1R/CQT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXS('EE87)S/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT('=I M9'1H/3-$,24^/&9O;G0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^-RPR,#`\ M+V9O;G0^/"]T9#X\+W1R/CQT"<@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$;&5F="!W:61T:#TS1#6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SY#97)T:69I8V%T97,@;V8@;F5E9#PO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4^/&1I=B!S='EL93TS1"=$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SYI;F1E9FEN:71E/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('-T>6QE M/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXR-2PR,#`\+V9O;G0^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^ M/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@5$585"U)3D1%3E0Z(#!P M="<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@ M5$585"U)3D1%3E0Z(#!P="<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE28C.#(Q-SMS($-O;G-O;&ED871E9"!3=&%T M96UE;G1S(&]F($]P97)A=&EO;G,@9F]R('1H92!T:')E92!M;VYT:',@96YD M960@4V5P=&5M8F5R(#,P+"`R,#$P(&EN8VQU9&5S("9N8G-P.R0V."XP(&UI M;&QI;VX@;V8@28C.#(Q-SMS($-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($]P M97)A=&EO;G,@9F]R('1H92!N:6YE(&UO;G1H2!I M;F-U2!R96QA=&5D('1O(&QE9V%L+"!A=61I="!A;F0@9FEN86YC:6%L(&%D M=FES;W)Y(&9E97,@87-S;V-I871E9"!W:71H('1H92!A8W%U:7-I=&EO;B!O M9B!#2%,N)B,Q-C`[)B,Q-C`[5&AE(&-O6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX\9&EV M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`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`[/"]F;VYT M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-3X\9&EV('-T M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT M97(^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/"]T6QE/3-$)U!!1$1)3D6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^4V5P=&5M8F5R M(#,P+#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,G!X.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`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`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`P.3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,G!X.R!415A4+4%,24=..B!L969T)R!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L@/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$ M,CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1C96YT97(^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX] M,T1C96YT97(^/&9O;G0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXH<')O(&9O M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQD:78@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!C;VQS M<&%N/3-$,CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q M-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXT-#$L,34S/"]F;VYT/CPO=&0^/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F M;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^,SDT+#4T.3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY.970@:6YC;VUE/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,2PY-C4\+V9O;G0^ M/"]T9#X\=&0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXU+#$S-SPO9F]N=#X\+W1D/CQT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/CPO M=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^,"XP-#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXP+C`P/"]F;VYT/CPO=&0^/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY$:6QU=&5D M(&EN8V]M92!P97(@8V]M;6]N('-H87)E/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M;F)S<#LD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^,"XP-#PO9F]N=#X\+W1D/CQT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXP+C`P/"]F M;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`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`P M<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<^3VX@2G5L>2`R.2P@,C`Q,"P@=&AE($-O;7!A;GD@86-Q=6ER M960@=&AE('!R97-C2!B=7-I;F5S2!O9B!D2!A;F0@82!S:7@@>65A2!A;F0@9')U9W-T;W)E+F-O;2!E;G1E M"!Y96%R2!P M86ED("9N8G-P.R0U+C`@;6EL;&EO;B!I;B!C87-H('5P;VX@8VQO2!R96-O2!T;R!$4R!0:&%R;6%C>2!O9B`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`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<^5&AE(&9O;&QO=VEN9R!T86)L92!S971S(&9O M6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5. M5#H@,'!T)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX\ M9&EV(&%L:6=N/3-$;&5F=#X\=&%B;&4@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)FYB6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXT-CD\+V9O;G0^/"]T9#X\=&0@ M"<@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F=#X\9&EV('-T>6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SY02!A;F0@97%U:7!M96YT M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXW-CPO9F]N M=#X\+W1D/CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!415A4 M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@"<@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!C;VQS<&%N/3-$,CX\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/"]T6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXU-#4\+V9O;G0^/"]T9#X\+W1R/CQT6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@#L@ M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXY+#`Y.3PO9F]N=#X\+W1D/CPO='(^/'1R M(&)G8V]L;W(],T0C8V-E969F/CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@-'!X)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1L969T('=I9'1H/3-$ M-S8E/CQD:78@6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`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`[26YT86YG:6)L92!!6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\ M8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$;&5F=#X\=&%B;&4@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L@/"]F M;VYT/CPO=&0^/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/CQD:78@"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT M97(^/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$P)2!C;VQS<&%N M/3-$,CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/"]T6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXV(&UO;G1H6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXR.#,\+V9O;G0^/"]T9#X\+W1R/CQT6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1C96YT97(^/&9O;G0@65A6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)U!!1$1)3D"<@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,3,E/CQD:78@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@ M5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXW+#8U-3PO9F]N M=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M;&5F="!W:61T:#TS1#"<@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT M/CPO=&0^/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^.2PP M.3D\+V9O;G0^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T-C(X.3,Q,E\V-3,P7S0U M-S%?.&5C8U]C960R-&4U.#5C8C0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-#8R.#DS,3)?-C4S,%\T-3'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A<'!L>6EN9R!A(&9A:7(M=F%L M=64@8F%S960@=&5S="XF(S$V,#LF(S$V,#M-86YA9V5M96YT(&%S2!O<&5R871I M;F<@86YD(')E<&]R=&%B;&4@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^ M/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1L969T/CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9&EV('-T>6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O M;G0@6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M6QE/3-$)U!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY(96%L=&@@ M4V5R=F-I97,\+V9O;G0^/"]D:78^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R/CQD:78@#L@5$585"U!3$E'3CH@;&5F="<@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R/CQD:78@#L@5$585"U!3$E'3CH@;&5F M="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXR-"PT.3@\+V9O;G0^ M/"]T9#X\=&0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXR-"PT.3@\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\+W1R/CQT"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F M="!W:61T:#TS1#8T)3X\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SY!9&IU6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXM/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@6QE/3-$)U!!1$1)3D"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$;&5F="!W:61T:#TS1#8T)3X\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SY"86QA;F-E(&%S(&]F(%-E<'1E;6)E#L@5$585"U!3$E'3CH@;&5F M="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXR-"PT.3@\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXS,C,L-SDX M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U!!1$1)3D'!E;G-EF5D(&]V97(@=&AE('!EF5D('5S M:6YG(&UE=&AO9',@=VAI8V@@87!PF%T:6]N(&]F('1H92!AF5D(&]N(&$@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^/'1R/CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1L969T('=I9'1H/3-$-3(E/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$ M)U!!1$1)3D"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O M;G0@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX] M,T1C96YT97(^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L@/"]F;VYT M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/CQD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X] M,T0R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R M/CQD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/CQD M:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E M(&-O;'-P86X],T0R/CQD:78@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/CQD:78@"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!W:61T:#TS M1#4R)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M(#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C M:R`R<'@@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C M96YT97(^/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY!;6]U M;G0\+V9O;G0^/"]D:78^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY!;6]R=&EZ871I;VX\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@#L@ M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SY!;6]U;G0\+V9O;G0^/"]D:78^/"]T9#X\+W1R M/CQT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F M="!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1&QE9G0@=VED=&@],T0Q,"4@8V]L6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\+W1R/CQT6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O M;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^26YD969I;FET92!56QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$P M)2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&QE9G0@ M=VED=&@],T0Q,"4@8V]L6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R M/CQT6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXY+#8P,#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXY+#8P,#PO9F]N=#X\+W1D/CPO M='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1L969T('=I M9'1H/3-$-3(E/CQD:78@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SYI;F1E9FEN:71E/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24^/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H="!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`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`P/"]F;VYT M/CPO=&0^/"]T6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)3X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/"]T6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q M-C`[/"]F;VYT/CPO=&0^/"]T6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXV(&UO;G1H6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^*#DU/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*3PO9F]N M=#X\+W1D/CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,3@X/"]F;VYT/CPO=&0^ M/"]T6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXQ('EE87(\+V9O;G0^/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXQ+#$V,3PO9F]N=#X\+W1D/CQT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^*#$Y-#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXH M-#4P/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*3PO9F]N=#X\+W1D M/CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,BPQ-3`\+V9O;G0^/"]T9#X\+W1R M/CQT6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXS('EE87)S/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24^/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^-RPR,#`\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)U!! M1$1)3D"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/CQD M:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXW+#8U-3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,G!X.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@#L@5$58 M5"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXI/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L@ M/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M('=I9'1H/3-$,24^/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,3@L M.#DY/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXH,BPQ.3@\+V9O;G0^/"]T M9#X\=&0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXI/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXQ-BPW,#$\+V9O;G0^/"]T9#X\+W1R/CQT"<@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!W:61T:#TS1#4R)3X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1L969T('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXS-"PR.3D\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXH,BPQ.3@\+V9O;G0^ M/"]T9#X\=&0@#L@5$585"U! M3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!W M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXI M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF;F)S<#LD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^,S(L,3`Q/"]F;VYT/CPO=&0^/"]T6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V M,#LF(S$V,#L@5&]T86P@86UOF%T:6]N(&]F(&EN=&%N9VEB;&4@87-S M971S('=A'!E;G-E(')E8V]R M9&5D(&EN(#(P,#DN/"]F;VYT/CPO9&EV/CQD:78@'!E;G-E(&9O6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXR,#$P("AT:')E92!M;VYT:"!P97)I;V0@ M96YD:6YG($1E8V5M8F5R(#,Q+"`R,#$P*3PO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)FYB6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXR,#$Q/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXU+#(W-CPO9F]N M=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y M,"4^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1% M6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXR,#$R/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXT+#4U,CPO9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET M93X\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^,BPP,#(\+V9O;G0^/"]T9#X\+W1R/CQT6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXQ+#(W-CPO9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L M;W(],T1W:&ET93X\=&0@"<@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!W:61T:#TS1#DP)3X\9&EV M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXR,#$U(&%N M9"!T:&5R96%F=&5R/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!W M:61T:#TS1#DP)3X\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SY4;W1A;#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB'1087)T7S0V,C@Y,S$R7S8U,S!?-#4W,5\X96-C7V-E M9#(T934X-6-B-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\T-C(X M.3,Q,E\V-3,P7S0U-S%?.&5C8U]C960R-&4U.#5C8C0O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SY396YI;W(@=6YS96-U6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF;F)S<#LD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,C(U+#`P,#PO9F]N=#X\+W1D M/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$;&5F="!W:61T:#TS1#@X)3X\9&EV('-T>6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SY396YI;W(@3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^.3,L M,S6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXR-#4\+V9O;G0^/"]T9#X\+W1R/CQT"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$;&5F="!W:61T:#TS1#@X)3X\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SY,97-S("T@;V)L:6=A=&EO;G,@;6%T=7)I;F<@ M=VET:&EN(&]N92!Y96%R/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@6QE/3-$)U!!1$1) M3D6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`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`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^26X@;W)D97(@=&\@9FEN M86YC92!T:&4@86-Q=6ES:71I;VX@;V8@0TA3+"!T:&4@0V]M<&%N>2!E;G1E MF5D M(&%N("9N8G-P.R0X-2XP(&UI;&QI;VX@2`H)B,X,C(P.T9A8VEL:71Y)B,X,C(Q.RD@=VET:"!A;B!A9F9I;&EA M=&4@;V8@2&5A;'1H8V%R92!&:6YA;F-E($=R;W5P+"!);F,N("@F(S@R,C`[ M2$9')B,X,C(Q.RDN)B,Q-C`[)B,Q-C`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`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SYO M9B!R97!R97-E;G1A=&EO;G,L(&-R;W-S+61E9F%U;'0@=&\@;W1H97(@;6%T M97)I86P@9&5B="P@8F%N:W)U<'1C>2!A;F0@:6YS;VQV96YC>2P@;6%T97)I M86P@:G5D9VUE;G1S(&%N9"!C:&%N9V5S(&EN(&-O;G1R;VPN)B,Q-C`[)B,Q M-C`[5&AE($-O;7!A;GD@=V%S(&EN(&-O;7!L:6%N8V4@=VET:"!A;&P@8V]V M96YA;G1S(&-O;G1A:6YE9"!I;B!T:&4@4V5N:6]R(%-E8W5R960@1F%C:6QI M='D@8W)E9&ET(&%G2!A;F0@=6YC;VYD:71I;VYA M;&QY(&=U87)A;G1E960L(&IO:6YT;'D@86YD('-E=F5R86QL>2P@;VX@82!S M96YI;W(@=6YS96-U2!A;F0@=6YC;VYD:71I;VYA;&QY+"!J;VEN M=&QY(&%N9"!S979E2X@ M5&AE(%-E;FEO2!T;R!E86-H('-U8G-I9&EA28C M.#(Q-SMS(&%B:6QI='D@=&\@;V)T86EN(&9U;F1S(&9R;VT@=&AE(&=U87)A M;G1O2!F M:6QE9"!A;B!/9F9E&-H86YG92`H=&AE("8C.#(R,#M%>&-H86YG M92!/9F9E&-E<'0@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T M)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<^3VX@;W(@869T97(@07!R:6P@,2P@,C`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`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX\ M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^ M5&AE(&9O;&QO=VEN9R!T86)L92!S971S(&9O&-E<'0@9F]R('!E6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^/'1R/CQT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`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`[(#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B M;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX] M,T1C96YT97(^/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^4V5P=&5M8F5R(#,P+#PO9F]N=#X\ M+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,G!X)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1L969T/CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`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`Q,#PO9F]N=#X\+V1I=CX\ M+W1D/CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!415A4+4%, M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O M;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)R!V M86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!C;VQS<&%N/3-$,CX\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ+#DV-3PO9F]N=#X\ M+W1D/CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X.R!415A4+4%, M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F M;VYT/CPO=&0^/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M*#(L,#6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXS."PY-C$\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,S@L.#`W/"]F;VYT/CPO=&0^/"]T M6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXH,"XP-#PO9F]N=#X\+W1D/CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X.R!415A4+4%,24=..B!L M969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXP+C,U/"]F;VYT/CPO=&0^/"]T6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,S@L.38Q/"]F;VYT M/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXT.2PR,S(\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@"<@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!W:61T:#TS1#4R)3X\9&EV('-T>6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#LF(S$V,#LF M(S$V,#LF(S$V,#M#;VUM;VX@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXW.#4\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@ M5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ+#(R,SPO9F]N M=#X\+W1D/CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!415A4 M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI M9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXU,S@\+V9O M;G0^/"]T9#X\+W1R/CQT"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$;&5F="!W:61T:#TS1#4R)3X\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXT,"PQ.#0\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^,SDL,S0U/"]F;VYT/CPO=&0^/"]T6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXH,"XP-#PO9F]N=#X\+W1D/CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@-'!X.R!415A4+4%,24=..B!L969T)R!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXP M+C,T/"]F;VYT/CPO=&0^/"]T&EM871E;'D@,3,N M,2!M:6QL:6]N('-H87)E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/&1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^3D]412`W M("8C.#(Q,3L@3U!%4D%424Y'(%-%1TU%3E13/"]F;VYT/CPO9&EV/CQD:78@ M2!H:7-T;W)I8V%L;'D@:&%D('1W;R!O M<&5R871I;F<@86YD(')E<&]R=&%B;&4@28C.#(Q-SMS(&]P M97)A=&EN9R!A;F0@28C M.#(Q-SMS(&QE9V%C>2!I;F9U2P@9'5R86)L92!M M961I8V%L(&5Q=6EP;65N="`H)B,X,C(P.T1-128C.#(R,3LI(&%N9"!H;VUE M(&AE86QT:"!B=7-I;F5S7!I8V%L;'D@2!P2!I;B!T:&5I6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@ M+SX\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<^5&AE(%!H87)M86-Y(%-E2!P:&%R;6%C>2!M86EL M(&]P97)A=&EO;G,@86YD(&-O;6UU;FET>2!P:&%R;6%C:65S+"!P2!B96YE9FET(&UA;F%G96UE;G0@*"8C.#(R,#M00DTF(S@R,C$[ M*2!S97)V:6-E6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX\9&EV('-T M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S M=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^5&AE($-O M;7!A;GDF(S@R,3<['!E;G-E+"!I;F-O;64@=&%X(&5X<&5NF%T:6]N(&%N9"!S=&]C:RUB87-E9"!C M;VUP96YS871I;VX@97AP96YS92`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0U/CQD M:78@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0U/CQD:78@#L@5$58 M5"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F M;VYT/CPO=&0^/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0U/CQD:78@#L@5$585"U!3$E'3CH@;&5F M="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`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`P.3PO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X M.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U7 M14E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B,Q-C`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!C;VQS<&%N/3-$ M,CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F M;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY2 M979E;G5E.CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1L969T(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!C;VQS<&%N/3-$,CX\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXQ,3$L.#0Y/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,S8L.#`Y/"]F M;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF;F)S<#LD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,C8T+#8R-3PO9F]N=#X\+W1D/CQT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S M;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXS,CDL M,S`T/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@ M5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXX.#`L,S8Q/"]F M;VYT/CPO=&0^/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXT-#$L,34S/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`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`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\+W1R/CQT6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F M;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\=&0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M2!396=M96YT(&)E9F]R92!C;W)P M;W)A=&4@;W9E6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#LF(S$V,#LF M(S$V,#LF(S$V,#M);F9U6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F M;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^,S$L-S`R/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/CPO=&0^/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M-RPT,C`\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\+W1R/CQT"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$;&5F="!W:61T:#TS1#4R)3X\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M0:&%R M;6%C>2!397)V:6-E6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#LF(S$V,#LF(S$V,#LF M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M4;W1A;"!396=M96YT($%D M:G5S=&5D($5"251$03PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^,C4L-C6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ-2PX M,3`\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^-#$L.30Q/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY#;W)P;W)A=&4@;W9E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXI M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXH,3DL.#,Q/"]F M;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*3PO9F]N=#X\+W1D/CPO='(^ M/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1L969T('=I9'1H/3-$-3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXH."PQ,C(\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXI/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXH M-#0W/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*3PO9F]N=#X\+W1D M/CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*#$Y+#4Q-3PO9F]N=#X\+W1D/CQT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY);F-O;64@=&%X M(&5X<&5N6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXI/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXH,2PY.#$\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXI/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXH,2PR-#D\ M+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXI/"]F;VYT/CPO=&0^/"]T M6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*#(L-#`T/"]F;VYT/CPO=&0^ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^*#$L,S4V/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*#8L,C$Q/"]F M;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*3PO9F]N=#X\+W1D/CQT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q M-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^*#,L-3DV/"]F;VYT/CPO=&0^/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`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`],T1N;W=R87`@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B,Q-C`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`] M,T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY3=&]C:RUB87-E9"!C;VUP96YS M871I;VX@97AP96YS93PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^*#$L,#DW/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*#@Y-SPO9F]N M=#X\+W1D/CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY!8W%U:7-I=&EO;BP@:6YT96=R M871I;VX@86YD('-E=F5R86YC92!E>'!E;G-E6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*#$L,#0P/"]F;VYT/CPO=&0^/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`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`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*3PO9F]N=#X\+W1D/CQT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`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`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY"860@9&5B="!E>'!E;G-E(')E M;&%T960@=&\@8V]N=')A8W0@=&5R;6EN871I;VX\+V9O;G0^/"]D:78^/"]T M9#X\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXM M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXM/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F M;VYT/CPO=&0^/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M,2PY-C4\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXU+#6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ,RPT,#D\ M+V9O;G0^/"]T9#X\=&0@#L@ M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SY#87!I=&%L($5X<&5N9&ET=7)E6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^.36QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S M<#LD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^-#@\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXR+#(R.3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M0:&%R M;6%C>2!397)V:6-E6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^,2PQ,#0\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,RPP-#0\+V9O;G0^/"]T9#X\=&0@ M6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/"]T6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@ M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^ M/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@#L@5$585"U!3$E'3CH@;&5F M="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\+W1R/CQT6QE/3-$ M)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXR+#0P M-3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X M.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)U!!1$1)3D6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q) M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/CPO=&0^ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^-"PU,C(\+V9O M;G0^/"]T9#X\=&0@#L@5$58 M5"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY$ M97!R96-I871I;VX@17AP96YS93H\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M);F9U6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/CPO=&0^/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M,C6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF;F)S<#LD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,BPS.#$\+V9O;G0^/"]T M9#X\=&0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXY,#0\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@ M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M0:&%R;6%C>2!397)V:6-E6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^.34T/"]F M;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXX-3@\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q M-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ+#DU,#PO M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI M9VX],T1B;W1T;VT@;F]W"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!W M:61T:#TS1#4R)3X\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M#;W)P;W)A=&4@=6YA M;&QO8V%T960\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@ M6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXS,C(\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXR,C$\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E' M3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXX,3$\+V9O;G0^/"]T9#X\=&0@ M#L@5$585"U!3$E'3CH@;&5F M="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXW-#(\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!W:61T:#TS1#4R)3X\ M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX] M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M4 M;W1A;#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)R!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)FYB6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S M<#LD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^,2PS-38\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXV+#(Q,3PO9F]N M=#X\+W1D/CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X.R!415A4 M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)U!!1$1)3D6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO M=&0^/"]T6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/CPO M=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^-#,X+#6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#LF(S$V,#LF(S$V,#LF M(S$V,#M0:&%R;6%C>2!397)V:6-E6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!W:61T:#TS1#4R M)3X\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M#;W)P;W)A=&4@=6YA;&QO8V%T960\ M+V9O;G0^/"]D:78^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24^/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^/"]T9#X\=&0@"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F="!W:61T:#TS1#4R M)3X\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V M,#M4;W1A;#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXW-#,L.#@Q M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`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`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O M;G0^/"]T9#X\+W1R/CQT6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT M/CPO=&0^/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^,CDY+#,P,#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T M9#X\+W1R/CQT"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F M="!W:61T:#TS1#4R)3X\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M0:&%R;6%C>2!3 M97)V:6-E6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$58 M5"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXR-"PT.3@\+V9O;G0^ M/"]T9#X\=&0@#L@5$585"U! M3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!W M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(S$V,#L\+V9O;G0^/"]T9#X\=&0@6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXR-"PT.3@\+V9O;G0^/"]T9#X\=&0@#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!W:61T:#TS1#$E/CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M+W1R/CQT6QE/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F M;VYT/CPO=&0^/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M,S(S+#'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@ M,'!T)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM M4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^0FEO4V-R:7`@ M17%U:71Y($EN8V5N=&EV92!0;&%N6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\ M+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^56YD97(@=&AE($-O;7!A;GDF(S@R,3<[2!);F-E;G1I=F4@4&QA;BP@87,@86UE;F1E M9"`H=&AE("8C.#(R,#LR,#`X(%!L86XF(S@R,C$[*2!T:&4@0V]M<&%N>2!M M87D@:7-S=64L(&%M;VYG(&]T:&5R('1H:6YGF5D('-H87)E2`S+#(W-2PP,#`@6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z M(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<^0FEO4V-R:7`O0TA3($5Q=6ET>2!0;&%N/"]F;VYT/CPO9&EV M/CQD:78@2!) M;F-E;G1I=F4@4&QA;BP@=VAI8V@@=V5R92!C;VYV97)T960@:6YT;R`S+#$P M-BPS,34@2!T:&4@0V]M<&%N>2!T:&4@0F]A2!T M:&4@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!4 M15A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^3V8@=&AE(&]P=&EO;G,@ M875T:&]R:7IE9"!A;F0@;W5T2!S:&%R97,@;V8@0FEO4V-R:7`@8V]M;6]N('-T;V-K M('-U8FIE8W0@=&\@82!R;VQL;W9E'!I6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I M=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L M:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^5&AE(')E;6%I;FEN9R`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`P M<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<^5&AE($-O;7!A;GD@2!R96-O9VYI M>F5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T960@=&\@'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^3D]412`Y("8C.#(Q,3L@0T].0T5. M5%)!5$E/3B!/1B!#4D5$250@4DE32SPO9F]N=#X\+V1I=CX\9&EV('-T>6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\ M+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^5&AE($-O;7!A;GD@<')O=FED97,@=')A9&4@8W)E9&ET('1O(&ET M&EM871E;'D@ M,3(E(&%N9"`Q-"4@;V8@2P@86YD(#$T)2!A;F0@,C,E(&]F(&%C8V]U;G1S(')E8V5I M=F%B;&4@87,@;V8@4V5P=&5M8F5R(#,P+"`R,#$P(&%N9"`R,#`Y+"!R97-P M96-T:79E;'DN/"]F;VYT/CPO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^3D]412`Q,"`F(S@R,3$[($E. M0T]-12!405A%4SPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX\9&EV('-T M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S M=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^5&AE($-O M;7!A;GD@=7-E6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@ M+SX\+V1I=CX\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`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`P M<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<^5&AE($-O;7!A;GD@"!N970@;&]S"!R871E(&9O2!R871E(&%S(&$@"!R871E(&5X<&5C=&5D('1O M(&)E(&%P<&QI8V%B;&4@=VAE;B!T:&4@9&5F97)R960@=&%X(&%S&5S(&9O6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF M>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^5&AE($-O;7!A M;GD@86YD(&ET28C.#(Q-SMS('5N8V5R=&%I;B!T M87@@<&]S:71I;VYS(&%R92!R96QA=&5D('1O('1A>"!Y96%R3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T-C(X M.3,Q,E\V-3,P7S0U-S%?.&5C8U]C960R-&4U.#5C8C0-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO-#8R.#DS,3)?-C4S,%\T-3'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!D28C.#(Q M-SMS(&EN=F5N=&]R>2!T;R!L:65N2XF(S$V,#LF(S$V,#M/;B!*=6YE(#$W+"`R M,#$P+"!T:&4@0V]M<&%N>2!F=7)T:&5R(&%M96YD960@=&AE(%!602!T;RP@ M86UO;F<@;W1H97(@=&AI;F=S+"!A9&0@0TA3(&%N9"!I=',@2!O8G1A M:6YE9"!C97)T86EN(&QE='1E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T M-C(X.3,Q,E\V-3,P7S0U-S%?.&5C8U]C960R-&4U.#5C8C0-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#8R.#DS,3)?-C4S,%\T-3'0O:'1M;#L@8VAA'0^,3`M M43QS<&%N/CPO'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^ M0FEO4V-R:7`L($EN8RX\2!#96YT3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,3`Q-#'0^+2TQ,BTS,3QS<&%N/CPO2!6;VQU;G1A'0^665S/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M M87,M;6EC'10 L87)T7S0V,C@Y,S$R7S8U,S!?-#4W,5\X96-C7V-E9#(T934X-6-B-"TM#0H` ` end XML 31 R7.xml IDEA: ACQUISITIONS 2.2.0.7 false ACQUISITIONS 006030 - Disclosure - ACQUISITIONS true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 Notes to Financial Statements [Abstract] 0 bios_NotesToFinancialStatementsAbstract bios false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 ACQUISITIONS 1 us-gaap_BusinessCombinationDisclosureTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTE 3 – ACQUISITIONS</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Critical Homecare Solutions Holdings, Inc.</font></font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 25, 2010, the Company acquired 1 00 percent of CHS, a leading provider of comprehensive home infusion therapy and home nursing products and services to patients suffering from acute and chronic conditions.  CHS’ home infusion business provides for the dispensing and administration of infusion pharmaceuticals, biopharmaceuticals, nutrients and related services and equipment to patients principally in the home.  Its home nursing service operations provide nursing and therapy visits as well as private duty nursing services to patients in the home.  The Company’s acquisition of CHS added 35 infusion pharmacies servicing 22 states, including 16 ambulatory treatment centers, and 33 nursing locations to the Company’s existing platform.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inl ine; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Consideration</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table sets forth the consideration transferred in connection with the acquisition of CHS and the aggregate purchase price allocation as of March 25, 2010 (in thousands):</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr bgcolor="#cceeff"><td valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0p t" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fair value of equity consideration:</font></div></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    BioScrip common stock issued (13.1 million shares)</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">91,614</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    BioScrip warrants issued (3.4 million warrants)</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,268</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="D ISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Rollover options (716,086 options)</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,802</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash paid to CHS stockholders</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline ; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99,626</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total consideration conveyed to CHS stockholders</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">206,310</font></td></tr><tr bgcolor ="#cceeff"><td valign="bottom" align="left" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash paid for merger related expenses incurred by CHS</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FA MILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,566</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Assumption and repayment of CHS debt</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">128,952</font>< ;/td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="88%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total amounts paid to execute the merger of CHS</font></div></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">349,828</font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block ; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Assets and Liabilities Acquired</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table sets forth the fair value of the assets acquired and liabilities assumed as a result of the acquisition of CHS (in thousands):</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /> </div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr bgcolor="#cceeff"><td valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0p t; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash and cash equivalents</font></div></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,162</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </f ont></td></tr><tr bgcolor="white"><td valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Receivables</font></div></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,333</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style ="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred taxes</font></div></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,182</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other current assets</font></div></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,993</font></td><td style="TEXT-ALIGN: left" valign="bott om" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Property and equipment</font></div></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="b ottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,042</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other assets</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,778</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td val ign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">     Total assets acquired</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new r oman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">65,490</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts payable</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE : 10pt; FONT-FAMILY: times new roman">(3,147</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISP LAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Notes payable</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,250</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td styl e="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amounts due to plan sponsors</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(8,180</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accrued expenses and other current liabilities</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font st yle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(34,007</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td> </tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred tax liabilities</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,144</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td><td style="TEXT-ALIGN: left" vali gn="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Total liabilities assumed</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"& gt;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(54,728</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="botto m" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Tangible assets acquired, net</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: time s new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,762</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Intangible assets acquired</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width=" 1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25,200</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#16 0;</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Debt assumed</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISP LAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(128,952</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">    Goodwill</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160 ;</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">299,300</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total consideration conveyed to CHS stockholders</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font&g t;</td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">206,310</font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The excess of the purchase price over the fair value of the tangible and identi fiable intangible assets acquired and liabilities assumed in the acquisition was allocated to goodwill.  The value of the goodwill represents the value the Company expects to be created by combining the various operations of CHS with the Company’s operations, including the ability to cross-sell all of their respective services on a national basis with an expanded footprint in home infusion and the opportunity to focus on higher margin therapies.  The CHS acquisition is included in the Company’s Infusion/Home Health Services segment. Of the goodwill recorded in the CHS acquisition, $21.1 million is deductible for tax purposes.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In accordance with ASC Topic 805, <font s tyle="DISPLAY: inline; FONT-STYLE: italic">Business Combinations</font> (“ASC 805”), the allocation of the purchase price in connection with the acquisition of CHS is subject to adjustment during the measurement period after the closing date (March 25, 2010) when additional information on assets and liability valuations becomes available.  The Company is still in the process of finalizing its valuation of certain assets and liabilities recorded in connection with the acquisition, including the collectability of accounts receivable, amounts due to plan sponsors and deferred taxes.  Accordingly, the provisional measurements recorded are subject to change and any changes will be recorded as adjustments to the fair value of those assets and liabilities; residual amounts will be allocated to goodwill.  Refer to Note 4 – Goodwill and Intangible Assets for changes in the carrying value of goodwill.</font></div>& lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> Intangible Assets</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes the identifiable intangible assets acquired (in thousands):</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"> </div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="bottom" align="left" width="74%"><font style="DISPLAY: inline; FONT- SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Estimated</font></div></td><td valign="bottom" align="left" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="74%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Useful Life</font></div></td><td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fair Value</font></div></td></tr><tr><td valign="bottom" align="left" width="74%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">& #160; </font></td><td valign="bottom" align="left" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="74%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Trademarks/trade names</font></div></td><td valign="bottom" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">various</font></div></td><td valign="bottom" align="right" width="1 %"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,400</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="74%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Infusion customer relationships</font></div></td><td valign="bottom" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3 years</font></div></td><td valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,200</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="74%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Certificates of need</font></div></td><td style="PADDING-BOTTOM: 2px" valign="bottom" width="14%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">indefinite</font></div></td><td style="PADDING-BOTTOM: 2px" valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,600</font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="74%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">   </font></td><td style="PADDING-BOTTOM: 4px" valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="PADDING-BOTTOM: 4px" valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25,200</font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Impact of Acquisition on Interim Financials</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has consolidated the results of CHS with its own financial results for the three months ended September 30, 2010.  The impact of the inclusion of CHS’ operating results with the Company’s Consolidated Statements of Operations for the three months ended September 30, 2010 includes $68.0 million of revenue, $31.4 million of gross profit and $9.3 million in operating income.  The impact of the inclusion of CHS’ operating results from March 26, 2010 through September 30, 2010 with the Company’s Consolidated Statements of Operations for the nine months ended September 30, 2010 includes $137.8 million of revenue, $65.5 million of gross profit and $19.7 million in operating income.  Operating profit for CHS does not include the allocation of corporate expenses that were previously incurred by CHS and have since been transferred to BioScrip corporate expenses as part of the integration execution.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the nine months ended September 30, 2010, the Company incurred $6.3 million of acquisition related costs.  These costs were primarily related to legal, audit and financial advisory fees assoc iated with the acquisition of CHS.  The costs were recognized in the acquisition and integration expenses line of the Unaudited Consolidated Statements of Operations.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company included the operating results of CHS in its consolidated statements of operations beginning on March 26, 2010.  The following table sets forth the unaudited pro forma combined results of operations as if the acquisition had occurred on the same terms as of January 1, 2010 and 2009.   Pro forma adjustments have been made related to amortization of intangible assets, interest expense, and income tax expense. The pro forma financial information does not reflect revenue opportunities and co st savings which the Company expects to realize as a result of the acquisition of CHS or estimates of charges related to the integration activity. The pro forma results for the nine months ended September 30, 2010 include the $6.3 million of acquisition related costs incurred by the Company.  Amounts are in thousands, except for earnings per share.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three M onths Ended</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" colspan="5"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colsp an="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &l t;/font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN - -LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style= "BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr><td valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(as reported)</font></div></td><td style ="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(pro forma)</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(pro forma)</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-F AMILY: times new roman"> </font></td><td valign="bottom" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(pro forma)</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr><td valign="bottom" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMIL Y: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Revenue</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">441,153</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">394,549</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,249,030</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bot tom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,175,431</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net income</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,965</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,137</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$ </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">112</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,241</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="52%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic income per common share</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.04</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%">& lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.10</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.00</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td st yle="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.24</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="52%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Diluted income per common share</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.04< ;/font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.10</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FO NT-SIZE: 10pt; FONT-FAMILY: times new roman">0.00</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.23</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bo ld; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">DS Pharmacy, Inc.</font></font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 29, 2010, the Company acquired the prescription pharmacy business and assets of DS Pharmacy, Inc. (“DS Pharmacy”), a wholly-owned subsidiary of drugstore.com, inc.  The acquisition provides the Company with an expanded presence in on-line pharmacy and a six year license of drugstore.com capabilities, trademarks and trade names.  In connection with the acquisition, the Company and drugstore.com entered into a Transitional Services Agreement and a Services Agreement pursuant to which, for a period of six years followi ng the closing of the acquisition, drugstore.com will provide marketing services.  The agreements also allow drugstore.com customers to continue to order from the Company through the drugstore.com website.  The Company paid $5.0 million in cash upon closing and will pay an additional earn-out in cash which is expected to range between $4.2 and $5.5 million based on the results of operations during the twelve month period post-closing.  The Company recorded a liability to DS Pharmacy of $4.7 million to account for the fair value of the earn-out payment liability as of September 30, 2010.  Any changes to the fair value of the earn-out payment liability going forward will be recorded quarterly as income or expense in the Consolidated Statements of Operations.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0p t" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the three months ended September 30, 2010, the Company incurred $0.4 million of integration related costs.  These costs were primarily related to overtime and temporary wage costs and other integration costs associated with the DS Pharmacy acquisition.  The costs were recognized in the acquisition and integration expenses line of the Unaudited Consolidated Statements of Operations.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Assets and Liabilities Acquired</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TE XT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table sets forth the fair value of the assets acquired and liabilities assumed as a result of the acquisition of DS Pharmacy (in thousands):</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"> </div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr bgcolor="#cceeff"><td valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Inventory</font></div></td><td style="TEXT-ALIGN: left" valign="bottom"><font style="DI SPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">469</font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Property and equipment</font></div></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign=" bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">76</font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  &# 160;  Tangible assets acquired</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">545</font></td></tr><tr bgcolor="white"><t d style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">     Intangible assets acquired</font></div></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid ; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,099</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="76%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total assets and total consideration</font></div></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right" valign="bottom" width="9%"><font st yle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,644</font></td></tr></table></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify "><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In accordance with ASC Topic 805, <font style="DISPLAY: inline; FONT-STYLE: italic">Business Combinations</font> (“ASC 805”), the allocation of the purchase price in connection with the acquisition of DS Pharmacy is subject to adjustment during the measurement period after the closing date (July 29, 2010) when additional information on assets and liability valuations becomes available.  The Company is still in the process of finalizing its valuation of certain assets recorded in connection with the acquisition.  Accordingly, the provisional measurements recorded are subject to change and any changes will be recorded as adjustments to the fair value of those assets and liabilities.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIG HT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> Intangible Assets</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes the identifiable intangible assets acquired (in thousands):</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div align="left"><table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%"><tr><td valign="bottom" align="left" width="75%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" width="13%"><div style="DISPLAY: block; M ARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Estimated</font></div></td><td valign="bottom" align="left" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td valign="bottom" align="left" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="75%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roma n">Useful Life</font></div></td><td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fair Value</font></div></td></tr><tr><td valign="bottom" align="left" width="75%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td valign="bottom" align="left" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times n ew roman"> </font></td><td valign="bottom" align="left" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" align="left" width="75%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Customer list</font></div></td><td valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6 months</font></div></td><td valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" val ign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">283</font></td></tr><tr bgcolor="white"><td valign="bottom" align="left" width="75%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Transitional services contract</font></div></td><td valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1 year</font></div></td><td valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAM ILY: times new roman"> </font></td><td style="TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,161</font></td></tr><tr bgcolor="#cceeff"><td style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="75%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">License and marketing related intangibles</font></div></td><td style="PADDING-BOTTOM: 2px" valign="bottom" width="13%"><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMIL Y: times new roman">6 years</font></div></td><td style="PADDING-BOTTOM: 2px" valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,655</font></td></tr><tr bgcolor="white"><td style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="75%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="PADDING-BOTTOM: 4px" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font></td><td style="PADDING-BOTTOM: 4px" valign="bottom" align="right" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td><td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,099</font></td></tr></table></div> NOTE 3 – ACQUISITIONSCritical Homecare Solutions Holdings, Inc.On March 25, 2010, the Company acquired 100 percent of CHS, a leading provider of false false false us-types:textBlockItemType textblock Description of a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. This element may be used as a single block of text to encapsulate the entire disclosure (including data and tables) regarding business combinations, including leverage buyout transactions (as applicable). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51, 52 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 88-16 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph 67-73 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph F4 -Subparagraph e -Appendix F false 1 2 false UnKnown UnKnown UnKnown false true XML 32 R17.xml IDEA: Entity Information 2.2.0.7 false Entity Information (USD $) 995400 - Document - Entity Information true false false false 1 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 u002 Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ false 2 false false u001 Standard http://www.xbrl.org/2003/instance shares xbrli 0 false 3 USD false false u000 Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 $ 3 Entity Registrant Name 1 dei_EntityRegistrantName dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 BioScrip, Inc. BioScrip, Inc. false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false xbrli:normalizedStringItemType normalizedstring The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false 4 Entity Central Index Key 1 dei_EntityCentralIndexKey dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 0001014739 0001014739 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false us-types:centralIndexKeyItemType na A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false 5 Current Fiscal Year End Date 1 dei_CurrentFiscalYearEndDate dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 --12-31 --12-31 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false xbrli:gMonthDayItemType monthday End date of current fiscal year in the format --MM-DD. No authoritative reference available. false 6 Entity Well-known Seasoned Issuer 1 dei_EntityWellKnownSeasonedIssuer dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Yes Yes false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false us-types:yesNoItemType na Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A. No authoritative reference available. false 7 Entity Voluntary Filers 1 dei_EntityVoluntaryFilers dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 No No false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false us-types:yesNoItemType na Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. No authoritative reference available. false 8 Entity Current Reporting Status 1 dei_EntityCurrentReportingStatus dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Yes Yes false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false us-types:yesNoItemType na Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. No authoritative reference available. false 9 Entity Filer Category 1 dei_EntityFilerCategory dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Accelerated Filer Accelerated Filer false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false us-types:filerCategoryItemType na Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. No authoritative reference available. false 10 Entity Public Float 1 dei_EntityPublicFloat dei false credit instant No definition available. false false false false false false false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 true true false false 125041731 125041731 false false false xbrli:monetaryItemType monetary State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K. No authoritative reference available. false 11 Entity Common Stock, Shares Outstanding 1 dei_EntityCommonStockSharesOutstanding dei false na instant No definition available. false false false false false false false false false false false false 1 false false false false 0 0 false false false 2 false true false false 53702311 53702311 false false false 3 false false false false 0 0 false false false xbrli:sharesItemType shares Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument No authoritative reference available. false 12 Document Fiscal Year Focus 1 dei_DocumentFiscalYearFocus dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 2010 2010 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false xbrli:gYearItemType positiveinteger This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. No authoritative reference available. false 13 Document Fiscal Period Focus 1 dei_DocumentFiscalPeriodFocus dei false na duration No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Q3 Q3 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false us-types:fiscalPeriodItemType na This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY. No authoritative reference available. false 3 11 false NoRounding NoRounding UnKnown false true -----END PRIVACY-ENHANCED MESSAGE-----

R	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the quarterly period ended September 30, 2010
	OR
£	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from ________ to _______

Delaware	05-0489664
(State or Other Jurisdiction	(I.R.S. Employer Identification No.)
of Incorporation or Organization)

100 Clearbrook Road, Elmsford, NY	10523
(Address of Principal Executive Offices)	(Zip Code)

Large accelerated filer: £	Accelerated filer: R	Non-accelerated filer: £	Smaller reporting company: £
(Do not check if a smaller reporting company)

PART I		FINANCIAL INFORMATION	Page Number
	Item 1.	Financial Statements	3
		Consolidated Balance Sheets at September 30, 2010 (unaudited) and December 31, 2009	3
		Unaudited Consolidated Statements of Operations for the three and nine months ended September 30, 2010 and 2009	4
		Unaudited Consolidated Statements of Cash Flows for the nine months ended September 30, 2010 and 2009	5
		Notes to the Unaudited Consolidated Financial Statements	6
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
	Item 3.	Quantitative and Qualitative Disclosure About Market Risk	27
	Item 4.	Controls and Procedures	27
PART II		OTHER INFORMATION	28
	Item 1.	Legal Proceedings	28
	Item 1A.	Risk Factors	28
	Item 6.	Exhibits	36
SIGNATURES
EXHIBITS

	September 30,			December 31,
	2010			2009
ASSETS	(unaudited)
Current assets
Cash and cash equivalents	$	50,979		$	-
Receivables, less allowance for doubtful accounts of $16,408 and $11,504 at September 30, 2010 and December 31, 2009, respectively		186,474			151,113
Inventory		66,322			51,256
Deferred taxes		19,960			12,913
Prepaid expenses and other current assets		16,519			3,999
Total current assets		340,254			219,281
Property and equipment, net		22,723			15,454
Deferred taxes		17,414			26,793
Goodwill		323,798			24,498
Intangible assets, net		32,101			-
Deferred financing costs		5,440			-
Other non-current assets		2,151			1,194
Total assets	$	743,881		$	287,220
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Current portion of long-term debt	$	3,864		$	30,389
Accounts payable		84,782			74,535
Claims payable		4,598			4,068
Amounts due to plan sponsors		16,170			4,938
Deferred revenue		3,527			-
Accrued expenses and other current liabilities		46,577			14,273
Total current liabilities		159,518			128,203
Long-term debt, net of current portion		314,752			-
Other non-current liabilities		3,796			3,224
Total liabilities		478,066			131,427
Stockholders' equity
Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued or outstanding	$	-		$	-
Common stock, $.0001 par value; 125,000,000 shares authorized; shares issued: 56,632,871 and 42,766,478, respectively; shares outstanding; 53,688,338 and 39,675,865, respectively		6			4
Treasury stock, shares at cost: 2,658,963 and 2,647,613, respectively		(10,496	)		(10,367	)
Additional paid-in capital		366,901			254,677
Accumulated deficit		(90,596	)		(88,521	)
Total stockholders' equity		265,815			155,793
Total liabilities and stockholders' equity	$	743,881		$	287,220

Fair value of equity consideration:
BioScrip common stock issued (13.1 million shares)	$	91,614
BioScrip warrants issued (3.4 million warrants)		12,268
Rollover options (716,086 options)		2,802
Cash paid to CHS stockholders		99,626
Total consideration conveyed to CHS stockholders	$	206,310

Cash paid for merger related expenses incurred by CHS		14,566
Assumption and repayment of CHS debt		128,952
Total amounts paid to execute the merger of CHS	$	349,828

Cash and cash equivalents	$	7,162
Receivables		37,333
Deferred taxes		6,182
Other current assets		4,993
Property and equipment		7,042
Other assets		2,778
Total assets acquired					65,490
Accounts payable		(3,147	)
Notes payable		(2,250	)
Amounts due to plan sponsors		(8,180	)
Accrued expenses and other current liabilities		(34,007	)
Deferred tax liabilities		(7,144	)
Total liabilities assumed					(54,728	)
Tangible assets acquired, net				$	10,762
Intangible assets acquired					25,200
Debt assumed					(128,952	)
Goodwill					299,300
Total consideration conveyed to CHS stockholders				$	206,310

	Estimated
	Useful Life	Fair Value

Trademarks/trade names	various	$	8,400
Infusion customer relationships	3 years		7,200
Certificates of need	indefinite		9,600
		$	25,200

Inventory	$	469
Property and equipment		76
Tangible assets acquired			$	545
Intangible assets acquired				9,099
Total assets and total consideration			$	9,644

	Infusion/Home			Pharmacy
	Health Servcies			Services		Total
Balance as of December 31, 2009	$	-		$	24,498	$	24,498
Preliminary goodwill valued as of the date of the CHS acquisition		304,185			-		304,185
Adjustments to goodwill related to CHS acquisition		(4,885	)		-		(4,885	)
Balance as of September 30, 2010	$	299,300		$	24,498	$	323,798

		September 30, 2010
		Gross					Net
	Estimated	Carrying		Accumulated			Carrying
	Useful Life	Amount		Amortization			Amount

Indefinite Useful Life
Certificates of need	indefinite	$	9,600	$	-		$	9,600
Nursing trademarks	indefinite		5,800		-			5,800
			15,400		-			15,400

Finite Useful Life
Customer list	6 months		283		(95	)		188
Transitional services contract	1 year		1,161		(194	)		967
Infusion trademarks	3 years		2,600		(450	)		2,150
Infusion customer relationships	3 years		7,200		(1,246	)		5,954
License and marketing related intangibles	6 years		7,655		(213	)		7,442
			18,899		(2,198	)		16,701

		$	34,299	$	(2,198	)	$	32,101

2010 (three month period ending December 31, 2010)	$	1,576
2011		5,276
2012		4,552
2013		2,002
2014		1,276
2015 and thereafter		2,019
Total	$	16,701

Senior unsecured notes	$	225,000
Senior secured facility		93,371
Capital leases		245
		318,616
Less - obligations maturing within one year		3,864
Long term debt - net of current portion	$	314,752